SUPPLEMENT

FY2024 — Results booklet

FY2024PDF · 116 pages4.9 MB
and cash dividend declaration
for the year ended 30 June 2024
REVIEWED
ANNUAL
FINANCIAL
RESULTS

-- 1 of 116 --

Discovery Limited
Registration number 1999/007789/06
CONTENTS
A. 	Notes to the condensed consolidated
financial statements
15 	A.1. Segment information
22 	A.2. Normalised profit from operations
22 	A.3. Earnings, headline earnings and normalised headline
earnings
24 	A.4. Revenue from non-insurance activities
24 	A.5. Borrowings at amortised cost
26 	A.6. Fair value hierarchy
B. 	Other significant items in these results
29 	B.1. Exchange rates to South African Rand used in the
preparation of these results
29 	B.2. Capital management, financial leverage ratio and covenants
31 	B.3. Impact of actuarial basis changes within the SA Life and
UK Life operating segments
31 	B.4. Change in hedge strategy – VitalityLife business
32 	B.5. Cash and cash equivalents
32 	B.6. Consolidation of Discovery Unit Trusts
32 	B.7. Material transactions with related parties
32 	B.8. Major customers and other Discovery entities not part
of Discovery Group
33 	B.9. Changes in directorate
33 	B.10. Events after reporting date and dividend declaration in
respect of the year ended 30 June 2024
C. 	Insurance and reinsurance contracts related
disclosure
1 	Results commentary
8 	Group statement of financial position
9 	Group income statement
10 	Group statement of other comprehensive income
11 	Group statement of cash flows
12 	Group statement of changes in equity
D. 	Adoption of new standards and
interpretations and restatements
95
D1.1. Adoption of new standards and interpretations
and restatements
97 	D.1.2. Impact of restatement on the Group Statement of
financial position
101 	D.1.3. Adoption of IFRS 17 Insurance Contracts
103 	D.1.4. Restatement as a result of prior period errors
111 	D.1.5. Changes in presentation of specified items in primary
statements and associated restatements for prior
period corrections
E. 	Accounting policies
116 	E.1. 	New Accounting Standards and amendments to
published Accounting Standards not yet effective
116 	E.2. 	Normalised headline earnings
116 	E.3. 	Basis of preparation
Independent auditors’ report on review of
condensed consolidated financial statements
Embedded value statement
118 	Embedded value statement
Independent auditors’ report on the review of the Embedded
Value Statement of Discovery Limited and its subsidiaries
120 	Table 1: Group embedded value
122 	Table 2: Value of in-force covered business
123 	Table 3: Group embedded value earnings
124 	Table 4: Components of Group embedded value earnings
124 	Table 5: Experience variances
125 	Table 6: Methodology and assumption changes
126 	Table 7: Embedded value of new business
127 	Table 8: Embedded value economic assumptions
128 	Table 9: Embedded value sensitivity
130 	Table 10: Value of new business sensitivity
Annexure A
133 	New business annualised premium income
134 	Income from non-insurance business lines
Annexure B
136 	Impact of corrections on normalised profit from operations
for six months ended 31 December 2023
Annexure C
138 	Regulatory capital
ibc 	Administration

-- 2 of 116 --

1
RESULTS COMMENTARY
Group overview and salient group results
The year under review was characterised by continued macroeconomic complexities. Global inflation rates declined from the prior year
highs, but cumulative interest rate increases heightened consumer pressures in many regions, constraining economic growth. The
uncertainty around elections in South Africa (SA) created further economic headwinds during the year. A positive election outcome
towards the end of the reporting period, following the formation of the Government of National Unity (GNU), resulted in a significant shift
in confidence, with some immediate relief in market indicators. The National Health Insurance (NHI) Act, which was signed over the
period, is not workable in its current form; however, the Group is engaging at multiple levels to facilitate a viable journey to universal
healthcare coverage in SA. In the United Kingdom (UK), fiscal challenges and the knock-on impact on the National Health Service (NHS)
backlogs, accelerated the demand for, and utilisation of, private medical insurance (PMI). Many markets in Asia experienced post-
COVID-19 recoveries; however, China continued to face significant macroeconomic and growth constraints.
Discovery Group achieved strong growth in the year ended 30 June 2024, with normalised operating
profit up 17% to R11 604 million, headline earnings up 7% to R7 202 million, normalised headline
earnings up 15% to R7 329 million, and core new business annualised premium income (API) up 18%
to R26 667 million.
SALIENT GROUP RESULTS
for the year ended 30 June 2024
Unit
June
2024
June
2023 	% Change
Normalised profit from operations1 	R million 	11 604 	9 917 	17%
Normalised headline earnings1 	R million 	7 329 	6 400 	15%
Headline earnings1 	R million 	7 202 	6 720 	7%
Basic earnings per share1 	Cents 	1 082.7 	972.6 	11%
Basic headline earnings per share1 	Cents 	1 089.4 	1 021.5 	7%
Basic normalised headline earnings per share1 	Cents 	1 108.6 	972.8 	14%
Net asset value1 	R million 	57 719 	49 724 	16%
Embedded value 	R million 	110 354 	98 176 	12%
Annualised ROEV 	% 	13.2 	13.2
Basic embedded value per share 	R 	166.95 	149.11 	12%
Financial leverage ratio, including 50% CSM (FLR)1,4 	% 	20.0 	20.4
Shareholder free cash increase, before ordinary dividend 	R million 	2 643 	397 	>100%
Final dividend per share 	Cents 	152.0 	110.0 	38%
Total income from non-insurance lines2 	R million 	6 191 	5 349 	16%
Core new business annualised premium income3 	R million 	26 667 	22 622 	18%
1 Includes restatements as a result of the adoption of IFRS 17 Insurance Contracts.
2 Restated to include solutions revenue from external clients for Vitality Network.
3 Core new business API excludes products of VitalityInvest, Discovery Business Insurance and PAHI reinsurance business in run down (refer Annexure A).
4 Allowing for the inclusion of 50% of the contractual service margin (CSM) net of reinsurance and net of tax in the denominator.
The Group focused on the following over the year:
1. Delivering strong growth in earnings, value, cash generation and capital resilience;
2. Entering a new phase in the lifecycle of the Group; and
3. Arranging the Group into two distinct composites to drive the new phase of growth.

-- 3 of 116 --

2	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
1. Delivering strong growth in earnings, value, cash generation and capital resilience
The IFRS 17 Insurance Contracts accounting standard became effective for the Discovery Group on 1 July 2023. Full-year earnings have been
reported under the standard for the first time, with a comparative restatement of the prior year, and a restatement of the opening Statement
of financial position as at 1 July 2022. The details of these restatements are covered in Section D.
The Group grew normalised profit from operations by 17% with strong contributions from Discovery SA and Vitality Global (VG), increasing
16% and 57% respectively. Vitality UK declined 14%, impacted by two specific issues: claims experience in VitalityHealth and a basis
strengthening for the back book under VitalityLife.
Normalised headline earnings grew 15% while headline earnings increased 7%, the difference explained by the considerable prior period fair
value gain from the UK interest rate swaption. The swaption was realised towards the end of the prior financial year, with no profit impact in
the current period. Consistent with prior reporting, headline earnings were normalised for this.
The Group’s embedded value increased to R110 billion, which represents a 13.2% return on embedded value (RoEV). This included a positive
contribution from experience variances over the period, reflecting the competitive dynamics of the Shared-value Insurance model, as well as
a strong improvement from non-covered businesses.
The Group demonstrated continued financial resilience over the year. The financial leverage ratio (FLR) improved to 20.0%, despite prudently
raising R1.5 billion of debt, ahead of the election in SA, to derisk the refinancing of a maturity towards the end of the current calendar year.
Capital and liquidity ratios remained strong across every business, and central liquidity increased, even before the additional debt. This was
driven by improved organic cash generation, with cash conversion now at 66% of after-tax normalised operating profit (64% in the prior
period), and lower spend on new initiatives. Ping An Health Insurance (PAHI) achieved a key milestone over the period, paying its maiden
shareholder dividend, with a payout ratio of 30% of 2023 calendar year distributable profits. Discovery’s share, after withholding tax, was
R255 million.
BUSINESS-UNIT PERFORMANCE
Normalised
profit from
operations
(Current year,
in ZAR million)
% change
(Current
year vs
prior year)
New
business API
(Current year,
in ZAR million
% change
(Current
year vs
prior year)
Discovery Health 	3 972 	7% 	11 069 	26%
Discovery Life 	4 765 	9% 	2 942 	4%
Discovery Invest 	1 522 	20% 	3 300 	8%
Discovery Insure1 	248 	>100% 	1 388 	11%
Discovery Bank 	(454) 	41% lower
Other SA initiatives and central costs 	(336) 	20% 	1 038 	38%
Discovery SA 	9 717 	16% 	19 737 	19%
VitalityHealth 	435 	(47%) 	2 488 	21%
VitalityLife 	375 	(20%) 	1 956 	14%
Closure costs of VitalityInvest and VitalityCar 	(75) 	84% lower
Other UK initiatives and central costs 	(88) 	10%
Vitality UK 	647 	(14%) 	4 444 	17%
Vitality Network 	533 	30%
VHI – Ping An Health Insurance (PAHI) 	1 124 	85% 	2 486 	14%
VHI – Other 	(386) 	98%
Other VG initiatives and central costs 	(31) 	11% lower
Vitality Global 	1 240 	57% 	2 486 	14%
Normalised profit from operations 	11 604 	17%
Normalised headline earnings 	7 329 	15%
Core new business API 	26 667 	18%
1 Includes Discovery Insure’s share of equity accounted profits of its associates.
RESULTS COMMENTARY continued

-- 4 of 116 --

3
DISCOVERY SA
DISCOVERY BANK
Unit
June
2024
June
2023 	% Change
Net non-interest revenue (NIR) 	R million 	1 367 	943 	45%
Net interest income (NII) 	R million 	779 	574 	36%
Operating loss before new business acquisition costs 	R million 	52 	479 	(89%)
Normalised loss from operations 	R million 	454 	767 	(41%)
Retail deposits 	R billion 	18.5 	14.3 	29%
Advances 	R billion 	6.6 	5.2 	27%
Average interest-earnings assets (IEA) 	R billion 	19.5 	15.0 	30%
Credit Loss Ratio1 (CLR) 	% 	2.78% 	2.70% 	3%
Number of accounts 	Number 	2 271 703 	1 625 912 	40%
Number of clients 	Number 	958 055 	702 131 	36%
1 CLR calculated as the expected credit loss (ECL) charge on the year-end advances balance.
Discovery Bank (DB) improved its operating loss before new business acquisition costs by 89%, and the overall loss was 41% better
than the prior year. DB’s total client base grew 36% to June 2024, and it achieved its ambition of one million clients post the year-end,
well ahead of its “by 2026” target.
DB remained focused on high-quality growth and customer primacy, given challenging macroeconomic conditions, with deposits
growing 29%. Advances grew steadily by 27%, and NII grew by 36%, as average interest-earning assets increased 30% and the net
interest margin increased by 7%. DB expanded its lending suite by launching a Revolving Credit Facility in December 2023, as well as
home loans in May 2024, both of which have seen pleasing initial take-up.
Non-interest revenue continued to grow steadily by 45% year-on-year, driven by the growth in clients, product take-up and the
resulting fee income per client. In line with DB’s growth trajectory, client engagement levels grew, with a 44% increase in payment
volumes and a 33% increase in spend values in June 2024 compared to the prior year.
DISCOVERY HEALTH
Unit
June
2024
June
2023 	% Change
Normalised profit from operations 	R million 	3 972 	3 698 	7%
New business API 	R million 	11 069 	8 761 	26%
Revenue1 	R million 	10 841 	9 967 	9%
Non-scheme and other revenue % of total revenue1 	% 	14.8% 	14.1% 	5%
Lives under administration 	Million 	3.92 	3.83 	2%
1 Prior year DH revenue has been reduced by R292 million, with a commensurate adjustment to expenses.
Discovery Health (DH) increased operating profit by 7% while continuing to invest in technology, innovation and artificial intelligence
(AI). The successful take-on of Sasolmed medical scheme administration significantly increased new business API, 75 000 lives.
In addition to the Discovery Health Medical Scheme (DHMS), DH administers 18 closed medical schemes, all of which performed
strongly. The growth of non-medical scheme products continued, with total non-scheme and other revenue now representing 15%
of total DH revenue, highlighting the growth opportunity through adjacencies.
DHMS remained resilient despite a relatively flat open medical scheme market and challenging macroeconomic environment. DHMS
maintained its market share of 57.9% in the open scheme market and projected 2024 solvency remains strong at 30%, significantly
higher than the 25% regulatory requirement.

-- 5 of 116 --

4	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
RESULTS COMMENTARY continued
DISCOVERY LIFE
Unit
June
2024
June
2023 	% Change
Normalised profit from operations 	R million 	4 765 	4 375 	9%
New business API 	R million 	2 942 	2 838 	4%
Premium income 	R million 	17 892 	16 620 	8%
Solvency ratio1,2 	% 	183% 	184%
RoEV 1 	% 	14% 	8%
VNB margin 1 	% 	3.8% 	2.5%
1 Including Discovery Invest.
2 The June 2023 solvency ratio reflects the final position disclosed in the June 2023 annual regulatory return.
Discovery Life (DL) grew profits 9%, despite the elevated prior year group life result, as individual life grew 11%. Overall claims experience
was better than expected, with elevated income disability claims in individual life being offset by favourable claims experience in group life.
Lapse and premium income experience remained favourable compared to expectation, but policy alterations were negatively impacted by
consumer pressure. The embedded value (including Invest) delivered an annualised RoEV of 14%, with non-economic experience variances
contributing positively overall, while economic assumptions were negatively impacted by higher real yields.
The actuarial basis was strengthened, taking into account the recent claims and policy alterations experience as well as planned
management actions, which was significantly absorbed by the contractual service margin (CSM), net of the related Other Comprehensive
Income (OCI). Expense estimates were updated to allow for the restructuring of the Corporate and Employee Benefits division.
The VNB margin for individual life increased significantly to 5% at June 2024, primarily due to efficient expense controls and improved
business mix over the year. DL maintained its leading position in the affluent retail protection market with an increase in market share to
27%, and growth across all key retail distribution channels. The strong improvement in the individual life VNB was partially offset by the
decline in group lifes, as lower new business volumes further impacted the margin.
DL’s resilience was demonstrated by its strong solvency and liquidity positions, with a solvency ratio of 183% and liquidity coverage
significantly above 100% of required risk appetite buffers. DL cash generation (including Invest) increased to R2 260 million (prior year
R1 960 million), before a R494 million net repayment of FinRe (prior year R165 million increase in net FinRe), with the cash conversion
ratio remaining in excess of 35%.
DISCOVERY INVEST
Unit
June
2024
June
2023 	% Change
Normalised profit from operations 	R million 	1 522 	1 273 	20%
Assets under administration 	R billion 	155 	140 	11%
Assets under management 	R billion 	105 	95 	11%
% linked assets in Discovery funds 	% 	80% 	80%
Net client cash flows 	R billion 	3.1 	5.9 	(47%)
New business API 	R million 	3 300 	3 050 	8%
Discovery Invest increased operating profit by 20%. Assets under management expanded 11%, and higher growth in superior margin offshore
and structured products drove increased fee income. In addition, the earnings profile of guaranteed endowments was amended to provide a
more even ongoing profit release profile over the duration of a policy, which was the main contributor to a one-off earnings rebase, amounting
to R93 million during this period.
New business improved by 8%, from higher sales of recurring premium linked products as well as increased guaranteed endowments. Net
client cash flows, while positive, declined following increased maturities and higher industry withdrawals from voluntary products and living
annuities, given increased demand for fixed annuities to capitalise on higher market interest rates.
DISCOVERY INSURE
Unit
June
2024
June
2023 	% Change
Personal lines 	R million 	199 	89 	124%
Equity accounted profits/(losses) 	R million 	49 	(16)
Operating profit 	R million 	248 	73 	>100%
Operating margin Personal lines 	% 	3.5% 	1.7%
New business API Personal lines 	R million 	1 388 	1 249 	11%
Gross written premiums 	R million 	5 726 	5 259 	9%
Discovery Insure’s (DI) personal lines business delivered strong profit growth, with a dramatic recovery in the second half of the year, following
a first half that was significantly impacted by severe weather events. The dynamics for the business have improved significantly, following
various initiatives in previous periods aimed at improving operating margins through reduced claims costs and operating expenses. The exit
from commercial lines will facilitate continued focus on further margin enhancement in the personal lines business.

-- 6 of 116 --

VITALITY UK
VITALITY LIFE
Unit
June
2024
June
2023 	% Change
Normalised profit/(loss) from operations 	GBP million 	15.9 	21.8 	(27%)
R million 	375 	468 	(20%)
Earned premium 	GBP million 	402 	366 	10%
R million 	9 464 	7 835 	21%
New business API 	GBP million 	83 	80 	4%
R million 	1 956 	1 721 	14%
Lives covered 	Number 	810 050 	764 699 	6%
VNB margin 	% 	(1.3%) 	(1.0%)
VitalityLife’s (VL) normalised operating profit declined 27% to £15.9 million (declined 20% to R375 million). In light of continued lower
lapses than expected for a block of whole-of-life business within the Prudential Assurance Company (PAC) book, VL strengthened the
lapse basis, resulting in a negative impact on earnings of £12.5 million for the period. While VL has contractual service (CSM) and risk
adjustment (RA) margins in excess of £400 million, these margins are not applicable to this particular cohort, resulting in the basis
change directly impacting in-period earnings. This is not expected to recur.
VL’s underlying business performance was robust, with a positive lapse rate and claims experience reflecting the continued
engagement in Vitality – driving positive actuarial dynamics. Lives covered increased by 6%, while earned premiums increased by
10%, highlighting the strong retention performance and high indexation increases.
New business volumes grew modestly over the year in a contracting UK market. In the first half, the margin was impacted by the
combination of low new business volumes and elevated inflation. However, VL implemented a deliberate price optimisation strategy
in the second half of the year, focusing on the quality of the portfolio. This resulted in an improvement in business mix and volumes,
and a step change in the value generated in the second half of the year.
VITALITY HEALTH
Unit
June
2024
June
2023 	% Change
Normalised profit/(loss) from operations 	GBP million 	18.5 	38.4 	(52%)
R million 	435 	823 	(47%)
Earned premiums 	GBP million 	699 	624 	12%
R million 	16 470 	13 364 	23%
New business API 	GBP million 	106 	96 	10%
R million 	2 488 	2 064 	21%
Lives covered 	Number 	1 027 569 	959 075 	7%
VitalityHealth (VH) delivered strong new business growth, with membership increasing 7% to exceed one million lives. Growth was
driven by increased demand for private medical insurance (PMI) given the backlogs experienced by the National Health Service (NHS).
Operating profit declined 52% to £18.5 million (declined 47% to R435 million) as there was a concomitant increase in claims during
the reporting period, which negatively impacted earnings by £30 million, given the lag of premium increases.
VH significantly increased prices in response to the higher claims, in line with the market, with little impact on observed lapse rates.
Post the reporting period, claim levels are in line with actuarial expectation. As such, margins are expected to recover strongly in the
2025 financial year.
5

-- 7 of 116 --

6	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
VITALITY GLOBAL
VITALITY HEALTH INTERNATIONAL
VITALITY NETWORK
RESULTS COMMENTARY continued
Unit
June
2024
June
2023 	% Change
PAHI (25%), after Discovery's costs 	R million 	1 124 	609 	85%
PAHI (25%), after Discovery's costs 	US$ million 	60.1 	33.8 	78%
Other VHI 	US$ million 	(20.7) 	(11.0) 	88%
VHI profit from operations – total 	US$ million 	39.4 	22.8 	73%
PAHI
New business PAHI own licence (100%) 	RMB million 	3 842 	3 428 	12%
New business PAHI own licence (25%) 	R million 	2 486 	2 185 	14%
Written premium – own licence 	RMB million 	16 118 	14 318 	13%
Written premium – reinsurance 	RMB million 	6 527 	5 314 	23%
Total written premium (100%) 	RMB million 	22 645 	19 632 	15%
PAHI profit before income and gains (100%) 	RMB million 	1 470 	881 	67%
PAHI Investment income and gains (100%) 	RMB million 	621 	456 	36%
PAHI pre-tax profit (100%) 	RMB million 	2 092 	1 337 	56%
Vitality Health International (VHI) increased profit by 73% to US$39.4 million in the year, driven predominantly by the Group’s share
of PAHI’s after-tax operating profit, less Discovery’s costs, increasing 78% to US$60.1 million. PAHI’s performance was driven by strong
and improving operating margins, consistently superior premium income growth compared to the industry, some benefit from a
lower tax rate in the first half, and the release of COVID-19 reserves in the second half.
PAHI maintained a robust balance sheet with a comprehensive solvency ratio of 320% and generated increased investment income
through a more stable investment strategy. In June 2024, PAHI paid a dividend to shareholders for the first time, representing 30%
of 2023 calendar year distributable profits, remaining strongly capitalised. Discovery’s share after withholding tax was R255 million.
New business on the PAHI insurance licence increased by 12% (14% in ZAR), supported by a rise in new business through
non-Ping An Life channels, and a market shift towards higher-end products. Total written premiums increased by 15%, aided by
continued improvement in retention and 23% growth in reinsurance premiums.
VHI represents a key future potential growth area for the Group. The business has invested in developing technology and distribution
to deliver a capability integrating wellness with disease management, by leveraging the Group’s broader health and wellness assets.
The focus in this year was particularly on Vitality USA, which has made good progress in building out its technology to facilitate its
strategy for the health plan market. Amplify Health has made continued progress with five healthcare cost-saving products deployed
in six Asia-Pacific markets.
Unit
June
2024
June
2023 	% Change
Revenue1 	US$ million 	101 	92 	10%
R million 	1 894 	1 632 	16%
Normalised profit from operations 	US$ million 	28.5 	23.1 	23%
R million 	533 	411 	30%
Integrated API by insurance partners 	US$ million 	1 575 	1 414 	11%
R million 	29 673 	25 165 	18%
Number of lives 	Million 	5.25 	4.47 	17%
1 Prior year has been restated by US$22 million (R396 million) to include solutions revenue from external clients.
Vitality Network (VN) grew operating profit 23% to US$28.5 million (30% to R533 million). Strong sales, membership, and revenue
growth in Asia drove 10% growth in total revenues, tempered by continued US dollar strength relative to many Asian currencies, in
particular relative to the yen. Total membership growth of 17% demonstrates the expanding global relevance of the Shared-value
Insurance model.
The business is appropriately scaled for further growth and the capital investment into the V1 Platform has now peaked. This is
expected to drive further margin expansion on the back of higher revenue growth.

-- 8 of 116 --

7
2. Entering a new phase in the lifecycle of the Group
Discovery Group has been through a cycle of significant investment over the past eight years, with a focus on globalising its capabilities,
footprint, and scale in the UK and beyond, as well as building new growth ventures, most notably Discovery Bank. This investment cycle
focused on creating new avenues for long-term growth, notwithstanding a temporary impact on financial metrics, given the related
j-curves and funding costs. The Group is now emerging from that phase into a new distinct phase, which marks the realisation of the
Group’s growth strategy.
Over the past two years, the Group has rigorously intensified its focus on scaling its emerging businesses and the initiatives that can
meaningfully impact the Group, while closing those with marginal benefits. The Group has also ensured financial discipline by removing
interest rate, currency and refinancing risks, and applied rigour to capital allocation and the utilisation of the emerging cash. Central
liquidity has been increasing as cash generation for the established and emerging businesses has increased, the UK becoming financially
independent, and new initiative spend decreasing.
In SA, DB continued to pass key milestones significantly ahead of expectation and is now well positioned to empower the whole of
Discovery SA as a full-service digital bank, offering comprehensive transactional and lending capabilities, with exceptional levels of
customer engagement. The Group has exited the commercial lines Discovery Business Insurance (DBI), and other smaller initiatives in
SA have been comfortably absorbed within the operating businesses. The reducing cash strain of new initiatives is coinciding with the
increasing cash generation profile of DL (and Invest), providing Discovery SA with a robust financial framework with which to drive its
ambition to be the leading financial services group in SA.
Vitality UK has built a prominent brand in a large and competitive market, with £1.1 billion premium revenue, nearly £200 million new
business API, and 1.8 million lives. With the closure of VitalityInvest and VitalityCar, it is now a focused new generation life and health
insurance business, well positioned for strong and sustainable growth, without recourse to Group funding as VL is now self-supporting.
VG has established itself as a leading wellness and healthcare platform, having expanded the Vitality Shared-value Insurance model in
a capital-light manner to 39 of the largest markets in the world. Vitality Global has built a powerful asset in the V1 platform, and the
investment cycle has now peaked. VN is driving operating margins as it continues to deepen its partnerships and it is focused on pursuing
expansion opportunities in large markets. PAHI has focused on operational delivery to evolve into a high-quality specialist health insurer,
with strong and sustainable margins.
3. Arranging the Group into two distinct businesses to drive the new phase of growth
Discovery has built two international businesses of scale in Vitality UK and VG. Each business has developed at a different pace, given the
prevailing considerations for each. The scale of the underlying businesses, the evolving data and its applicability, the focus on a unified
product strategy and model, and the opportunity for consistent IP and technology have created the opportunity for Vitality Limited, a
single global business of scale, with significant organic growth potential.
Prospects and dividend
Discovery’s growth strategy is based on the efficacy, repeatability and scalability of its model through organic growth and global
partnerships. Following rigorous focus over the past few years on emerging and new initiatives, as well as on cash generation and
utilisation, the Group firmly believes it has entered a new distinct phase, which it expects to have a material impact on profitability,
cash generation, returns and leverage. The Group is well positioned for sustained growth through two powerful and focused structures;
Discovery SA and Vitality Limited, with strong growth platforms in each. The Group expects the medium-term growth in profit from
operations to exceed the longer-term target of CPI+10%, without recourse to further external capital.
At the Group’s June 2023 financial year results announcement, Discovery described its dividend policy under IFRS 17. The annual ordinary
dividend is expected to be covered approximately five times by normalised headline earnings, with interim ordinary dividends expected to
be paid in the range of 30% to 40% of the expected total annual ordinary dividend, with the remainder of the dividend to be paid as a final
dividend. In line with this, the Group has declared its final ordinary dividends for the period at 152 cents per share, representing an
annual cover ratio of 5 times.
Notes to analysts
Any forecast financial information contained in this announcement has not been reviewed or reported on by the Company’s external
auditors.
Discovery has published supplemental unaudited information on the website. For this and other results information, visit
https://www.discovery.co.za/corporate/investor-relations and go to Financial and annual reports.
On behalf of the Board
ME Tucker
Chairperson
Sandton
18 September 2024

-- 9 of 116 --

8	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
GROUP STATEMENT OF FINANCIAL POSITION
as at 30 June 2024
R million
Group
2024
Restated 1
Group
2023
Restated1
Group
1 July 2022
Assets
Goodwill 	5 292 	5 406 	4 912
Intangible assets 	7 239 	7 064 	6 584
Property and equipment 	3 581 	3 910 	3 811
Assets arising from insurance contracts issued 	41 816 	33 624 	29 761
Assets arising from reinsurance contracts held 	837 	604 	873
Deferred tax asset 	5 631 	6 370 	5 717
Assets arising from contracts with customers 	2 598 	2 221 	1 709
Investment in equity-accounted investees 	8 189 	7 398 	6 338
Financial assets
– Loans and advances to customers at amortised cost 	6 028 	4 702 	3 944
– Investments at amortised cost 	11 100 	9 910 	7 161
– Investments at fair value through profit or loss 	165 671 	152 515 	138 095
– Derivative financial instruments at fair value through profit or loss 	43 	119 	276
Contract receivables and other receivables 	6 729 	5 684 	5 224
Non-current assets held for sale 	136 	– 	171
Current tax asset 	250 	41 	183
Cash and cash equivalents 	18 971 	19 171 	17 186
TOTAL ASSETS 	284 111 	258 739 	231 945
Equity
Capital and reserves
Ordinary share capital and share premium 	10 667 	10 351 	10 178
Perpetual preference share capital 	779 	779 	779
Other reserves 	6 275 	4 690 	2 455
Retained earnings 	39 998 	33 900 	27 402
Equity attributable to equity holders of the Company 	57 719 	49 720 	40 814
Non-controlling interest 	* 	4 	5
TOTAL EQUITY 	57 719 	49 724 	40 819
Liabilities
Liabilities arising from insurance contracts issued 	105 070 	94 660 	83 924
Liabilities arising from reinsurance contracts held 	5 396 	4 819 	5 252
Deferred tax liability 	8 184 	6 706 	6 327
Contract liabilities to customers 	512 	656 	944
Third-party interest in consolidated funds 	31 456 	28 346 	24 320
Financial liabilities
– Borrowings at amortised cost 	21 662 	20 586 	20 584
– Other financial payables at amortised cost 	8 007 	8 568 	8 075
– Deposits from customers 	18 467 	14 333 	10 881
– Investment contracts at fair value through profit or loss 	25 710 	28 903 	28 955
– Derivative financial instruments at fair value through profit or loss 	31 	20 	202
Provisions 	449 	187 	170
Other payables 	1 216 	1 066 	1 003
Current tax liability 	232 	165 	489
TOTAL LIABILITIES 	226 392 	209 015 	191 126
TOTAL EQUITY AND LIABILITIES 	284 111 	258 739 	231 945
* Amount less than R500 000.
1 The comparative information has been restated for the initial adoption of IFRS 17, restatements due to correction of prior period errors and the order of liquidity was
updated to better reflect the liquidity of financial statement line items. Refer to note D.1. for more detail.

-- 10 of 116 --

9
GROUP INCOME STATEMENT
for the year ended 30 June 2024
R million
Group
2024
Restated1
Group
2023
Insurance revenue 	51 857 	45 254
Insurance service expenses 	(46 145) 	(39 826)
Net expenses from reinsurance contracts 	(915) 	(126)
Insurance service result 	4 797 	5 302
Net financial result from insurance finance income and expense 	(7 245) 	(7 395)
– Net finance expense from insurance contracts 	(6 902) 	(7 089)
– Net finance expense from reinsurance contracts 	(343) 	(306)
Investment income using the effective interest rate method 	860 	616
Net fair value gains on financial assets at fair value through profit or loss 	16 245 	17 232
Fair value adjustment to liabilities under investment contracts 	(2 142) 	(3 099)
Third party interest: fair value adjustment to liabilities under investment contracts 	(2 873) 	(2 978)
Other gains on financial instruments 	5 	–
Net insurance and investment results 	9 647 	9 678
Fee income from administration businesses 	14 093 	13 224
Vitality income 	4 655 	3 891
Net banking fee and commission income 	1 398 	965
– Banking fee and commission income 	1 872 	1 292
– Banking fee and commission expense 	(474) 	(327)
Net bank interest and similar income 	779 	574
– Bank interest and similar income using the effective interest rate 	1 840 	1 318
– Bank interest and similar expense using the effective interest rate 	(1 061) 	(744)
Other income 	1 380 	1 544
Non-insurance revenue and income 	22 305 	20 198
Net income 	31 952 	29 876
Non-insurance acquisition costs 	(988) 	(880)
Expected credit losses 	(183) 	(139)
Marketing and administration expenses 	(19 644) 	(18 540)
Impairment of goodwill 	– 	(9)
Operating profit 	11 137 	10 308
Gain/(loss) on dilution and disposal of equity-accounted investments 	22 	(5)
Share of net profits from equity-accounted investments 	975 	525
Profit before financing and income tax 	12 134 	10 828
Interest expenses on borrowings and lease liabilities 	(2 036) 	(1 919)
Foreign exchange (losses)/gains 	(87) 	149
Profit before income tax 	10 011 	9 058
Income tax expense 	(2 647) 	(2 486)
Profit for the year 	7 364 	6 572
Profit attributable to:
– Ordinary shareholders 	7 283 	6 510
– Preference shareholders 	91 	69
– Non-controlling interest 	(10) 	(7)
7 364 	6 572
Earnings per share for profit attributable to ordinary shareholders
of the company during the year (cents):
– Basic 	1 082.7 	972.6
– Diluted 	1 076.3 	967.8
1 The comparative information has been restated for the initial adoption of IFRS 17, restatements due to correction of prior period errors and additional subtotals have
been included to enhance understandability of income statement. Refer to note D.1. for more detail.

-- 11 of 116 --

10	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
GROUP STATEMENT OF OTHER COMPREHENSIVE INCOME
for the year ended 30 June 2024
R million
Group
2024
Restated1
Group
2023
Profit for the year 	7 364 	6 572
Income and expenses that will be reclassified to profit or loss when specific conditions
are met:
Currency translation differences 	(823) 	3 316
Unrealised (losses)/gains 	(846) 	3 431
Tax on unrealised losses/(gains) 	23 	(115)
Cash flow hedges 	(61) 	76
– Unrealised (losses)/gains 	(65) 	76
– Tax on unrealised (gains)/losses 	– 	–
– Gains/(losses) reclassified to profit or loss 	4 	(1)
– Tax on reclassified (gains)/losses 	– 	1
Net finance income/(expense) from insurance contracts issued 	2 672 	(2 444)
– Unrealised income/(expense) 	3 595 	(3 381)
– Tax on unrealised (income)/expense 	(923) 	937
Net finance income/(expense) from reinsurance contracts held 	(221) 	454
– Unrealised (expense)/income 	(290) 	617
– Tax on unrealised expense/(income) 	69 	(163)
Share of other comprehensive income from equity-accounted investments 	(236) 	433
– Change in fair value of debt instruments at fair value through other comprehensive income 	45 	(10)
– Currency translation differences 	(281) 	443
Total income and expenses that will be reclassified to profit or loss when specific conditions
are met 	1 331 	1 835
Income and expenses that will not be reclassified to profit or loss
– Change in fair value of equity instruments at fair value through other comprehensive income 	17 	8
Total income and expenses that will not be reclassified to profit or loss 	17 	8
Other comprehensive income for the year, net of tax 	1 348 	1 843
Total comprehensive income for the year 	8 712 	8 415
Attributable to:
– Ordinary shareholders 	8 625 	8 353
– Preference shareholders 	91 	69
– Non-controlling interest 	(4) 	(7)
Total comprehensive income for the year 	8 712 	8 415
1 The comparative information has been restated for the initial adoption of IFRS 17 and restatements due to correction of prior period errors.
Refer to note D.1. for more detail.

-- 12 of 116 --

11
GROUP STATEMENT OF CASH FLOWS
for the year ended 30 June 2024
R million
Group
2024
Restated 1
Group
2023
Cash flows from operating activities 	2 733 	4 221
Cash generated from operations 	2 997 	1 083
Interest received 	2 325 	1 825
Interest paid 	(2 627) 	(2 245)
Taxation paid 	(1 522) 	(1 839)
Net movement in operating assets and liabilities 	1 560 	5 397
– Increase in operating assets 	(7 513) 	(5 297)
– Increase in operating liabilities 	9 073 	10 694
Cash flows from investing activities 	(1 886) 	(2 202)
Purchase of property and equipment 	(414) 	(551)
Proceeds from disposal of property and equipment 	29 	2
Purchase of intangible assets 	(1 789) 	(1 760)
Acquisition of business net of cash 	– 	(3)
Additional investment in equity-accounted investments 	(17) 	(182)
Proceeds from disposal of sale of non-current assets held for sale 	– 	184
Dividends from equity-accounted investments 	305 	108
Cash flows from financing activities 	(780) 	(1 234)
Purchase of treasury shares 	(131) 	–
Dividends paid to ordinary shareholders 	(1 178) 	–
Dividends paid to preference shareholders 	(91) 	(69)
Proceeds from borrowings 	2 005 	7 442
Repayment of borrowings 	(1 385) 	(8 607)
Net increase in cash and cash equivalents 	67 	785
Cash and cash equivalents at beginning of the year 	19 138 	17 030
Effects of exchange rate changes on cash and cash equivalents 	(240) 	1 323
Cash and cash equivalents at end of the year 	18 965 	19 138
Reconciliation to statement of financial position
Cash and cash equivalents 	18 971 	19 171
Bank overdraft included in borrowings at amortised cost 	(6) 	(33)
Cash and cash equivalents at end of the year 	18 965 	19 138
1 The comparative information has been restated for the initial adoption of IFRS 17 and restatements due to correction of prior period errors.
Refer to note D.1. for more detail.

-- 13 of 116 --

13	12	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
Attributable to equity holders of the Company 	Attributable to equity holders of the Company
R million
Share capital
and
share
premium
Perpetual
preference
share
capital
Share-based
payment
reserve
Investment
reserve1
Insurance
finance
reserve
Foreign
currency
translation
reserve
Hedging
reserve
Retained
earnings 	Total
Non-
controlling
interest
Total
Equity
Year ended 30 June 2024
At beginning of the year 	10 351 	779 	1 190 	19 	(3 184) 	6 624 	41 	33 900 	49 720 	4 	49 724
Total comprehensive income for the year 	– 	91 	– 	62 	2 451 	(1 110) 	(61) 	7 283 	8 716 	(4) 	8 712
Profit for the year 	– 	91 	– 	– 	– 	– 	– 	7 283 	7 374 	(10) 	7 364
Other comprehensive income 	– 	– 	– 	62 	2 451 	(1 110) 	(61) 	– 	1 342 	6 	1 348
Transactions with owners 	316 	(91) 	243 	– 	– 	– 	– 	(1 185) 	(717) 	– 	(717)
Share issue 	432 	– 	– 	– 	– 	– 	– 	– 	432 	– 	432
Increase in treasury shares 	(563) 	– 	– 	– 	– 	– 	– 	– 	(563) 	– 	(563)
Delivery of treasury shares 	447 	– 	(440) 	– 	– 	– 	– 	(7) 	– 	– 	–
Employee share option schemes:
– Value of employee services, net of tax 	– 	– 	683 	– 	– 	– 	– 	– 	683 	– 	683
Dividends paid to preference shareholders 	– 	(91) 	– 	– 	– 	– 	– 	– 	(91) 	– 	(91)
Dividends paid to ordinary shareholders 	– 	– 	– 	– 	– 	– 	– 	(1 178) 	(1 178) 	– 	(1 178)
At end of the year 	10 667 	779 	1 433 	81 	(733) 	5 514 	(20) 	39 998 	57 719 	– 	57 719
Year ended 30 June 2023
At beginning of the year 	10 178 	779 	798 	35 	– 	2 823 	(35) 	38 972 	53 550 	5 	53 555
– New IFRS transitional adjustments 	– 	– 	– 	(14) 	(1 194) 	– 	– 	(11 373) 	(12 581) 	– 	(12 581)
– Prior period error adjustments 	– 	– 	– 	– 	– 	42 	– 	(197) 	(155) 	– 	(155)
Restated balance at beginning of the year2 	10 178 	779 	798 	21 	(1 194) 	2 865 	(35) 	27 402 	40 814 	5 	40 819
Total comprehensive income for the year 	– 	69 	– 	(2) 	(1 990) 	3 759 	76 	6 510 	8 422 	(7) 	8 415
Profit for the year 	– 	69 	– 	– 	– 	– 	– 	6 510 	6 579 	(7) 	6 572
Other comprehensive income 	– 	– 	– 	(2) 	(1 990) 	3 759 	76 	– 	1 843 	– 	1 843
Transactions with owners 	173 	(69) 	392 	– 	– 	– 	– 	(12) 	484 	6 	490
Share issue 	514 	– 	– 	– 	– 	– 	– 	– 	514 	– 	514
Increase in treasury shares 	(514) 	– 	– 	– 	– 	– 	– 	– 	(514) 	– 	(514)
Delivery of treasury shares 	173 	– 	(161) 	– 	– 	– 	– 	(12) 	– 	– 	–
Acquisition of subsidiaries with non-controlling interest 	– 	– 	– 	– 	– 	– 	– 	– 	– 	6 	6
Employee share option schemes:
– Value of employee services, net of tax 	– 	– 	553 	– 	– 	– 	– 	– 	553 	– 	553
Dividends paid to preference shareholders 	– 	(69) 	– 	– 	– 	– 	– 	– 	(69) 	– 	(69)
At end of the year 	10 351 	779 	1 190 	19 	(3 184) 	6 624 	41 	33 900 	49 720 	4 	49 724
1 This relates to fair value adjustments on those equity instruments designated at fair value through other comprehensive income (FVOCI) and those debt
instruments measured at FVOCI, in terms of IFRS 9 Financial Instruments.
2 The comparative information has been restated for the initial adoption of IFRS 17 and restatements due to correction of prior period errors.
Refer to note D.1. for more detail.
GROUP STATEMENT OF CHANGES IN EQUITY
for the year ended 30 June 2024

-- 14 of 116 --

DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4	14
S E C T I O N A
NOTES TO THE CONDENSED
CONSOLIDATED FINANCIAL STATEMENTS
A.1 	Segment information
A.2 	Normalised profit from operations
A.3 	Earnings, headline earnings and
normalised headline earnings
A.5 	Borrowings at amortised cost
A.6 	Fair value hierarchy
A.4 	Revenue from non-insurance activities
DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4

-- 15 of 116 --

15
A.1 	SEGMENT INFORMATION
Discovery’s operating segments are reported in a manner consistent with the internal reporting provided to the chief operating
decision-maker (CODM). The CODM has been identified as the Group Executive Committee who makes strategic decisions
regarding these businesses.
An operating segment is a component of an entity:
(a) That engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses
relating to transactions with other components of the same entity.
(b) Whose operating results are regularly reviewed by the entity’s CODM to make decisions about resources to be allocated to
the segment and assess its performance; and
(c) For which discrete financial information is available.
An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations
may be operating segments before earning revenues.
Discovery will report separately information about an operating segment that meets any of the following quantitative thresholds:
(a) Its reported revenue, including both sales to external customers and intersegment sales or transfers, is 10 percent or more of
the combined revenue, internal and external, of all operating segments.
(b) The absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount, of (i) the
combined reported profit of all operating segments that did not report a loss and (ii) the combined reported loss of all
operating segments that reported a loss; and
(c) Its assets are 10 percent or more of the combined assets of all operating segments.
Operating segments that do not meet any of the quantitative thresholds may be considered reportable, and separately disclosed,
if management believes that information about the segment would be useful to users of the financial statements.
Discovery may combine information about operating segments that do not meet the quantitative thresholds with information
about other operating segments that do not meet the quantitative thresholds to produce a reportable segment only if the
operating segments have similar economic characteristics.
The Group has identified its reportable segments based on a combination of products and services offered to customers and the
location of the markets served.
A. 	Notes to the condensed consolidated financial statements
DISCLOSURE
for the year ended 30 June 2024

-- 16 of 116 --

16	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
A. 	Notes to the condensed consolidated financial statements continued
A.1 	SEGMENT INFORMATION continued
The following summary describes the operations of each of the Group’s reportable segments:
SA Health
 Administers and provides managed care services
to medical schemes in South Africa.
 Renders administration services to other business
segments within the Group.
 Together with Medical Services Organisation
International (MSO), a subsidiary company, deliver
health insurance, healthcare risk management
and third-party administration services within rest
of Africa markets.
 Offers non-medical scheme-related products such
as Gap Cover for unexpected medical costs and
Flexicare – which provides quality, affordable
access to primary healthcare for employees unable
to access medical scheme benefits.
SA Life
Offers a range of insurance and financial solutions
to the Group’s clients against the financial impact
of lifestyle-changing events in South Africa.
SA Invest
Offers, through a range of investment fund choices,
including Discovery managed unit trusts, a
comprehensive and flexible range of investment
choices. These products are sold through a number
of investment wrappers including Discovery Life
policies and are offered to individuals in South Africa.
In 2023, Invest launched Cogence with BlackRock,
which is a shared-value discretionary fund manager.
SA Insure
Offers a range of personal line insurance (motor,
building, household content and portable
possessions) to the Group’s SA clients against the
financial impact of loss or damage. The segment
also includes Discovery’s equity-accounted
interests including Cambridge Mobile Telematics
(CMT).
SA Bank
Offers retail banking solutions, including deposits
and loans and advances, to clients in the South
African market. The Bank is still in a start-up phase.
UK Health
Offers consumer-engaged private medical
insurance products to employer groups and
individuals in the UK. All contracts in this segment
are short-term insurance contracts.
UK Life
Offers a risk-only life assurance product. All
contracts in this segment are long-term assurance
contracts offered to both employer groups and
individuals in the UK.
All other
segments
Includes those segments that do not meet the quantitative thresholds set out in IFRS 8 Operating Segments and
cannot be aggregated with another reportable segment. It includes the following operating segments:
 SA Composite:
– SA Vitality, which offers health and lifestyle benefits with selected partners to the Group’s SA clients.
– SA Insure commercial: provides commercial short-term risk insurance products to the South African
market. Discovery has announced that it is exiting this business with all remaining covers to be terminated
by 31 August 2024.
– Discovery Umbrella: offers pension and provident fund solutions that encourage employees to reach their
retirement goals with unique rewards, benefits and digital engagement.
– SA Distribution: provides sales and distribution services in respect of all SA products.
– Other new group initiatives, including Vitality Green, as well as unallocated central costs.
 UK Composite:
– Includes immaterial interests in equity-accounted interests and UK Invest (closed down).
 Vitality Global Composite:
– Vitality Health International, leverages Discovery Health and Vitality’s intellectual property to create
strategic partnerships through equity-accounted interests in health insurance and health technology and
solutions businesses, which includes the equity-accounted interests in Ping An Health Insurance and
Amplify Health.
– Vitality Network, which provides a Vitality platform to international insurance businesses.
– Central costs.

-- 17 of 116 --

17
A.1 	SEGMENT INFORMATION continued
The Group Executive Committee assesses the performance of the reportable segments based on normalised profit/loss
from operations. Items which are excluded from the normalised profit/loss from operations are separately disclosed in
the segment information to reconcile to the segment results and Group income statement. The segment information is
presented on the same basis as reported to the CODM.
The segment total is then adjusted for accounting reclassifications and entries required to produce results compliant with
the IFRS Accounting Standards., i.e. IFRS reporting adjustments, these adjustments include the following:
(a) Unit trusts which the Group controls in terms of IFRS 10 Consolidated Financial Statements are consolidated into
Discovery’s results for IFRS purposes. The IFRS reporting adjustments include the effects of consolidating the unit
trusts into Discovery’s results, effectively being the income and expenses relating to units held by third parties.
(b) The effects of eliminating intercompany transactions on consolidation and normalised operating profit adjustments;
and
(c) The effects of reclassifying items to align to the IFRS Group income statement.
Effective 1 July 2023, the following changes have been made to the Segment information and the comparative information
has been restated accordingly:
1. 	The Segment information has been updated, consistent with the changes to the Group income statement, to reflect
the new presentation requirements of IFRS 17.
2. 	SA Vitality is no longer presented as a separate reportable segment. Instead, SA Vitality is presented as part of ‘All
other segments’.
3. 	Africa Health results are included in the SA Health segment as management control of this operation had been
moved from Vitality Global to Discovery Health. This was previously disclosed in ‘All other segments’ as a
new initiative.
4. 	Definitions of ’Investment income on assets backing policyholder liabilities‘ and ’Investment income earned on
shareholder investments and cash‘ have been refined in order to achieve consistent treatment across the regulated
insurance entities of the Group. Discovery includes in ’Investment income on assets backing policyholder liabilities‘ all
investment income from those assets backing client and policyholder liabilities, including those assets held for
regulatory capital requirements and related additional risk appetite margins. This refinement resulted in a
reallocation of investment income such that the component attributable to normalised profit from operations,
increased by R266 million for the year ended 30 June 2024 (30 June 2023: R186 million) while investment income
earned on shareholder investments and cash decreased by the same amount.
5. 	In line with current year management view of intra-segment transactions, SA Health has been restated to reduce
other income by R292 million, with a corresponding decrease in marketing and administration expenses. This change
in management view of SA Health segment information had no resultant change in the Group income statement.
6. 	‘All other segments’ changed its management view of which costs it considers being refund of expenses incurred
(included within marketing and administration expenses) versus whether those costs are for services provided
(included in Vitality Income). ‘All other segments’ have been accordingly adjusted to increase Vitality income with
R257 million with an equal increase in marketing and administration expenses. This change in management view of
the ‘All other segments’ had no resultant change in the Group income statement.

-- 18 of 116 --

19	18	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
R million
SA
Health
SA
Life
SA
Invest
SA
Insure
SA
Bank
UK
Health
UK
Life
All other
segments
Segment
total
IFRS
reporting
adjustments
IFRS
total
30 June 2024
Income statement
Insurance revenue 	435 	17 249 	4 360 	5 737 	– 	16 474 	6 904 	698 	51 857 	– 	51 857
– Contracts measured under the General measurement model/Variable fee approach 	– 	13 741 	4 360 	– 	– 	– 	6 904 	– 	25 005 	– 	25 005
– Contracts measured under Premium allocation approach 	435 	3 508 	– 	5 737 	– 	16 474 	– 	698 	26 852 	– 	26 852
Insurance service expenses 	(341) 	(15 235) 	(2 671) 	(5 471) 	– 	(15 456) 	(6 217) 	(754) 	(46 145) 	– 	(46 145)
– Claims and benefits 	(224) 	(12 104) 	(462) 	(3 540) 	– 	(9 562) 	(3 098) 	(472) 	(29 462) 	– 	(29 462)
– Insurance service expense and other 	(54) 	(1 124) 	(1 148) 	(1 069) 	– 	(4 127) 	(509) 	(135) 	(8 166) 	– 	(8 166)
– Insurance acquisition cash flows 	(63) 	(2 007) 	(1 061) 	(862) 	– 	(1 767) 	(2 610) 	(147) 	(8 517) 	– 	(8 517)
Insurance service result (pre-reinsurance) 	94 	2 014 	1 689 	266 	– 	1 018 	687 	(56) 	5 712 	– 	5 712
Net expenses from reinsurance contracts 	(1) 	(458) 	– 	(24) 	– 	(8) 	(408) 	(16) 	(915) 	– 	(915)
– Reinsurance expense 	(1) 	(3 692) 	– 	(474) 	– 	(8) 	(5 738) 	(275) 	(10 188) 	– 	(10 188)
– Insurance claims recovered from reinsurers 	– 	3 234 	– 	450 	– 	– 	5 330 	259 	9 273 	– 	9 273
Insurance service result 	93 	1 556 	1 689 	242 	– 	1 010 	279 	(72) 	4 797 	– 	4 797
Net financial result from insurance finance income and expense 	– 	2 674 	(9 850) 	– 	– 	– 	231 	– 	(6 945) 	(300) 	(7 245)
– Net finance income/(expense) from insurance contracts 	– 	2 869 	(9 850) 	– 	– 	– 	379 	– 	(6 602) 	(300) 	(6 902)
– Net finance expense from reinsurance contracts 	– 	(195) 	– 	– 	– 	– 	(148) 	– 	(343) 	– 	(343)
Investment income using the effective interest rate method 	– 	22 	49 	209 	– 	175 	65 	22 	542 	318 	860
Net fair value (losses)/gains on financial instruments at fair value through profit or loss 	(6) 	971 	10 098 	1 	1 	60 	– 	1 401 	12 526 	3 719 	16 245
Fair value adjustments to liabilities under investment contracts 	– 	(1) 	(738) 	– 	– 	– 	– 	(1 403) 	(2 142) 	– 	(2 142)
Third party interest: fair value adjustments to liabilities under investment contracts 	– 	– 	– 	– 	– 	– 	– 	– 	– 	(2 873) 	(2 873)
Intersegment funding 	(13) 	(169) 	169 	13 	– 	– 	– 	– 	– 	– 	–
Other gains on financial instruments 	– 	– 	– 	– 	5 	– 	– 	– 	5 	– 	5
Net insurance and investment results 	74 	5 053 	1 417 	465 	6 	1 245 	575 	(52) 	8 783 	864 	9 647
Fee income from administration businesses 	9 233 	– 	1 712 	– 	– 	54 	– 	3 094 	14 093 	– 	14 093
Vitality income 	– 	– 	– 	– 	– 	640 	264 	3 751 	4 655 	– 	4 655
Net banking fee and commission income 	– 	– 	– 	– 	1 367 	– 	– 	31 	1 398 	– 	1 398
– Banking fee and commission income 	– 	– 	– 	– 	1 872 	– 	– 	– 	1 872 	– 	1 872
– Banking fee and commission expense 	– 	– 	– 	– 	(505) 	– 	– 	31 	(474) 	– 	(474)
Net bank interest and similar income 	– 	– 	– 	– 	779 	– 	– 	– 	779 	– 	779
– Bank interest and similar income using the effective interest rate 	– 	– 	– 	– 	1 840 	– 	– 	– 	1 840 	– 	1 840
– Bank interest and similar expense using the effective interest rate 	– 	– 	– 	– 	(1 061) 	– 	– 	– 	(1 061) 	– 	(1 061)
Other income 	1 173 	3 	– 	16 	– 	42 	– 	86 	1 320 	60 	1 380
Non-insurance revenue and income 	10 406 	3 	1 712 	16 	2 146 	736 	264 	6 962 	22 245 	60 	22 305
Net income 	10 480 	5 056 	3 129 	481 	2 152 	1 981 	839 	6 910 	31 028 	924 	31 952
Non-insurance acquisition costs 	– 	– 	(880) 	– 	– 	– 	– 	(108) 	(988) 	– 	(988)
Expected credit losses 	– 	– 	– 	– 	(183) 	– 	– 	– 	(183) 	– 	(183)
Marketing and administration expenses
– depreciation and amortisation 	(171) 	– 	(17) 	(72) 	(339) 	(465) 	(49) 	(822) 	(1 935) 	(224) 	(2 159)
– derecognition of intangible assets and property and equipment 	– 	– 	– 	(16) 	– 	(1) 	– 	(38) 	(55) 	– 	(55)
– impairment of intangible assets and property and equipment 	– 	– 	– 	– 	– 	(13) 	– 	(9) 	(22) 	– 	(22)
– other expenses 	(6 337) 	(291) 	(710) 	(194) 	(2 084) 	(1 065) 	(421) 	(6 164) 	(17 266) 	(142) 	(17 408)
Share of net profits from equity-accounted investments 	– 	– 	– 	49 	– 	(2) 	6 	972 	1 025 	(50) 	975
Normalised profit/(loss) from operations 	3 972 	4 765 	1 522 	248 	(454) 	435 	375 	741 	11 604 	508 	12 112
Investment income earned on shareholder investments and cash 	120 	27 	16 	– 	– 	– 	– 	155 	318 	(318) 	–
Intercompany investment income 	– 	– 	– 	– 	– 	– 	– 	1 046 	1 046 	(1 046) 	–
Net fair value gains/(losses) on financial assets at fair value through profit or loss 	– 	87 	75 	– 	– 	– 	– 	– 	162 	(162) 	–
Gain/(loss) from dilution of equity accounted investments 	– 	– 	– 	22 	– 	– 	– 	– 	22 	– 	22
Amortisation of intangibles from business combinations 	– 	– 	– 	(49) 	– 	– 	– 	(56) 	(105) 	105 	–
Market rentals related to Head Office building adjusted for finance costs and depreciation 	– 	– 	– 	– 	– 	– 	– 	(105) 	(105) 	105 	–
Restructuring costs 	– 	– 	– 	– 	– 	– 	– 	(48) 	(48) 	48 	–
Interest expenses on borrowings and lease liabilities 	(2) 	(1) 	– 	– 	– 	(17) 	(217) 	(1 513) 	(1 750) 	(286) 	(2 036)
Intercompany finance expenses on borrowings 	(412) 	– 	– 	– 	– 	– 	(464) 	(170) 	(1 046) 	1 046 	–
Foreign exchange (losses)/gains 	(6) 	(11) 	(20) 	– 	– 	– 	– 	(50) 	(87) 	– 	(87)
Profit/(loss) before income tax 	3 672 	4 867 	1 593 	221 	(454) 	418 	(306) 	– 	10 011 	– 	10 011
Income tax expense 	(987) 	(1 314) 	(339) 	(58) 	171 	(144) 	25 	(1) 	(2 647) 	– 	(2 647)
Profit/(loss) for the year 	2 685 	3 553 	1 254 	163 	(283) 	274 	(281) 	(1) 	7 364 	– 	7 364
Profit attributable to:
– Ordinary shareholders 	2 695 	3 553 	1 254 	163 	(283) 	274 	(281) 	(92) 	7 283 	– 	7 283
– Preference shareholders 	– 	– 	– 	– 	– 	– 	– 	91 	91 	– 	91
– Non-controlling interest 	(10) 	– 	– 	– 	– 	– 	– 	(10) 	– 	(10)
A. 	Notes to the condensed consolidated financial statements continued
A.1 	SEGMENT INFORMATION continued

-- 19 of 116 --

21	20	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
A. 	Notes to the condensed consolidated financial statements continued
A.1 	SEGMENT INFORMATION continued
R million
SA
Health
SA
Life
SA
Invest
SA
Insure
SA
Bank
UK
Health
UK
Life
All other
segments
Segment
total
IFRS
reporting
adjustments
IFRS
total
Restated
30 June 2023
Income statement
Insurance revenue 	303 	16 758 	3 231 	5 176 	– 	13 670 	5 580 	536 	45 254 	– 	45 254
– Contracts measured under the General measurement model/Variable fee approach 	– 	13 464 	3 231 	– 	– 	– 	5 580 	– 	22 275 	– 	22 275
– Contracts measured under Premium allocation approach 	303 	3 294 	– 	5 176 	– 	13 670 	– 	536 	22 979 	– 	22 979
Insurance service expenses 	(234) 	(14 699) 	(2 050) 	(4 893) 	– 	(12 178) 	(5 112) 	(660) 	(39 826) 	– 	(39 826)
– Claims and benefits 	(152) 	(11 282) 	(331) 	(3 246) 	– 	(7 341) 	(2 316) 	(410) 	(25 078) 	– 	(25 078)
– Insurance service expense and other 	(47) 	(1 632) 	(957) 	(867) 	– 	(3 435) 	(748) 	(150) 	(7 836) 	– 	(7 836)
– Insurance acquisition cash flows 	(35) 	(1 785) 	(762) 	(780) 	– 	(1 402) 	(2 048) 	(100) 	(6 912) 	– 	(6 912)
Insurance service result (pre-reinsurance) 	69 	2 059 	1 181 	283 	– 	1 492 	468 	(124) 	5 428 	– 	5 428
Net (expenses)/income from reinsurance contracts 	– 	(225) 	– 	(70) 	– 	(9) 	154 	24 	(126) 	– 	(126)
– Reinsurance expense 	(1) 	(3 549) 	– 	(413) 	– 	(1 846) 	(3 482) 	(222) 	(9 513) 	– 	(9 513)
– Insurance claims recovered from reinsurers 	1 	3 324 	– 	343 	– 	1 837 	3 636 	246 	9 387 	9 387
Insurance service result 	69 	1 834 	1 181 	213 	– 	1 483 	622 	(100) 	5 302 	– 	5 302
Net financial result from insurance finance income and expense 	– 	2 225 	(9 815) 	– 	– 	– 	(26) 	– 	(7 616) 	221 	(7 395)
– Net finance income/(expense) from insurance contracts 	– 	2 450 	(9 815) 	– 	– 	– 	55 	– 	(7 310) 	221 	(7 089)
– Net finance expense from reinsurance contracts 	– 	(225) 	– 	– 	– 	– 	(81) 	– 	(306) 	– 	(306)
Investment income using the effective interest rate method 	– 	28 	51 	145 	– 	90 	71 	15 	400 	216 	616
Net fair value (losses)/gains on financial instruments at fair value through profit or loss 	(6) 	760 	10 904 	– 	– 	– 	– 	1 788 	13 446 	3 786 	17 232
Fair value adjustments to liabilities under investment contracts 	– 	(3) 	(1 326) 	– 	– 	– 	– 	(1 770) 	(3 099) 	– 	(3 099)
Third party interest: fair value adjustments to liabilities under investment contracts 	– 	– 	– 	– 	– 	– 	– 	– 	– 	(2 978) 	(2 978)
Intersegment funding 	– 	(126) 	126 	– 	– 	– 	– 	– 	– 	– 	–
Net insurance and investment results 	63 	4 718 	1 121 	358 	– 	1 573 	667 	(67) 	8 433 	1 245 	9 678
Fee income from administration businesses 	8 575 	– 	1 566 	17 	– 	46 	– 	3 020 	13 224 	– 	13 224
Vitality income 	– 	– 	– 	– 	– 	462 	238 	3 448 	4 148 	(257) 	3 891
Net banking fee and commission income 	– 	– 	– 	– 	943 	– 	– 	22 	965 	– 	965
– Banking fee and commission income 	– 	– 	– 	– 	1 292 	– 	– 	– 	1 292 	– 	1 292
– Banking fee and commission expense 	– 	– 	– 	– 	(349) 	– 	– 	22 	(327) 	– 	(327)
Net bank interest and similar income 	– 	– 	– 	– 	574 	– 	– 	– 	574 	– 	574
– Bank interest and similar income using the effective interest rate 	– 	– 	– 	– 	1 318 	– 	– 	– 	1 318 	– 	1 318
– Bank interest and similar expense using the effective interest rate 	– 	– 	– 	– 	(744) 	– 	– 	– 	(744) 	– 	(744)
Other income 	1 089 	3 	– 	14 	– 	48 	– 	85 	1 239 	305 	1 544
Non-insurance revenue and income 	9 664 	3 	1 566 	31 	1 517 	556 	238 	6 575 	20 150 	48 	20 198
Net income 	9 727 	4 721 	2 687 	389 	1 517 	2 129 	905 	6 508 	28 583 	1 293 	29 876
Non-insurance acquisition costs 	– 	– 	(780) 	– 	– 	– 	– 	(100) 	(880) 	– 	(880)
Expected credit losses 	– 	– 	– 	– 	(139) 	– 	– 	– 	(139) 	– 	(139)
Marketing and administration expenses
– depreciation and amortisation 	(144) 	– 	(12) 	(64) 	(314) 	(420) 	(49) 	(799) 	(1 802) 	(168) 	(1 970)
– derecognition of intangible assets and property and equipment 	(4) 	– 	– 	(3) 	– 	(241) 	(19) 	(57) 	(324) 	– 	(324)
– impairment of intangible assets and property and equipment 	– 	– 	– 	– 	– 	(45) 	– 	– 	(45) 	– 	(45)
– other expenses 	(5 881) 	(346) 	(622) 	(233) 	(1 831) 	(790) 	(371) 	(5 973) 	(16 047) 	(154) 	(16 201)
Share of net profits from equity-accounted investments 	– 	– 	– 	(16) 	– 	1 	2 	584 	571 	(46) 	525
Normalised profit/(loss) from operations 	3 698 	4 375 	1 273 	73 	(767) 	634 	468 	163 	9 917 	925 	10 842
Fair value losses on VitalityLife interest rate derivatives 	– 	– 	– 	– 	– 	– 	516 	– 	516 	(516) 	–
Investment income earned on shareholder investments and cash 	92 	– 	20 	– 	– 	– 	– 	104 	216 	(216) 	–
Intercompany investment income 	– 	– 	– 	– 	– 	– 	– 	1 184 	1 184 	(1 184) 	–
Net fair value gains/(losses) on financial assets at fair value through profit or loss 	– 	45 	95 	– 	– 	– 	– 	(2) 	138 	(138) 	–
Gain/(loss) from dilution of equity accounted investments 	– 	– 	– 	(5) 	– 	– 	– 	– 	(5) 	– 	(5)
Impairment of goodwill 	– 	– 	– 	– 	– 	– 	– 	(9) 	(9) 	– 	(9)
Amortisation of intangibles from business combinations 	– 	– 	– 	(46) 	– 	– 	– 	(56) 	(102) 	102 	–
Market rentals related to Head Office building adjusted for finance costs and depreciation 	– 	– 	– 	– 	– 	– 	– 	(134) 	(134) 	134 	–
Interest expenses on borrowings and lease liabilities 	(2) 	(1) 	– 	– 	– 	(8) 	(195) 	(1 422) 	(1 628) 	(291) 	(1 919)
Intercompany finance expenses on borrowings 	(348) 	– 	– 	– 	– 	– 	(316) 	(520) 	(1 184) 	1 184 	–
Foreign exchange (losses)/gains 	(4) 	33 	36 	– 	– 	1 	– 	83 	149 	– 	149
Profit/(loss) before income tax 	3 436 	4 452 	1 424 	22 	(767) 	627 	473 	(609) 	9 058 	– 	9 058
Income tax expense 	(941) 	(1 192) 	(377) 	(24) 	226 	(141) 	(65) 	28 	(2 486) 	– 	(2 486)
Profit/(loss) for the year 	2 495 	3 260 	1 047 	(2) 	(541) 	486 	408 	(581) 	6 572 	– 	6 572
Profit attributable to:
– Ordinary shareholders 	2 502 	3 260 	1 047 	(2) 	(541) 	486 	408 	(650) 	6 510 	– 	6 510
– Preference shareholders 	– 	– 	– 	– 	– 	– 	– 	69 	69 	– 	69
– Non-controlling interest 	(7) 	– 	– 	– 	– 	– 	– 	– 	(7) 	– 	(7)

-- 20 of 116 --

A.3 	EARNINGS, HEADLINE EARNINGS AND NORMALISED HEADLINE EARNINGS
22	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
A.2 	NORMALISED PROFIT FROM OPERATIONS
The following table shows the main components of the normalised profit from operations for the year ended 30 June 2024:
A. 	Notes to the condensed consolidated financial statements continued
R million
Group
2024
Restated
Group
2023
%
Change
Discovery Health 	3 972 	3 698 	7
Discovery Life 	4 765 	4 375 	9
Discovery Invest 	1 522 	1 273 	20
Discovery Insure – Personal lines 	248 	73 	>100
Discovery Bank 	(454) 	(767) 	(41)
Other initiatives and central costs* 	(336) 	(281) 	20
Normalised profit from SA composite 	9 717 	8 371 	16
VitalityHealth1 	435 	823 	(47)
VitalityLife 	375 	468 	(20)
Closure costs of VitalityInvest* and VitalityCar in rundown2 	(75) 	(455) 	(84)
Other initiatives and central costs* 	(88) 	(80) 	10
Normalised profit from UK Composite 	647 	756 	(14)
Vitality Health International – Ping An Health Insurance* 	1 124 	609 	85
Vitality Health International – Other* 	(386) 	(195) 	98
Vitality Network* 	533 	411 	30
Other initiatives and central costs* 	(31) 	(35) 	(11)
Normalised profit from Vitality Global composite 	1 240 	790 	57
Normalised profit from operations 	11 604 	9 917 	17
* Presented in ‘All other segments’ on the Segment information disclosure note in section 1.1.
1 For the year ended 30 June 2023, the difference between VitalityHealth normalised profit compared to that shown in the segment information is the
accelerated write-off of VitalityCar’s capitalised systems and intangible assets, with a pre-tax impact of R189 million. The write-off is disclosed as described
in footnote 2 below.
2 Closure costs of VitalityInvest and VitalityCar are separately presented as in run down and include:
– VitalityInvest R75 million (2023: R266 million)
– VitalityCar nil (2023: R189 million)
R million
Group
2024
Restated
Group
20231
Number of shares used in calculation
Weighted number of shares in issue ('000) 	661 071 	658 045
Diluted weighted number of shares ('000) 	665 016 	661 328
Earnings per share (cents):
– basic 	1 082.7 	972.6
– diluted 	1 076.3 	967.8
Headline earnings per share (cents):
– basic 	1 089.4 	1 021.5
– diluted 	1 083.0 	1 016.4
Normalised headline earnings per share (cents)1:
– basic 	1 108.6 	972.8
– diluted 	1 102.1 	967.9
Weighted average number of ordinary shares
Issued ordinary shares at 1 July 	658 424 	656 957
Effect of share options exercised and vesting of share awards 	2 647 	1 088
Weighted-average number of ordinary shares at 30 June (basic) 	661 071 	658 045
Effect of share options exercised and vesting of share awards 	3 945 	3 283
Weighted-average number of ordinary shares at 30 June (diluted) 	665 016 	661 328
EARNINGS RECONCILIATION
Profit attributable to the ordinary shareholders 	7 283 	6 510
Adjusted for:
– Profit attributable to non-forfeitable dividend share plan 	(125) 	(112)
Basic earnings attributable to the ordinary shareholders 	7 158 	6 398
1 The comparative information has been for the initial adoption of IFRS 17 and restatements due to correction of prior period errors.
Refer to note D.1. for more detail.

-- 21 of 116 --

A.3 	EARNINGS, HEADLINE EARNINGS AND NORMALISED HEADLINE EARNINGS
continued
HEADLINE EARNINGS RECONCILIATION
Headline earnings per share is disclosed per the JSE Listings Requirements and is calculated in accordance with the circular titled
Headline Earnings issued by SAICA, as amended from time to time. Headline earnings per share is based on the net profit after
tax attributable to ordinary shareholders adjusted for items of a capital nature and the weighted average number of ordinary
shares in issue.
R million
Group 2024 	Restated Group 2023
Gross 	Tax 	Net 	Gross 	Tax 	Net
Basic earnings attributable to
the ordinary shareholders 	7 158 	6 398
Adjusted for:
IFRS 3: Goodwill impairment 	– 	– 	– 	9 	– 	9
IAS 38: Impairment of intangibles 	8 	(2) 	6 	– 	– 	–
IAS 16: (Gain)/loss on disposal
of property and equipment 	(1) 	– 	(1) 	8 	(1) 	7
IAS 16: Loss on derecognition
of property and equipment 	10 	(3) 	7 	34 	(7) 	27
IAS 36: Impairment of property
and equipment 	14 	– 	14 	45 	– 	45
IAS 38: Gains/losses on derecognition
of intangible assets 	45 	(10) 	35 	290 	(60) 	230
IAS 28: (Gains)/losses on the dilution
and disposal of equity-accounted
investments 	(22) 	5 	(17) 	5 	(1) 	4
Headline earnings 	7 202 	6 720
NORMALISED HEADLINE EARNINGS RECONCILIATION
Normalised headline earnings is calculated per Discovery’s policy as set out in the Accounting Policies in note E.2. Management
considers that Normalised headline earnings is an appropriate alternative performance measure to enhance the comparability
and understanding of the financial performance of the Group.
R million
Group 2024 	Restated Group 2023
Gross 	Tax 	Net 	Gross 	Tax 	Net
Headline earnings 	7 202 	6 720
Adjusted for:
– Gain on fair value changes in
respect of interest rate
derivatives in VitalityLife1 	– 	– 	– 	(516) 	106 	(410)
– Amortisation of intangible
assets arising from business
combinations 	56 	(15) 	41 	56 	(12) 	44
– Restructuring costs 	48 	(11) 	37 	– 	– 	–
Adjustments attributable to
equity-accounted investments:
– Amortisation of intangible assets
arising from business
combinations 	– 	– 	49 	– 	– 	46
Normalised headline earnings
(basic and diluted) 	7 329 	6 400
1 30 June 2023 has been corrected from the previously published information in the unaudited interim results for the six months ended 31 December 2023.
23

-- 22 of 116 --

24	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
A.4 	REVENUE FROM NON-INSURANCE ACTIVITIES
A.5 	BORROWINGS AT AMORTISED COST
R million 	Reference
Group
2024
Group
2023
Borrowing from banks and listed debt 	17 511 	16 328
– UK borrowings 	A.5.1. 	3 549 	3 682
– South African borrowings 	A.5.2. 	13 962 	12 646
Bank overdraft in underlying liabilities of consolidated Unit Trusts 	6 	33
Lease liabilities 	4 145 	4 225
– 1 Discovery Place (1 DP) 	3 246 	3 326
– Other lease liabilities 	899 	899
Total borrowings at amortised cost 	21 662 	20 586
A.5.1 UK borrowings facilities
UK BORROWINGS
Carrying value
million
Facility amount
GBP million 	Variable rate
Capital repayment
and maturity date
Group 2024 	Group 2023
GBP 	R 	GBP 	R
25 	SONIA + 275bps1 	At maturity – 23 December 2025 	25 	589 	25 	597
75 	SONIA + 300bps1 	At maturity – 21 December 2025 	74 	1 714 	75 	1 793
55 	SONIA + 285bps1 	At maturity – 12 December 2025 	54 	1 246 	54 	1 292
153 	3 549 	154 	3 682
1 Interest payable quarterly in arrears.
Total finance costs in respect of the UK borrowings for the year ended 30 June 2024 was £13 million (R306 million)
(2023: £10.1 million (R216 million)).
Discovery Group’s Revenue includes ‘Fee income from administration business’, ‘Vitality income’ and ‘Banking fee and
commission income’.
The split of revenue per geographical region and reportable segment can be viewed in Note A.1.1 Segmental information.
The split of revenue according to the timing of satisfaction of performance obligation, i.e. ‘over time’ or a ‘point-in-time’ is as
follows:
R million
Group
2024
Restated1
Group
2023
Fee income from administration business 	14 093 	13 224
– Over time 	14 070 	13 197
– Point-in-time 	23 	27
Vitality income 	4 655 	3 891
– Over time 	3 178 	2 660
– Point-in-time 	1 477 	1 231
Banking fee and commission income 	1 872 	1 292
– Over time 	836 	687
– Point-in-time 	1 036 	605
1 The comparative information has been restated to include Intellectual Property fees previously separately presented, within Fee income from administration
business. In addition, some changes were affected with specified cash flows as a result of adoption of IFRS 17.
A. 	Notes to the condensed consolidated financial statements continued

-- 23 of 116 --

25
A.5 	BORROWINGS AT AMORTISED COST continued
A.5.2 South African borrowings
CREDIT RATING
In December 2023 Moody’s Investors Service (“Moody’s”) reaffirmed Discovery Limited’s global-scale long-term issuer rating of Ba3
and the national-scale long-term issuer rating at A1.za. The outlook remained unchanged as stable, aligned to the outlook of
the country.
Total finance costs in respect of South African borrowings and related hedges for the year ended 30 June 2024 was
R1 226 million (2023: R1 225 million).
DISCOVERY LIMITED
Carrying value
R million
Facility amount
R million 	Variable rate
Interest
per annum
Capital repayment
and maturity date
Group
2024
Group
2023
Listed DMTN 4
500 	3-month Jibar + 205bps 	4.25%1,3 	At maturity – 21 August 2023 	– 	505
200 	– 	10.46%2 	At maturity – 21 November 2024 	202 	202
800 	3-month Jibar + 191bps 	8.40%1,3 	At maturity – 21 November 2024 	809 	808
1 200 	3-month Jibar + 191bps 	7.30%1,3 	At maturity – 21 November 2024 	1 215 	1 218
700 	3-month Jibar + 180bps 	8.49% 1,3 	At maturity – 21 August 2026 	707 	707
300 	3-month Jibar + 180bps 	7.60%1,3 	At maturity – 21 August 2026 	304 	304
792 	3-month Jibar + 173bps 	7.98%1,3 	At maturity – 21 May 2027 	800 	799
226 	3-month Jibar + 180bps 	7.98%1,3 	At maturity – 21 May 2029 	228 	228
576 	3-month Jibar + 140bps 	– 3 	At maturity – 21 November 2027 	582 	–
924 	3-month Jibar + 159bps 	– 3 	At maturity – 21 November 2029 	935 	–
Unlisted DMTN5
2 500 	– 	9.62%3 	At maturity – 22 February 2025 	2 525 	2 522
1 650 	– 	9.55%3 	At maturity – 10 March 2026 	1 659 	1 658
Other
1 000 	3-month Jibar + 190bps 	8.38%1,3 	At maturity – 2 March 2028 	999 	997
500 	3-month Jibar + 190bps 	– 3 	At maturity – 2 March 2028 	499 	–
Total Discovery Limited Borrowings 	11 464 	9 948
1 The interest rate has been fixed through interest rate swaps.
2 Interest is payable semi-annually in arrears.
3 Interest payable quarterly in arrears.
4 DMTN refers to the R10 billion Discovery Domestic Medium Term Note (DMTN) program registered in 2017.
5 During the financial year ended 30 June 2020, Discovery Limited refinanced R3.6 billion bank syndicated loans through the issue of unlisted DMTN notes.
The notes, although underwritten by a bank until maturity, are structured to enable short-term issuances into the commercial paper market on an ongoing
basis.
DISCOVERY CENTRAL SERVICES
Carrying value
R million
Facility amount
R million
Interest rate
per annum
Capital repayment and
maturity date
Group
2024
Group
2023
1 400 	9.97%1,2 	At maturity – 20 December 2028 	1 407 	1 408
650 	11.56%3 	At maturity – 29 October 2027 	396 	445
691 	3-month Jibar + 190bps1 	At maturity – 30 June 2027 	695 	694
1 500 	3-month Jibar + 145bps1 	At maturity – 8 June 2024 	– 	151
750 	Prime rate less 145bps4 	At maturity – 364-day notice 	– 	–
Total Discovery Central Services Borrowings 	2 498 	2 698
1 Interest payable quarterly in arrears.
2 The interest rate on the facility has changed from a floating interest rate of 3-month Jibar + 205bps to a fixed interest rate of 9.97% due to refinancing of
the loan during the current financial year.
3 Instalments of interest and capital is monthly.
4 The revolving credit facility is a committed 364-day notice facility granted in November 2023. A commitment fee of 0.60% per annum is paid monthly in
arrears on the undrawn portion. This facility was not drawn down during the financial year. Subsequent to year-end, the facility was reduced to
R500 million.

-- 24 of 116 --

26	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
A. 	Notes to the condensed consolidated financial statements continued
A.6 	FAIR VALUE HIERARCHY
R million 	Level 1 	Level 2 	Level 3 	Total
30 June 2024
Financial assets
Financial instruments mandatorily at fair value through
profit or loss:
– Equity portfolios 	52 145 	8 089 	16 	60 250
– Debt portfolios 	45 473 	1 626 	– 	47 099
– Money market portfolios 	– 	15 786 	– 	15 786
– Multi-asset portfolios 	– 	42 536 	– 	42 536
Derivative financial instruments at fair value:
– used as cash flow hedges 	– 	14 	– 	14
– not designated as hedging instruments 	– 	29 	– 	29
Total financial assets 	97 618 	68 080 	16 	165 714
Non-financial assets
Non-current asset held for sale1 	– 	– 	136 	136
Total financial assets 	– 	– 	136 	136
Financial liabilities
Third-party interest in consolidated funds 	– 	31 456 	– 	31 456
Investment contracts at fair value through profit or loss 	– 	25 710 	– 	25 710
Derivative financial instruments at fair value:
– used as cash flow hedges 	– 	24 	– 	24
– not designated as hedging instruments 	– 	7 	– 	7
Total financial liabilities 	– 	57 197 	– 	57 197
1 The fair value was determined from an agreed sales price between unrelated parties.
R million 	Level 1 	Level 2 	Level 3 	Total
30 June 2023 Restated
Financial assets
Financial instruments mandatorily at fair value through
profit or loss:
– Equity portfolios 	50 204 	6 321 	– 	56 525
– Debt portfolios 	40 852 	1 721 	– 	42 573
– Money market portfolios 	– 	19 745 	– 	19 745
– Multi-asset portfolios 	– 	33 672 	– 	33 672
Derivative financial instruments at fair value:
– used as cash flow hedges 	– 	59 	– 	59
– not designated as hedging instruments 	– 	60 	– 	60
Total financial assets 	91 056 	61 578 	– 	152 634
Financial liabilities
Third-party interest in consolidated funds 	– 	28 346 	– 	28 346
Investment contracts at fair value through profit or loss 	– 	28 903 	– 	28 903
Derivative financial instruments at fair value:
– used as cash flow hedges 	– 	1 	– 	1
– not designated as hedging instruments 	– 	19 	– 	19
Total financial liabilities 	– 	57 269 	– 	57 269
The Group’s financial instruments measured at fair value have been disclosed using a fair value hierarchy. The hierarchy has
three levels that reflect the significance of the inputs used in measuring fair value. These are as follows:
Level 1: includes financial instruments that are measured using unadjusted, quoted prices in an active market for identical financial
instruments. Quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service
or regulatory agency and those prices represent actual and regularly occurring market transactions on an arm’s length basis.
Level 2: includes financial instruments that are valued using techniques based significantly on observable market data.
Instruments in this category are valued using:
(a) quoted prices for similar instruments or identical instruments in markets which are not considered to be active; or
(b) valuation techniques where all the inputs that have a significant effect on the valuation are directly or indirectly based on
observable market data.
Level 3: includes financial instruments that are valued using valuation techniques that incorporate information other than
observable market data and where at least one input (which could have a significant effect on the instruments’ valuation) cannot
be based on observable market data.
There were no transfers between level 1 and 2 during the current financial period.

-- 25 of 116 --

27
A.6 	FAIR VALUE HIERARCHY continued
Specific valuation techniques used to value financial instruments in level 2
If a quoted market price is not available on a recognised stock exchange or from a broker for non-exchange traded financial
instruments, the fair value of the instrument is estimated by the asset managers, using valuation techniques including the use
of recent arm’s length market transactions, reference to the current fair value of another instrument that is substantially the
same, discounted cash flow techniques, option pricing models or other valuation techniques that provide a reliable estimate of
prices obtained in actual market transactions.
Valuation techniques used in determining the fair value of assets and liabilities:
Instruments 	Valuation technique
Main inputs and assumptions
for level 2 fair value hierarchy
items
Within equity
portfolios,
Equity-linked
notes
The calculation of the daily value of the equity-linked investments is
made by the provider of the note. Discovery has procedures in place
to ensure that these prices are correct. Aside from the daily
reasonableness checks versus similar funds and movement since
the prior day’s price, the fund values are calculated with reference
to a specific formula or index, disclosed to the policyholders, which
is recalculated by Discovery in order to check if the price provided
by the provider is correct.
– discount rate
– spot price of the underlying
Debt portfolios
and Money
market
instruments
Money market instruments are valued by discounting the future
cash flows using a risk-adjusted discount rate.
– discount rate, credit spread
Multi-assets 	The fair values of third-party financial liabilities arising on the
consolidation of mutual funds are determined using the quoted put
(exit) price provided by the fund manager and discounted for the
applicable notice period. The fair value of a financial liability with a
demand feature is not less than the amount payable on demand,
discounted from the first date on which the amount could be
required to be paid.
– discount rate
Third-party
interest in
consolidated
funds and
Investment
contracts at fair
value through
profit or loss
Unit-linked policies: assets which are linked to the investment
contract liabilities are accounted for by the Group. The investment
contract obliges the Group to use these assets to settle these
liabilities. Therefore, the fair value of third-party interest in
consolidated funds and investment contract liabilities is determined
with reference to the fair value of the underlying assets (i.e. amount
payable on surrender of the policies).
Annuity: certain discounted cash flow models are used to determine
the fair value of the stream of future payments.
– discount rate
– spot price of the underlying
Derivatives 	Standard derivative contracts are valued using market accepted
models and quoted parameter inputs. More complex derivative
contracts are modelled using more sophisticated modelling
techniques applicable to the instrument. Techniques include:
 Discounted cash flow model
 Black-Scholes model
 Combination technique models
– discount rate
– spot price of the underlying
– correlation factors
– volatilities
– earnings yield
– valuation multiples

-- 26 of 116 --

DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4	28
S E C T I O N B
OTHER SIGNIFICANT ITEMS
IN THESE RESULTS
B.1 	Exchange rates to the South African Rand used in the
preparation of these results
B.2 	Capital management, financial leverage ratio and
covenants
B.3 	Impact of actuarial basis changes within the SA Life
and UK Life operating segments
B.6 	Consolidation of Discovery Unit Trusts
B.5 	Cash and cash equivalents
B.7 	Material transactions with related parties
B.8 	Major customers and other Discovery entities not part
of Discovery Group
B.10 	Events after reporting date and dividend declaration
in respect of the year ended 30 June 2024
B.9 	Changes in directorate
B.4 	Change in hedge strategy – VitalityLife business
DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4

-- 27 of 116 --

29
B.1 	EXCHANGE RATES TO THE SOUTH AFRICAN RAND USED IN THE PREPARATION
OF THESE RESULTS
Closing rates 	Average rates
Exchange rate to SA rand
June
2024
June
2023
June
2024
June
2023
US dollar 	18.26 	18.87 	18.71 	17.79
Pound sterling 	23.07 	23.99 	23.55 	21.43
Chinese Yuan 	2.51 	2.60 	2.59 	2.55
B.2 	CAPITAL MANAGEMENT, FINANCIAL LEVERAGE RATIO AND COVENANTS
The Group’s capital is defined as capital and reserves attributable to shareholders, as presented in the Group statement of
financial position. The Group’s objectives when managing capital are:
 To comply with the statutory capital requirements required by the regulators of the insurance markets in which the Group
operates;
 To maintain a capital buffer in excess of the statutory capital requirements in order to reduce the risk of breaching the
statutory requirements in the event of deviations from the main assumptions affecting the Group’s insurance businesses;
 To ensure that sufficient capital is available to fund the Group’s working capital and strategic capital requirements;
 To achieve an optimal and efficient capital funding profile; and
 To consider capital management needs both in the short term and over a five-year planning horizon.
Discovery has a Finance and Capital Committee that ensures alignment in strategic financial management between the centre and
subsidiaries within South Africa, UK and US. The committee is the governance body for all capital allocation activities across the
Group ultimately overseen by the Board.
A range of capital raising options are available to manage the capital structure of the Group, which includes the issue of new
shares, debt, financial reinsurance arrangements and other hybrid instruments.
Financial leverage ratio
As part of the capital management process, the Group monitors its capital structure utilising various measures, one of which is
the Financial Leverage Ratio (FLR). This ratio is calculated as total debt 1 divided by total debt plus total equity. The Group’s strategy
is to maintain a prudent FLR of 28.0% per the Group Risk Appetite statement. However, the 28.0% measure is merely a risk
appetite indicator and does not necessarily indicate any form of a breach in terms of regulatory or covenant restrictions.
The table below summarises the FLR position as at the end of the reporting period. With the adoption of IFRS 17, a significant
amount has been reallocated to contractual service margin (CSM) and risk adjustment. In line with developing market practice this
CSM balance, which is available for release to profit in future years or to absorb any adverse changes, is taken into account in the
calculation of the FLR. While some insurers recognise more than 50%, it appears that most ratings agencies apply the inclusion of
at least 50% of the CSM into the equity denominator. The current limit of 28% remains conservative.
As a risk mitigation measure and to avail itself of favourable debt markets, Discovery raised R1.5 billion domestic medium term
notes in May 2024 as an early refinance mechanism in anticipation of the DMTN maturing in November 2024. The proceeds are
currently held in cash and will be applied to maturing debt in November 2024. This caused a temporary increase in the FLR of 1.1%.
R million
June
2024
June
2023
restated
1 July
2022
restated
– Borrowings at amortised cost1 	17 517 	16 361 	16 464
– Guaranteed deposit facilities 	– 	– 	300
Total debt and guarantees 1 	17 517 	16 361 	16 764
Total equity 	57 719 	49 724 	40 819
Total Contractual Service Margin (CSM) 2 	25 070 	28 119 	25 956
Financial leverage ratio % (50% CSM factored in)3 	20.0% 	20.4% 	23.8%
1 Excluding all lease liabilities under IFRS 16 Leases of R4 145 million (30 June 2023: R4 225 million).
2 CSM is net of reinsurance and net of tax.
3 FLR restated for prior periods due to recognition of 50% of CSM net of reinsurance and net of tax into the equity denominator.
The FLR at 30 June 2024 is within Discovery’s risk appetite.
B. 	Other significant items in these results

-- 28 of 116 --

30	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
B. 	Other significant items in these results continued
B.2 	CAPITAL MANAGEMENT, FINANCIAL LEVERAGE RATIO AND COVENANTS
continued
Debt covenants
The following are the key debt covenant ratios and their proximity to minimum requirements as per the contractual financial
covenants.
Debt covenant 	Minimum requirement
June
2024
June
2023
Restated
Group debt1 to EBITDA Ratio2 	Less than 2.5 times 	1.4 times 	1.4 times
Group financial indebtedness to embedded value
– Group financial indebtedness is as per Group
debt in the calculation above
Less than 30% of Group
Embedded value
16.7% 	17.6%
Discovery Life Statutory Capital Requirement
(SCR)
SCR cover must be more than
1.1 times
1.8 times 	1.9 times
Group embedded value 	Greater than R30 billion 	R110 354 million 	R98 176 million
New business embedded value must not
be negative
Positive value of new business for
3 consecutive 6-month periods
June 2024:
R1 148 million
December 2023:
R684 million
June 2023:
R500 million
June 2023:
R500 million
December 2022:
R940 million
June 2022:
R1 124 million
1 Group debt is contractually defined and means the aggregate consolidated financial indebtedness of the Group and excludes items such as the
1 Discovery Place (Discovery head office building in Sandton, South Africa) lease and includes guarantees issued to third parties.
2 EBITDA is contractually defined and specifically includes items such as dividends from associates, rental paid on 1DP and excludes items deemed
extraordinary and specified Financial Reinsurance (FinRe) arrangements.

-- 29 of 116 --

31
B.3 	IMPACT OF ACTUARIAL BASIS CHANGES WITHIN THE SA LIFE AND UK LIFE
OPERATING SEGMENTS
The actuarial bases of Discovery Life and VitalityLife are actively maintained to ensure that the most up to date view of best
estimate expectations of the future are accurately reflected.
 Financial risk assumptions are updated based on the current market prices as at the reporting date. Following the adoption
of IFRS 17 and given the election allowed for in the standard, the impact of changes to these assumptions are now accounted
through Other Comprehensive Income (OCI).
 Non-economic assumptions and estimates may also be revised in accordance with developing experience and expectations of
future developments. Such basis changes are typically based on longer term observations of underlying trends and experience.
Both Discovery Life and VitalityLife concluded a comprehensive review of its estimates during the year ended 30 June 2024 taking
into account the external economic environment, emerging experience, expected long term experience, management actions in
response to emerging experience and additional learnings from its fully retrospective IFRS 17 transition.
Discovery Life
Emerging negative policy alterations experience has resulted in various management actions being implemented by business as
well as strengthening the short-term and long- term assumptions. A review of long-term claims estimates was also undertaken
including consideration being given to emerging morbidity claims experience. Expense estimates were also updated to allow for
the restructuring of the Corporate and Employee Benefits division. These changes, including experience variances in the period,
have contributed to a reduction in the Contractual Service Margin (CSM) balance of cR5.4 billion (net of reinsurance) with an
offsetting improvement in OCI balances of cR2.3 billion. The improvement in the negative OCI balance over the period is a result
of the impact of the basis changes measured at initial recognition rates which are significantly larger compared to the impact
measured on current discount rates. Changes in estimates in aggregate did not materially impact earnings for the year. Whilst the
reduced CSM balance negatively impacted earnings through a lower CSM release in the year, this was largely offset by a reduction
in the loss component on onerous groups as a result of changes in estimates and actions implemented.
When measured on initial recognition rates, the impact of the variances and basis changes taken through CSM is significantly
larger than when discounted at the risk discount rate which is used in the Embedded Value (EV) calculation, noting further that
the EV impact is net of tax and has its tail curtailed at 40 years. This, combined with a positive basis change affecting the VIF in
isolation, leads to a positive impact on EV relative to IFRS 17.
VitalityLife
VitalityLife’s underlying performance was robust with new business value generation improving in the second half of the year. In
light of continued lower lapses than expected for a block of whole of life business within the Prudential Assurance Company (PAC)
book, VitalityLife strengthened the lapse basis resulting in a negative impact on earnings of £12.5 million (R294 million) for the
period. While VitalityLife has contractual service (CSM) and risk adjustment (RA) margins in excess of £400 million, these margins
are not applicable to this particular cohort resulting in the basis change directly impacting in period earnings. This is not expected
to recur.
The reserves are measured using the UK swap curve with impacts arising from changes in the swap curve being reflected in OCI.
In the period, the UK swap curve reduced at early duration and increased at long durations. This resulted in a favourable impact
of £48.8 million (R1 149 million) reflected in OCI for the year.
Higher than expected inflation in the UK resulted in the level of policyholder premiums increasing by more than expected where
policies have an indexation feature. Whilst the customers’ future benefits also increase in value, there is an overall positive impact
on future profitability with £4.8 million (R113 million) reflected in OCI for the year.
A decrease in discount rates has no impact on the CSM and does not directly impact the Group income statement given the
election of OCI. There is however a beneficial impact on the VIF leading to a positive impact in the EV calculation.
B.4 	CHANGE IN HEDGE STRATEGY – VITALITYLIFE BUSINESS
The introduction of IFRS 17 enabled VitalityLife to use the OCI election to remove the volatility of reported financial performance
arising from changes in economic assumptions and present a more reflective performance of the business over the long term.
Given this change, several of the VitalityLife swaps were exited shortly before the end of the year ended 30 June 2023. In addition,
the swaption purchased in June 2022 was sold in June 2023 as the business is now able to manage any remaining risk within its
risk appetite without incurring the ongoing costs of purchasing swaptions. The net fair value gain relating to these derivatives for
the comparative year ended 30 June 2023 of £19.1 million, net of tax, (R410 million) was excluded in the presentation of
normalised profit from operations measure and other normalised measures. VitalityLife continues to hold certain interest rate
swaps and total returns swaps (“TRS”) to manage the interest rate risk on the legacy PAC book of business. These instruments are
now contracted on the balance sheet of the PAC and, therefore, deemed integral to the underlying insurance contracts entered
into under IFRS17, and valuation movements are treated accordingly.

-- 30 of 116 --

32	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
B. 	Other significant items in these results continued
B.5 	CASH AND CASH EQUIVALENTS
Cash generated from operations increased by R1 914 million compared to the prior year. Cash outflows from investing activities
improved compared to the prior year by R316 million. This includes the R255 million relating to Discovery’s share after
withholding tax of the dividend paid by Ping An Health Insurance Company of China, Limited (PAHI) to shareholders in June 2024
for the first time, representing 30% of 2023 calendar year distributable profits. Cash outflows from financing activities improved
by R454 million compared to the prior year, after recommencement of the payment of dividends to ordinary shareholders of
R1 178 million but including the early refinancing of R1 500 million (see B.2). These movements were offset by a decrease in the
net movement in operating assets and liabilities largely driven by policyholder movements.
B.6 	CONSOLIDATION OF DISCOVERY UNIT TRUSTS
Unit trusts which the Group controls in terms of IFRS 10 Consolidated Financial Statements are consolidated into Discovery’s results
for accounting purposes, which results in the recognition of the underlying assets and liabilities of each of the funds.
As these policies are linked, the consolidation of the Discovery Unit Trusts has no impact on the net asset value for shareholders.
Assets and liabilities of these Discovery Unit Trusts however increased by R3 595 million, compared to the prior financial year
ended 30 June 2023, with movements in the following line items on the Group’s statement of financial position:
R million
June
2024
Restated
June
2023 	Movements
Investments at fair value through profit or loss 	28 192 	25 439 	2 753
Contract receivables and other receivables 	1 184 	643 	541
Cash and cash equivalents 	2 735 	2 435 	300
Other assets 	1 	– 	1
Total change in assets 	32 112 	28 517 	3 595
Third-party interest in consolidated funds 	31 456 	28 346 	3 110
Borrowings at amortised costs (bank overdraft) 	6 	33 	(27)
Other payables and provisions 	693 	482 	211
Liabilities arising from insurance contracts issued1 	(47) 	(346) 	299
Other liabilities1 	4 	2 	2
Total change in liabilities 	32 112 	28 517 	3 595
1 The comparative balances have been restated for the reclassification of balances between Liabilities arising from insurance contracts issued and
Other liabilities.
There are significant trade volumes in the underlying funds of Discovery Unit Trusts. The net cash outflow of the movement in
policyholder investments for the period is R556 million and has been included in the ‘Increase in operating assets’ line item on the
Group’s statement of cash flows.
B.7 	MATERIAL TRANSACTIONS WITH RELATED PARTIES
Discovery Long-term Incentive Plan Trust
At the Annual General Meeting (AGM) held on 28 November 2019, the shareholders approved the establishment of the Discovery
Long- term Incentive Plan Trust (Trust) with the purpose, inter alia, to subscribe, purchase and/or otherwise acquire and hold
Discovery ordinary shares from time to time for the benefit of the share-based payment plan for employees, in accordance with
the requirements of the Trust. During the year ended 30 June 2024, 3 227 675 (2023: 4 182 946) new shares were issued by
Discovery Limited to the Trust at a value of R432 million (2023: R514 million). The Trust further acquired 960 301 shares in the
market, valued at R113 million. In addition, during the year ended 30 June 2024, shares of 3 660 857 vested with participants. In
terms of IFRS Accounting Standards, while held in the Trust, these shares are treated as treasury shares and not treated as issued
for accounting purposes.
B.8 	MAJOR CUSTOMERS AND OTHER DISCOVERY ENTITIES NOT PART OF
DISCOVERY GROUP
Discovery Health Medical Scheme (DHMS)
Discovery Health administers DHMS and provides managed care services, for which it charges an administration fee and a
managed healthcare fee, respectively. These fees are determined on an annual basis and approved by the trustees of DHMS.
The fees for all services totalled R7 940 million for the year ended 30 June 2024 (2023: R7 414 million). Discovery offers the
members of DHMS access to the Vitality programme.

-- 31 of 116 --

33
B.9 	CHANGES IN DIRECTORATE
Changes to the Board of Discovery Limited from 1 July 2023 to the date of this announcement are as follows:
 Ms LM Chiume was appointed to the board as an independent non-executive director effective from 18 September 2023.
She is a member of the Discovery Limited Audit Committee and the Group and South African Risk and Compliance
Committees. She brings a wealth of financial services and investment experience.
 Ms KC Ramon was appointed to the board as an independent non-executive director effective from 18 September 2023
and as a member of the Discovery Limited Audit Committee and the Social and Ethics Committee. She brings diverse
leadership and board experience in multiple sectors. Effective 17 November 2023, she was appointed as a member of both
the Treating Customers Fairly and Remuneration Committees.
Following the formal retirement of Dr Vincent Maphai and Mrs Sindi Zilwa, effective 16 November 2023 as non-executive Directors
of the Company and subsequent retirement as members of the Committees on which they serve, the Committee compositions
have been revised with effect from 17 November 2023:
 Mr TT Mboweni has been appointed as a member of the Nominations Committee.
 Ms FN Khanyile has been nominated as the chairperson of the Social and Ethics Committee.
 Ms KC Ramon has been appointed as a member of the Treating Customers Fairly and Remuneration Committees, respectively.
Following the above, all Discovery Board Committees remain duly constituted.
B.10 EVENTS AFTER REPORTING DATE
The following non-adjusting events occurred between the end of the reporting period and the date when the annual financial
results were authorised for issue.
B.10.1 Dividend declaration in respect of the year ended 30 June 2024
B PREFERENCE SHARE CASH DIVIDEND DECLARATION
On Wednesday, 28 August 2024, the Board of directors declared a final gross cash dividend of 585.89041 cents (468.71233 cents
net of dividend withholding tax) per B preference share for the period 1 January 2024 to 30 June 2024, payable from the income
reserves of the Company.
A dividend withholding tax of 20% will be applicable to all shareholders who are not exempt.
The issued preference share capital at the declaration date is 8 million B preference shares.
The salient dates for the dividend will be as follows:
Last day of trade to receive a dividend 	Tuesday, 17 September 2024
Shares commence trading “ex” dividend 	Wednesday, 18 September 2024
Record date 	Friday, 20 September 2024
Payment date 	Monday, 23 September 2024
B preference share certificates may not be dematerialised or rematerialised between Wednesday, 18 September 2024 and Friday,
20 September 2024, both days inclusive.
ORDINARY SHARE CASH DIVIDEND DECLARATION
On Wednesday, 18 September 2024, the Board of Directors declared a final gross cash dividend of 152.00000 cents
(121.60000 cents net of dividend withholding tax) per ordinary share, out of the income reserves of the Company.
A dividend withholding tax of 20% will be applicable to all shareholders who are not exempt.
The number of ordinary shares in issue at the date of declaration is 676 374 092.
The salient dates for the dividend will be as follows:
Last day of trade to receive a dividend 	Tuesday, 15 October 2024
Shares commence trading “ex” dividend 	Wednesday, 16 October 2024
Record date 	Friday, 18 October 2024
Payment date 	Monday, 21 October 2024
Ordinary share certificates may not be dematerialised or rematerialised between Wednesday, 16 October 2024 and Friday,
18 October 2024, both days inclusive.

-- 32 of 116 --

DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
34
S E C T I O N C
INSURANCE AND REINSURANCE
CONTRACTS RELATED DISCLOSURE
DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4

-- 33 of 116 --

35
C.2.1 	INTRODUCTION AND OVERVIEW
This section provides information on the group’s core insurance business as well as disclosures that enable the assessment of
the effect of insurance and reinsurance contracts held on the Group statement of financial position, Group income statement
and Group statement of cash flows. In addition to the disclosures in terms of IFRS 17 Insurance Contracts (IFRS 17).
R million
Group
June
2024
Restated
Group
June
2023
Restated
Group
1 July
2022
Assets
Assets arising from insurance contracts issued 	41 816 	33 624 	29 761
Assets arising from reinsurance contracts held 	837 	604 	873
Equity
Other reserves1 	733 	3 184 	1 194
Liabilities
Liabilities arising from insurance contracts issued 	105 070 	94 660 	83 924
Liabilities arising from reinsurance contracts held 	5 396 	4 819 	5 252
1 The other reserve balance relates to the insurance finance reserve only.
R million
Group
June
2024
Restated
Group
June
2023
Insurance revenue 	51 857 	45 254
Insurance service expenses 	(46 145) 	(39 826)
Net expenses from reinsurance contracts 	(915) 	(126)
Insurance service result 	4 797 	5 302
Refer to section C.2.4 for the detailed analysis of the insurance risk and management.
C: 	Insurance and reinsurance contracts related disclosure

-- 34 of 116 --

36	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.2 	INSURANCE AND REINSURANCE CONTRACTS DISCLOSURES AND
RECONCILIATIONS
The following disclosures enable the user to assess the effect of insurance contracts issued and reinsurance contracts held on
Discovery’s financial position, financial performance and cash flows. In addition to the disclosures on significant judgements
and estimates above, the following disclosures provide a quantitative summary of the amount recognised in the financial
statements.
IFRS 17 requires that in determining the level at which an aggregated group of insurance contracts can provide useful
information to the user, Discovery considers:
 The type of contract which would consider the nature of the product and the measurement model.
 The geographical areas may expose the entity to different sets of risks, even for similar products.
 Reportable segments.
Having applied the guidance, Discovery has aggregated its portfolios for the disclosures as set out below.
SA Life and Invest (Risk) | GMM
(Life: Individual Life, Dollar LifePlan,
Health Protection Plans, Standalone Global Educator;
Invest: Guaranteed endowments)
SA Life and Invest (Participating) | VFA
(Unit-linked invest products,
Discovery Retirement Optimiser)
SA Life and Invest: Group Life and other | PAA
(Group Risk, Funeral and other including Discovery Card
Protector, Standalone Cancer Protector and LifeDrive)
SA Insure and other | PAA
(Personal and Commercial lines, GAP and Trauma Cover,
Travel Cover and AfricaHealth)
UK Life (Risk) | GMM
(Own Licence and PAC book)
UK Health | PAA
(Private Medical Insurance)
SA Composite 	UK Composite

-- 35 of 116 --

37
C.2.2 	INSURANCE AND REINSURANCE CONTRACTS DISCLOSURES AND
RECONCILIATIONS continued
The following index is a summary of all the quantitative disclosures set out in the notes:
Note 	Description
Analysis of
financial
position
C.2.3.1 Summary of insurance contracts issued
and reinsurance contracts held
The note summarises the total value of insurance and
reinsurance contracts held across the disclosed
portfolios, showing separately those insurance and
reinsurance contracts in a net liability or net asset
position.
C.2.3.2 Insurance acquisition assets 	The note provides a movement in the Insurance
acquisition assets, reflecting the movement in the
capitalised initial acquisition cash flows of the
VitalityHealth portfolio.
Reconciliation of insurance contracts
Analysis by remaining coverage and incurred claims
GMM
C.2.3.3.1 SA Life and Invest (Risk)
C.2.3.3.2 UK Life (Risk)
VFA
C.2.3.5.1 SA Life and Invest (Participating)
PAA
C.2.3.7.1 SA Life and Invest: Group Life and other
C.2.3.7.2 SA Insure and other
C.2.3.7.3 UK Health
Reconciliation of reinsurance contracts
Analysis by remaining coverage and incurred claims
GMM
C.2.3.8.1 SA Life and Invest (Risk)
C.2.3.8.2 UK Life (Risk)
PAA
C.2.3.10.1 SA Life and Invest: Group Life and other
C.2.3.10.2 SA Insure and other
C.2.3.10.3 UK Health
The notes provide a detailed reconciliation of disclosed
portfolios showing the build-up of:
 The liability for remaining coverage (LRC) reflects
Discovery’s obligation for the unexpired portion of
the coverage period. For contracts measured using
the simplified approach, LRC includes the unearned
premium.
 The liability of incurred claims (LIC) reflects
Discovery’s obligation to cover the insured events
that have occurred.
Reconciliation of insurance contracts
Analysis by measurement component
GMM
C.2.3.4.1 SA Life and Invest (Risk)
C.2.3.4.2 UK Life (Risk)
VFA
C.2.3.6.1 SA Life and Invest (Participating)
Reconciliation of reinsurance contracts
Analysis by measurement component
GMM
C.2.3.9.1 SA Life and Invest (Risk)
C.2.3.9.2 UK Life (Risk)
The notes provide a detailed reconciliation of disclosed
portfolios showing the build-up of the measurement
components, namely:
 Estimates of the present value of expected
fulfilment cash flows.
 The Risk adjustment.
 The Contractual service margin reflects unearned
profit. The CSM is further separated to reflect how
the CSM was calculated at transition, being
modified retrospectively or fully retrospectively.

-- 36 of 116 --

38	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
Note 	Description
Analysis of
income
statement
C.2.3.11 Insurance revenue 	The note provides a breakdown of the makeup of
insurance revenue for each disclosed portfolio
business unit.
For those contracts not measured using the PAA
approach, the amount reflects the provision of
services and the recovery of insurance acquisition
cash flows. The provision of services is represented by
the change in the LRC, namely:
 CSM recognised during the period for the service
provided.
 The change in the Risk adjustment for non-financial
risk.
 Expected claims and insurance services expenses.
 Experience adjustments.
C.2.3.12 Net investment result 	The note provides a holistic combined view of the
following:
 The investment returns on financial assets held.
 The insurance and reinsurance finance income and
expenses, including the amounts recognised in
profit or loss and other comprehensive income
(OCI).
Additional
information
Effect of contracts initially recognised in the
year:
C.2.3.13.1 Effects of insurance contracts initially
recognised in the year.
C.2.3.13.2 Effect of reinsurance contracts initially
recognised in the year.
The notes provide a breakdown of the contracts
initially recognised during the period for each
disclosed portfolio business unit.
 For insurance contracts, differentiate between
profitable contracts recognised with CSM and
onerous contracts.
 Reinsurance contracts reflect contracts originated
with and without the loss-recovery component.
The note provides, for each disclosed portfolio
business unit, the expected recognition of CSM, with
interest accretion over the lifetime of the group of
insurance contracts.
C.2.3.14 Contractual service margin. 	The note also sets out the release of accumulated IFIE
OCI balances into profit or loss.
C.2.3.15 OCI run-off 	The note provides, for each disclosed portfolio
business unit, the expected run-off of the IFIE reserve,
with interest accretion over the lifetime of the group
of insurance contracts.
C.2.3.16 Claims development 	The note provides, for the annuity type benefits, the
comparison between actual in-period claims and
previous estimates of the claims amount
C.2.3.17 Significant accounting estimates,
judgements in applying accounting policies
The note provides the significant accounting
estimates, judgements in applying accounting polices
12 on the insurance contracts.
C.2.2 	INSURANCE AND REINSURANCE CONTRACTS DISCLOSURES AND
RECONCILIATIONS continued

-- 37 of 116 --

39
C.2.2 	INSURANCE AND REINSURANCE CONTRACTS DISCLOSURES AND
RECONCILIATIONS continued
Definitions and Abbreviations
The following abbreviations and terms are commonly used within the accounting policy:
Abbreviations 	Meaning
CSM 	Contractual Service Margin
DISCOVERY 	Discovery Group
DPF 	Direct Participation Features
DRO 	Discovery Retirement Optimiser
EFCF 	Expected Fulfilment Cash Flows
FINANCIAL RISK 	The risk of a possible future change in one or more of a specified interest rate, financial instrument
price, commodity price, currency exchange rate, index of prices or rates, credit rating or credit
index or other variable, provided in the case of a non-financial variable that the variable is not
specific to a party to the contract.
GMM 	General Measurement Model
IACF 	Initial Acquisition Cash Flows
IFIE 	Insurance finance income and expense comprises the change in the carrying amount of the group
of insurance contracts arising from:
 the effect of the time value of money and changes in the time value of money, and
 the effect of financial risk and changes in financial risk
IFRS 	IFRS® Accounting Standards
IFRS 17 	IFRS 17 Insurance Contracts (effective for Discovery post 1 July 2023)
IFRS 17 margins 	IFRS 17 margins refers to the contractual service margin plus the risk adjustment
ISE 	Insurance Service Expenses
LIC 	Liability for Incurred Claims
LRC 	Liability for Remaining Coverage
OCI 	Other Comprehensive Income
PAA 	Premium Allocation Approach
VFA 	Variable Fee Approach

-- 38 of 116 --

40	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS
C.2.3.1 Summary of insurance contracts issued and reinsurance contracts held
Group
R million
(Assets)/Liabilities 	Navigation
SA Life
and
Invest
Risk
(GMM)
UK Life
Risk
(GMM)1
SA Life
and
Invest
Participating
(VFA)
SA Life
and
Invest:
Group Life
and other
(PAA)
SA
Insure
(PAA)
UK
Health
(PAA)1 	Total
Year ended 30 June 2024
Insurance Contracts 	A= D + E 	2 242 	(15 269) 	73 721 	5 888 	896 	(4 224) 	63 254
Reinsurance Contracts 	B = F 	126 	5 270 	– 	(685) 	(139) 	(13) 	4 559
Total 	C = A +B 	2 368 	(9 999) 	73 721 	5 203 	757 	(4 237) 	67 813
Insurance contracts issued
Assets arising from
insurance contracts
– Insurance contract balances 	(22 323) 	(15 269) 	– 	– 	– 	683 	(36 909)
– Assets for insurance
acquisition cash flows 	(4 907) 	(4 907)
Total 	D 	(22 323) 	(15 269) 	– 	– 	– 	(4 224) 	(41 816)
Liabilities arising from
insurance contracts
– Insurance contract balances 	24 565 	– 	73 721 	5 888 	896 	– 	105 070
E 	24 565 	– 	73 721 	5 888 	896 	– 	105 070
Reinsurance contracts held
Reinsurance contract assets 	– 	– 	– 	(685) 	(139) 	(13) 	(837)
Reinsurance contract liabilities 	126 	5 270 	– 	– 	– 	– 	5 396
Total 	F 	126 	5 270 	– 	(685) 	(139) 	(13) 	4 559
Year ended 30 June 2023
Insurance Contracts 	4 365 	(12 059) 	66 308 	5 109 	822 	(3 509) 	61 036
Reinsurance Contracts 	567 	4 252 	– 	(529) 	(71) 	(4) 	4 215
Total 	4 932 	(7 807) 	66 308 	4 580 	751 	(3 513) 	65 251
Insurance contracts issued
Assets arising from
insurance contracts
– Insurance contract balances 	(18 056) 	(12 059) 	– 	– 	– 	1 035 	(29 080)
– Assets for insurance
acquisition cash flows 	– 	– 	– 	– 	– 	(4 544) 	(4 544)
Total 	(18 056) 	(12 059) 	– 	– 	– 	(3 509) 	(33 624)
Liabilities arising from
insurance contracts
– Insurance contract balances 	22 421 	– 	66 308 	5 109 	822 	– 	94 660
22 421 	– 	66 308 	5 109 	822 	– 	94 660
Reinsurance contracts held
Reinsurance contract assets 	– 	– 	– 	(529) 	(71) 	(4) 	(604)
Reinsurance contract liabilities 	567 	4 252 	– 	– 	– 	– 	4 819
Total 	567 	4 252 	– 	(529) 	(71) 	(4) 	4 215
Cross reference to related notes
of insurance contracts issued
– Analysis by remaining
coverage and incurred claims 	C2.3.3.1 	C2.3.3.2 	C2.3.5.1 	C2.3.7.1 	C2.3.7.2 	C2.3.7.3
– Analysis by measurement
component 	C2.3.4.1 	C2.3.4.2 	C2.3.6.1
– Insurance acquisition assets 	C2.3.2
Cross reference to related notes
of reinsurance contracts held
– Analysis by remaining
coverage and incurred claims 	C2.3.8.1 	C2.3.8.2 	C2.3.10.1 	C2.3.10.2 	C2.3.10.3
– Analysis by measurement
component 	C2.3.9.1 	C2.3.9.2
1 The UK Life (Risk and UK Health comparative period been restated from the reconciliation published in the unaudited Discovery Group interim disclosures for
the six-month period ended 31 December 2023. The effect of these changes are noted in item 5 of D.1.4.

-- 39 of 116 --

41
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.2 Movement in asset for insurance acquisition cash flows
Group
R million
UK
Health
(PAA)
Year ended 30 June 2024
Balance at the beginning of the year 	4 544
Amounts Incurred during the year 	1 659
Amounts derecognised and included in the measurement of insurance contracts 	(1 111)
Effect of movements in exchange rates 	(185)
Balance at the end of the year 	4 907
Year ended 30 June 2023
Balance at the beginning of the year 	3 358
Amounts Incurred during the year 	1 355
Amounts derecognised and included in the measurement of insurance contracts 	(893)
Effect of movements in exchange rates 	724
Balance at the end of the year 	4 544
Balance as at 1 July 2022
Presented in insurance contract assets 	3 358
Balance as at 30 June 2024
Presented in insurance contract assets 	4 907
Balance as at 30 June 2023
Presented in insurance contract assets 	4 544

-- 40 of 116 --

43	42	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.3 Reconciliation of Insurance contracts – GMM
C.2.3.3.1 SA LIFE AND INVEST (RISK)
ANALYSIS BY REMAINING COVERAGE AND INCURRED CLAIMS
Group
R million
(Assets)/Liabilities 	Navigation
2024 	2023
Liabilities for
Remaining Coverage
Liabilities
for Incurred
Claims 	Total
Liabilities for
Remaining Coverage
Liabilities
for Incurred
Claims 	Total
Excluding
loss
component
Loss
component
Excluding
loss
component
Loss
component
Opening assets arising from
insurance contracts issued 	(26 510) 	1 833 	6 621 	(18 056) 	(27 422) 	1 424 	6 339 	(19 659)
Opening liabilities arising from
insurance contracts issued 	22 236 	185 	– 	22 421 	21 091 	133 	– 	21 224
Net balance at beginning
of the year 	A 	(4 274) 	2 018 	6 621 	4 365 	(6 331) 	1 557 	6 339 	1 565
Adjust: transfer of product from SA
Life and Invest (Participating) to SA
Life and Invest (Risk) 	(22) 	128 	106
Opening assets arising from
insurance contracts issued (rebased) 	(27 444) 	1 552 	6 339 	(19 553)
Opening liabilities arising from
insurance contracts issued (rebased) 	21 091 	133 	21 224
Net balance at beginning of the
year (rebased) 	(4 274) 	2 018 	6 621 	4 365 	(6 353) 	1 685 	6 339 	1 671
Changes in the income statement
and OCI
Insurance revenue transitional split
Contracts under the modified
retrospective approach 	(367) 	– 	– 	(367) 	(334) 	– 	– 	(334)
All other contracts 	(14 405) 	– 	– 	(14 405) 	(13 503) 	– 	– 	(13 503)
B 	(14 772) 	– 	– 	(14 772) 	(13 837) 	– 	– 	(13 837)
Insurance service expenses
Incurred claims and other insurance
service expenses 	– 	– 	11 009 	11 009 	– 	– 	10 348 	10 348
Amortised assets for insurance
acquisition cash flows 	2 142 	– 	– 	2 142 	1 713 	– 	– 	1 713
Adjustment to liability for incurred
claims 	– 	– 	37 	37 	– 	– 	– 	–
Losses and reversal of losses on
onerous contracts 	– 	(362) 	– 	(362) 	– 	304 	– 	304
C 	2 142 	(362) 	11 046 	12 826 	1 713 	304 	10 348 	12 365
Investment components 	D 	(5 242) 	– 	5 242 	– 	(3 817) 	3 817 	–
Insurance service result 	E = B +C + D 	(17 872) 	(362) 	16 288 	(1 946) 	(15 941) 	304 	14 165 	(1 472)
Net finance expenses from insurance
contracts 	F 	(2 501) 	9 	416 	(2 076) 	3 046 	29 	191 	3 266
Net changes to income statement
and OCI 	G = E +F 	(20 373) 	(353) 	16 704 	(4 022) 	(12 895) 	333 	14 356 	1 794
Cash Flows
Premiums received 	20 319 	– 	– 	20 319 	17 477 	– 	– 	17 477
Insurance acquisition cash flows 	(2 714) 	– 	– 	(2 714) 	(2 503) 	– 	– 	(2 503)
Claims and other directly attributable
expenses paid 	– 	– 	(15 706) 	(15 706) 	– 	– 	(14 074) 	(14 074)
Total cash flows 	H 	17 605 	– 	(15 706) 	1 899 	14 974 	– 	(14 074) 	900
Net balance at the end of the year 	J = A + G +H 	(7 042) 	1 665 	7 619 	2 242 	(4 274) 	2 018 	6 621 	4 365
Closing assets arising from insurance
contracts issued 	(31 412) 	1 470 	7 619 	(22 323) 	(26 510) 	1 833 	6 621 	(18 056)
Closing liabilities arising from
insurance contracts issued 	24 370 	195 	– 	24 565 	22 236 	185 	– 	22 421
Net balance at the end of the year 	(7 042) 	1 665 	7 619 	2 242 	(4 274) 	2 018 	6 621 	4 365

-- 41 of 116 --

45	44	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.3 Reconciliation of Insurance contracts – GMM continued
C.2.3.3.2 UK LIFE (RISK)
ANALYSIS BY REMAINING COVERAGE AND INCURRED CLAIMS
Group
R million
(Assets)/Liabilities 	Navigation
2024 	20231
Liabilities for Remaining
Coverage
Liabilities
for Incurred
Claims 	Total
Liabilities for Remaining
Coverage
Liabilities
for Incurred
Claims 	Total
Excluding
loss
component
Loss
component
Excluding
loss
component
Loss
component
Opening assets arising from insurance
contracts issued 	(19 017) 	5 327 	1 631 	(12 059) 	(13 500) 	4 388 	1 131 	(7 981)
Net balance at beginning of the year 	A 	(19 017) 	5 327 	1 631 	(12 059) 	(13 500) 	4 388 	1 131 	(7 981)
Changes in the income statement
and OCI
Insurance revenue transitional split
All other contracts 	(6 904) 	– 	– 	(6 904) 	(5 581) 	– 	– 	(5 581)
B 	(6 904) 	– 	– 	(6 904) 	(5 581) 	– 	– 	(5 581)
Insurance service expenses
Incurred claims and other insurance
service expenses 	– 	– 	3 453 	3 453 	– 	– 	2 759 	2 759
Amortised assets for insurance
acquisition cash flows 	2 610 	– 	– 	2 610 	2 047 	– 	– 	2 047
Adjustment to liability for incurred
claims 	– 	– 	– 	– 	– 	– 	– 	–
Losses and reversal of losses on
onerous contracts 	– 	154 	– 	154 	– 	306 	– 	306
C 	2 610 	154 	3 453 	6 217 	2 047 	306 	2 759 	5 112
Investment components 	D 	46 	– 	(46) 	– 	236 	– 	(236) 	–
Insurance service result 	E = B + C + D 	(4 248) 	154 	3 407 	(687) 	(3 298) 	306 	2 523 	(469)
Net finance expenses from insurance
contracts 	F 	(2 625) 	(137) 	– 	(2 762) 	(1 032) 	(248) 	– 	(1 280)
Net changes to income statement
and OCI 	G = E + F 	(6 873) 	17 	3 407 	(3 449) 	(4 330) 	58 	2 523 	(1 749)
Cash Flows
Premiums received 	7 807 	– 	– 	7 807 	5 909 	– 	– 	5 909
Insurance acquisition cash flows 	(4 929) 	– 	– 	(4 929) 	(4 103) 	– 	– 	(4 103)
Claims and other directly attributable
expenses paid 	– 	– 	(3 178) 	(3 178) 	– 	– 	(2 278) 	(2 278)
Total cash flows 	H 	2 878 	– 	(3 178) 	(300) 	1 806 	– 	(2 278) 	(472)
Effect of movements in exchange rates 	I 	810 	(204) 	(67) 	539 	(2 993) 	881 	255 	(1 857)
Net balance at the end of the year 	J = A + G + H + I 	(22 202) 	5 140 	1 793 	(15 269) 	(19 017) 	5 327 	1 631 	(12 059)
Closing assets arising from insurance
contracts issued 	(22 202) 	5 140 	1 793 	(15 269) 	(19 017) 	5 327 	1 631 	(12 059)
Net balance at the end of the year 	(22 202) 	5 140 	1 793 	(15 269) 	(19 017) 	5 327 	1 631 	(12 059)
1 The UK Life (Risk) comparative period has been restated from the reconciliation published in the unaudited Discovery Group interim disclosures for the
six-month period ended 31 December 2023. The effect of these changes are noted in item 5 of D.1.4.

-- 42 of 116 --

47	46	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.4 Movement in Insurance contract balances: GMM
C.2.3.4.1 SA LIFE AND INVEST (RISK)
ANALYSIS BY MEASUREMENT COMPONENT
Group
R million
(Assets)/Liabilities 	Navigation
2024 	2023
Estimates
of PVFCF
RA for
non-
financial
Risk
CSM
Total
Estimates
of PVFCF
RA for
non-financial
Risk
CSM
Total
Other
contracts
Other
contracts
Opening assets arising from insurance contracts
issued 	(52 454) 	6 960 	27 438 	(18 056) 	(55 257) 	7 765 	27 833 	(19 659)
Opening liabilities arising from insurance contracts
issued 	21 521 	86 	814 	22 421 	20 578 	72 	574 	21 224
Net balance at beginning of the year 	A 	(30 933) 	7 046 	28 252 	4 365 	(34 679) 	7 837 	28 407 	1 565
Adjust: transfer of product from SA Life and
Invest (Participating) to SA Life and Invest (Risk) 	1 731 	(183) 	(1 442) 	106
Opening assets arising from insurance contracts
issued (rebased) 	(53 526) 	7 582 	26 391 	(19 553)
Opening liabilities arising from insurance contracts
issued (rebased) 	20 578 	72 	574 	21 224
Net balance at beginning of the year (rebased) 	(30 933) 	7 046 	28 252 	4 365 	(32 948) 	7 654 	26 965 	1 671
Changes in the income statement and OCI
Changes that relate to current services
CSM recognised for services provided 	– 	– 	(1 859) 	(1 859) 	– 	– 	(1 835) 	(1 835)
Change in Risk Adjustment for non-financial risk
that relates to expired risk 	– 	(617) 	– 	(617) 	– 	(599) 	– 	(599)
Experience adjustments 	663 	– 	– 	663 	513 	– 	– 	513
Changes that relate to future services 	– 	– 	– 	– 	–
Contracts initially recognised in the period 	(2 257) 	430 	1 888 	61 	(2 203) 	450 	1 836 	83
Changes in estimates that adjust CSM 	5 264 	176 	(5 440) 	– 	1 548 	(193) 	(1 355) 	–
Changes in estimates that result in onerous contract
losses or reversal of losses 	(354) 	81 	– 	(273) 	350 	(16) 	– 	334
Servicing expenses and commission for onerous
contracts 	42 	– 	– 	42 	32 	– 	– 	32
Changes that relate to past services 	– 	– 	– 	–
Adjustment to liability for incurred claims 	– 	37 	– 	37 	– 	2 	– 	2
Insurance service result 	B 	3 358 	107 	(5 411) 	(1 946) 	240 	(356) 	(1 354) 	(1 470)
Net finance expenses from insurance contracts 	C 	(5 334) 	792 	2 466 	(2 076) 	877 	(252) 	2 641 	3 266
Net changes to income statement and OCI 	D= B + C 	(1 976) 	899 	(2 945) 	(4 022) 	1 117 	(608) 	1 287 	1 796
Cash flows 	E 	1 899 	– 	– 	1 899 	898 	– 	– 	898
Net balance at the end of the year 	G = A + D + E 	(31 010) 	7 945 	25 307 	2 242 	(30 933) 	7 046 	28 252 	4 365
Closing assets arising from insurance contracts
issued 	(54 499) 	7 810 	24 366 	(22 323) 	(52 454) 	6 960 	27 438 	(18 056)
Closing liabilities arising from insurance contracts
issued 	23 489 	135 	941 	24 565 	21 521 	86 	814 	22 421
Net balance at the end of the year 	(31 010) 	7 945 	25 307 	2 242 	(30 933) 	7 046 	28 252 	4 365

-- 43 of 116 --

49	48	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.4 Movement in Insurance contract balances: GMM continued
C.2.3.4.2 UK LIFE (RISK)
ANALYSIS BY MEASUREMENT COMPONENT
Group
R million
(Assets)/Liabilities 	Navigation
2024 	20231
Estimates
of PVFCF
RA for
non-
financial
Risk
CSM
Total
Estimates
of PVFCF
RA for
non-financial
Risk
CSM
Total
Other
contracts
Other
contracts
Opening assets arising from insurance contracts
issued 	(27 886) 	2 020 	13 807 	(12 059) 	(21 174) 	1 740 	11 452 	(7 982)
Net balance at beginning of the year 	A 	(27 886) 	2 020 	13 807 	(12 059) 	(21 174) 	1 740 	11 452 	(7 982)
Changes in the income statement and OCI
Changes that relate to current services
CSM recognised for services provided 	– 	– 	(1 242) 	(1 242) 	– 	– 	(1 102) 	(1 102)
Change in Risk Adjustment for non-financial risk that
relates to expired risk 	– 	(209) 	– 	(209) 	– 	(221) 	– 	(221)
Experience adjustments 	224 	– 	– 	224 	266 	– 	– 	266
Changes that relate to future services 	– 	– 	0 	–
Contracts initially recognised in the period 	(1 573) 	368 	1 482 	277 	(1 226) 	330 	1 167 	271
Changes in estimates that adjust CSM 	447 	(3) 	(444) 	– 	135 	12 	(147) 	–
Changes in estimates that result in onerous contract
losses or reversal of losses 	224 	39 	– 	263 	278 	39 	– 	317
Insurance service result 	B 	(678) 	195 	(204) 	(687) 	(547) 	160 	(82) 	(469)
Net finance expenses from insurance contracts 	C 	(3 108) 	107 	239 	(2 762) 	(1 206) 	(219) 	145 	(1 280)
Net changes to income statement and OCI 	D = B + C 	(3 786) 	302 	35 	(3 449) 	(1 753) 	(59) 	63 	(1 749)
Cash flows 	E 	(300) 	– 	– 	(300) 	(22) 	– 	– 	(22)
Effect of movements in exchange rates 	F 	1 153 	(83) 	(531) 	539 	(4 937) 	339 	2 292 	(2 306)
Net balance at the end of the year 	G = A + D + E + F 	(30 819) 	2 239 	13 311 	(15 269) 	(27 886) 	2 020 	13 807 	(12 059)
Closing assets arising from insurance contracts
issued 	(30 819) 	2 239 	13 311 	(15 269) 	(27 886) 	2 020 	13 807 	(12 059)
Net balance at the end of the year 	(30 819) 	2 239 	13 311 	(15 269) 	(27 886) 	2 020 	13 807 	(12 059)
1 The UK Life (Risk) comparative period has been restated from the reconciliation published in the unaudited Discovery Group interim disclosures for
the six-month period ended 31 December 2023. The effect of these changes are noted in item 5 of D.1.4.

-- 44 of 116 --

51	50	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.5 Movement in Insurance contract balances: VFA
C.2.3.5.1 SA LIFE AND INVEST (PARTICIPATING)
ANALYSIS BY REMAINING COVERAGE AND INCURRED CLAIMS
Group
R million
(Assets)/Liabilities 	Navigation
2024 	2023
Liabilities for Remaining
Coverage (LRC) 	Liabilities
for Incurred
Claims
(LIC) 	Total
Liabilities for Remaining
Coverage (LRC) Liabilities
for Incurred
Claims
(LIC) 	Total
Excluding
loss
component
Loss
component
Excluding
loss
component
Loss
component
Opening liabilities arising from insurance
contracts issued 	66 236 	72 	– 	66 308 	56 983 	136 	– 	57 119
Net balance at beginning of the year 	A 	66 236 	72 	– 	66 308 	56 983 	136 	– 	57 119
Adjust: transfer of product from SA
Life and Invest (Participating) to SA
Life and Invest (Risk) 	2 	(64) 	(62)
Opening assets arising from insurance
contracts issued (rebased) 	– 	–
Opening liabilities arising from insurance
contracts issued (rebased) 	56 985 	72 	– 	57 057
Net balance at beginning of the year
(rebased) 	66 236 	72 	– 	66 308 	56 985 	72 	– 	57 057
Changes in the income statement
and OCI
Insurance revenue transitional split
Contracts under the modified
retrospective approach 	(3 157) 	– 	– 	(3 157) 	(2 809) 	– 	– 	(2 809)
Other contracts 	(172) 	– 	– 	(172) 	(53) 	– 	– 	(53)
B 	(3 329) 	– 	– 	(3 329) 	(2 862) 	– 	– 	(2 862)
Insurance service expenses
Incurred claims and other insurance
service expenses 	– 	– 	999 	999 	– 	– 	1 020 	1 020
Experience adjustments adjusting CSM 	86 	46 	– 	132 	(77) 	– 	– 	(77)
Amortised assets for insurance
acquisition cash flows 	758 	– 	– 	758 	694 	– 	– 	694
Losses and reversal of losses on onerous
contracts 	– 	5 	– 	5 	– 	– 	– 	–
C 	844 	51 	999 	1 894 	617 	– 	1 020 	1 637
Investment components 	D 	(11 577) 	– 	11 577 	– 	(9 191) 	9 191 	–
Insurance service result 	E = B + C + D 	(14 062) 	51 	12 576 	(1 435) 	(11 436) 	– 	10 211 	(1 225)
Net finance expenses from insurance
contracts 	F 	7 810 	– 	– 	7 810 	8 283 	– 	– 	8 283
Net changes to income statement
and OCI 	G = E + F 	(6 252) 	51 	12 576 	6 375 	(3 153) 	– 	10 211 	7 058
Cash Flows
Premiums received 	14 294 	– 	– 	14 294 	13 089 	– 	– 	13 089
Insurance acquisition cash flows 	(680) 	– 	– 	(680) 	(685) 	– 	– 	(685)
Claims and other directly attributable
expenses paid 	– 	– 	(12 576) 	(12 576) 	– 	– 	(10 211) 	(10 211)
Total cash flows 	H 	13 614 	– 	(12 576) 	1 038 	12 404 	– 	(10 211) 	2 193
Net balance at the end of the year 	J = A + G + H 	73 598 	123 	– 	73 721 	66 236 	72 	– 	66 308
Closing liabilities arising from insurance
contracts issued 	73 598 	123 	– 	73 721 	66 236 	72 	– 	66 308
Net balance at the end of the year 	73 598 	123 	– 	73 721 	66 236 	72 	– 	66 308

-- 45 of 116 --

53	52	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.6 Movement in Insurance contract balances: VFA
C.2.3.6.1 SA LIFE AND INVEST (PARTICIPATING)
ANALYSIS BY MEASUREMENT COMPONENT
Group
R million
(Assets)/Liabilities 	Navigation
2024 	2023
Estimates
of PVFCF
RA for
non-financial
Risk
CSM
Total
Estimates
of PVFCF
RA for
non-financial
Risk
CSM
Total
Transition:
Modified
retro-
spective
Other
contracts
Transition:
Modified
retrospective
Other
contracts
Opening liabilities arising from insurance
contracts issued 	59 328 	912 	5 430 	638 	66 308 	52 546 	663 	3 910 	– 	57 119
Net balance at beginning of the year 	59 328 	912 	5 430 	638 	66 308 	52 546 	663 	3 910 	– 	57 119
Adjust: transfer of product from SA
Life and Invest (Participating) to SA
Life and Invest (Risk) 	(1 729) 	166 	1 501 	(62)
(rebased) 	– 	– 	– 	– 	–
Opening liabilities arising from insurance
contracts issued (rebased) 	50 817 	829 	5 411 	– 	57 057
Net balance at beginning of the year
(rebased) 	A 	59 328 	912 	5 430 	638 	66 308 	50 817 	829 	5 411 	– 	57 057
Changes in the income statement
and OCI
Changes that relate to current services
CSM recognised for services provided 	– 	– 	(1 080) 	(142) 	(1 222) 	– 	– 	(1 072) 	(29) 	(1 101)
Change in Risk Adjustment for non-
financial risk that relates to expired risk 	– 	(212) 	– 	– 	(212) 	– 	(149) 	– 	– 	(149)
Experience adjustments 	(93) 	– 	63 	1 	(29) 	7 	– 	2 	(9) 	–
Changes that relate to future services
Contracts initially recognised in the
period 	(510) 	70 	– 	490 	50 	(831) 	70 	– 	782 	21
Changes in estimates that adjust CSM 	289 	(83) 	(122) 	(84) 	– 	(531) 	116 	362 	53 	–
Changes in estimates that result in
onerous contract losses or reversal
of losses 	(23) 	1 	– 	– 	(22) 	1 	3 	– 	– 	4
Insurance service result 	B 	(337) 	(224) 	(1 139) 	265 	(1 435) 	(1 354) 	40 	(708) 	797 	(1 225)
Net finance expenses from insurance
contracts 	C 	6 613 	85 	984 	128 	7 810 	7 672 	43 	727 	(159) 	8 283
Net changes to income statement
and OCI 	D = B + C 	6 276 	(139) 	(155) 	393 	6 375 	6 318 	83 	19 	638 	7 058
Cash flows 	E 	1 038 	– 	– 	– 	1 038 	2 193 	– 	– 	– 	2 193
Net balance at the end of the year 	G = A + D + E 	66 642 	773 	5 275 	1 031 	73 721 	59 328 	912 	5 430 	638 	66 308
Closing liabilities arising from insurance
contracts issued 	66 642 	773 	5 275 	1 031 	73 721 	59 328 	912 	5 430 	638 	66 308
Net balance at the end of the year 	66 642 	773 	5 275 	1 031 	73 721 	59 328 	912 	5 430 	638 	66 308

-- 46 of 116 --

55	54	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.7 Movement in Insurance contract balances: PAA
C.2.3.7.1 SA LIFE AND INVEST: GROUP LIFE AND OTHER
ANALYSIS BY REMAINING COVERAGE AND INCURRED CLAIMS
Group
R million
(Assets)/Liabilities 	Navigation
2024 	2023
Liabilities
for
Remaining
Coverage
Liabilities for Incurred Claims
Total
Liabilities
for
Remaining
Coverage
Liabilities for Incurred Claims
Total
Estimates
of PVFCF
RA for
non-financial
risk
Estimates
of PVFCF
RA for
non-financial
risk
Opening liabilities arising from
insurance contracts held 	(162) 	5 167 	104 	5 109 	(127) 	4 840 	91 	4 804
Net balance at beginning
of the year 	A 	(162) 	5 167 	104 	5 109 	(127) 	4 840 	91 	4 804
Insurance revenue 	B 	(3 517) 	– 	– 	(3 517) 	(3 307) 	– 	– 	(3 307)
Insurance service expenses
Incurred claims and other insurance
service expenses 	– 	3 028 	(32) 	2 996 	– 	2 600 	12 	2 612
Gross claims and insurance service
expenses 	– 	3 028 	(32) 	2 996 	– 	2 600 	12 	2 612
Salvages 	– 	– 	– 	– 	– 	– 	– 	–
Amortisation of assets for insurance
acquisition cash flows 	169 	– 	– 	169 	141 	– 	– 	141
Adjustment to liability for incurred
claims 	– 	– 	19 	19 	– 	– 	– 	–
C 	169 	3 028 	(13) 	3 184 	141 	2 600 	12 	2 753
Insurance service result 	D = B + C 	(3 348) 	3 028 	(13) 	(333) 	(3 166) 	2 600 	12 	(554)
Net finance expenses from
insurance contracts issued 	E 	– 	329 	7 	336 	200 	1 	201
Net changes to statement of
profit or loss and OCI 	F = D +E 	(3 348) 	3 357 	(6) 	3 	(3 166) 	2 800 	13 	(353)
Cash flows
Premiums received 	3 537 	– 	– 	3 537 	3 272 	– 	– 	3 272
Insurance acquisition cash flows 	(169) 	– 	– 	(169) 	(141) 	– 	– 	(141)
Claims and other directly
attributable expenses paid 	– 	(2 592) 	– 	(2 592) 	– 	(2 473) 	– 	(2 473)
Gross claims and insurance service
expenses paid 	– 	(2 592) 	– 	(2 592) 	(2 473) 	– 	(2 473)
Salvages 	– 	– 	– 	– 	– 	– 	–
Total cash flows 	G 	3 368 	(2 592) 	– 	776 	3 131 	(2 473) 	– 	658
Net balance at the end of year 	K = A + F + G 	(142) 	5 932 	98 	5 888 	(162) 	5 167 	104 	5 109
Closing liabilities arising from
insurance contracts held 	(142) 	5 932 	98 	5 888 	(162) 	5 167 	104 	5 109
Net balance at the end of year 	(142) 	5 932 	98 	5 888 	(162) 	5 167 	104 	5 109

-- 47 of 116 --

57	56	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.7 Movement in Insurance contract balances: PAA continued
C.2.3.7.2 SA INSURE AND OTHER
ANALYSIS BY REMAINING COVERAGE AND INCURRED CLAIMS
Group
R million
(Assets)/Liabilities 	Navigation
2024 	2023
Liabilities
for
Remaining
Coverage
Liabilities for Incurred Claims
Total
Liabilities
for
Remaining
Coverage
Liabilities for Incurred Claims
Total
Estimates
of PVFCF
RA for
non-financial
risk
Estimates
of PVFCF
RA for
non-financial
risk
Opening liabilities arising from
insurance contracts issued 	52 	758 	12 	822 	77 	749 	13 	839
Net balance at beginning
of the year 	A 	52 	758 	12 	822 	77 	749 	13 	839
Insurance revenue 	B 	(6 861) 	– 	– 	(6 861) 	(6 000) 	– 	– 	(6 000)
Insurance service expenses
Incurred claims and other
insurance service expenses 	– 	5 445 	5 	5 450 	– 	4 828 	– 	4 828
Gross claims and insurance service
expenses 	– 	5 904 	5 	5 909 	– 	5 207 	– 	5 207
Salvages 	– 	(459) 	– 	(459) 	– 	(379) 	– 	(379)
Amortisation of assets for
insurance acquisition cash flows1 	1 053 	– 	– 	1 053 	916 	– 	– 	916
Adjustment to liability for incurred
claims 	– 	61 	2 	63 	– 	141 	(1) 	140
C 	1 053 	5 506 	7 	6 566 	916 	4 969 	(1) 	5 884
Insurance service result 	D = B + C 	(5 808) 	5 506 	7 	(295) 	(5 084) 	4 969 	(1) 	(116)
Net changes to statement
of profit or loss and OCI 	F = D 	(5 808) 	5 506 	7 	(295) 	(5 084) 	4 969 	(1) 	(116)
Cash flows 	– 	– 	– 	–
Premiums received 	6 827 	– 	– 	6 827 	5 975 	– 	– 	5 975
Insurance acquisition cash flows 	(1 053) 	(21) 	– 	(1 074) 	(916) 	– 	– 	(916)
Claims and other directly
attributable expenses paid 	– 	(5 378) 	(5) 	(5 383) 	– 	(4 961) 	– 	(4 961)
Gross claims and insurance service
expenses paid 	– 	(5 825) 	(5) 	(5 830) 	– 	(5 346) 	– 	(5 346)
Salvages 	– 	447 	– 	447 	– 	385 	– 	385
Total cash flows 	G 	5 774 	(5 399) 	(5) 	370 	5 059 	(4 961) 	– 	98
Effect of movements in exchange
rates 	H 	1 	(2) 	– 	(1) 	– 	1 	– 	1
Net balance at the end of year 	K = A + F + G + H 	19 	863 	14 	896 	52 	758 	12 	822
Closing liabilities arising from
insurance contracts issued 	19 	863 	14 	896 	52 	758 	12 	822
Net balance at the end of year 	19 	863 	14 	896 	52 	758 	12 	822
1 The comparative reconciliation has been restated to present the insurance acquisition cash flow as part of the liabilities arising from insurance contracts.
The restatement does not impact the total insurance service expenses disclosed in the reconciliation, the split between LIC and LRC has been updated.

-- 48 of 116 --

59	58	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.7 Movement in Insurance contract balances: PAA continued
C.2.3.7.3 UK HEALTH
ANALYSIS BY REMAINING COVERAGE AND INCURRED CLAIMS
Group
R million
(Assets)/Liabilities 	Navigation
2024 	20231
Liabilities
for
Remaining
Coverage
Liabilities for Incurred Claims
Total
Liabilities
for
Remaining
Coverage
Liabilities for Incurred Claims
Total
Estimates
of PVFCF
RA for
non-financial
risk
Estimates
of PVFCF
RA for
non-financial
risk
Opening assets arising from
insurance contracts held 	(372) 	1 350 	57 	1 035 	105 	989 	37 	1 131
Net balance at beginning
of the year 	A 	(372) 	1 350 	57 	1 035 	105 	989 	37 	1 131
Insurance revenue 	B 	(16 474) 	– 	– 	(16 474) 	(13 670) 	– 	– 	(13 670)
Insurance service expenses
Incurred claims and other
insurance service expenses 	– 	13 713 	(26) 	13 687 	– 	10 765 	11 	10 776
Gross claims and insurance service
expenses 	– 	13 713 	(26) 	13 687 	– 	10 765 	11 	10 776
Salvages 	– 	– 	– 	– 	– 	– 	– 	–
Amortisation of assets for
insurance acquisition cash flows 	1 767 	– 	– 	1 767 	1 403 	– 	– 	1 403
Losses and reversal of losses on
onerous contracts 	– 	– 	– 	– 	(1) 	– 	– 	(1)
C 	1 767 	13 713 	(26) 	15 454 	1 402 	10 765 	11 	12 178
Insurance service result 	D = B + C 	(14 707) 	13 713 	(26) 	(1 020) 	(12 268) 	10 765 	11 	(1 492)
Net changes to statement of
profit or loss and OCI 	F = D 	(14 707) 	13 713 	(26) 	(1 020) 	(12 268) 	10 765 	11 	(1 492)
Cash flows
Premiums received 	16 502 	– 	– 	16 502 	13 324 	– 	– 	13 324
Insurance acquisition cash flows 	(755) 	– 	– 	(755) 	(607) 	– 	– 	(607)
Claims and other directly
attributable expenses paid 	– 	(13 936) 	– 	(13 936) 	– 	(10 619) 	– 	(10 619)
Gross claims and insurance
service expenses paid 	– 	(13 936) 	– 	(13 936) 	– 	(10 619) 	– 	(10 619)
Salvages 	– 	– 	– 	– 	– 	– 	– 	–
Total cash flows 	G 	15 747 	(13 936) 	– 	1 811 	12 717 	(10 619) 	– 	2 098
Allocation from assets for
insurance acquisition cash
flows to group of insurance
contracts 	H 	(1 111) 	– 	– 	(1 111) 	(893) 	– 	– 	(893)
Effect of movements in exchange
rates 	I 	17 	(47) 	(2) 	(32) 	(33) 	215 	9 	191
Net balance at the end of year 	K = A + F + G + H + I 	(426) 	1 080 	29 	683 	(372) 	1 350 	57 	1 035
Closing assets arising from
insurance contracts issued 	(426) 	1 080 	29 	683 	(372) 	1 350 	57 	1 035
Net balance at the end of year 	(426) 	1 080 	29 	683 	(372) 	1 350 	57 	1 035
1 The UK Health comparative period has been restated from the reconciliation published in the unaudited Discovery Group interim disclosures for the
six-month period ended 31 December 2023. The effect of these changes are noted in item 5 of D.1.4.

-- 49 of 116 --

61	60	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.8 Movement in reinsurance contract balances: GMM
C.2.3.8.1 SA LIFE AND INVEST (RISK)
ANALYSIS BY REMAINING COVERAGE AND INCURRED CLAIMS
Group
R million
(Assets)/Liabilities 	Navigation
2024 	2023
Assets for Remaining
Coverage (ARC)
Assets for
Incurred
Claims (AIC) 	Total
Assets for Remaining
Coverage (ARC)
Assets for
Incurred
Claims (AIC) 	Total
Excluding loss
recovery
component
Loss
recovery
component
Excluding loss
recovery
component
Loss
recovery
component
Opening liabilities arising from
reinsurance contracts held 	3 027 	(202) 	(2 258) 	567 	3 423 	(148) 	(2 151) 	1 124
Net balance at beginning of the year 	A 	3 027 	(202) 	(2 258) 	567 	3 423 	(148) 	(2 151) 	1 124
Changes in the income statement
and OCI
Allocation of reinsurance premiums
paid 	3 387 	– 	– 	3 387 	3 268 	– 	– 	3 268
Amounts recoverable from reinsurers
Recoveries of incurred claims and other
insurance service expenses 	– 	– 	(3 002) 	(3 002) 	– 	– 	(3 131) 	(3 131)
Recoveries and reversals of recoveries
of losses on onerous underlying
contracts 	– 	39 	– 	39 	– 	(55) 	– 	(55)
Adjustments to assets for incurred
claims 	– 	– 	(10) 	(10) 	– 	– 	– 	–
B 	3 387 	39 	(3 012) 	414 	3 268 	(55) 	(3 131) 	82
Net expenses from reinsurance
contracts 	C = B 	3 387 	39 	(3 012) 	414 	3 268 	(55) 	(3 131) 	82
Net finance expenses from reinsurance
contracts 	D 	177 	(5) 	(106) 	66 	(154) 	1 	(17) 	(170)
Net changes to income statement
and OCI 	E = B + D 	3 564 	34 	(3 118) 	480 	3 114 	(54) 	(3 148) 	(88)
Cash Flows
Premiums paid 	(3 942) 	– 	– 	(3 942) 	(3 510) 	– 	– 	(3 510)
Claims recovered 	– 	– 	3 021 	3 021 	– 	– 	3 041 	3 041
Total cash flows 	F 	(3 942) 	– 	3 021 	(921) 	(3 510) 	– 	3 041 	(469)
Net balance at the end of the year 	G = A +E + F 	2 649 	(168) 	(2 355) 	126 	3 027 	(202) 	(2 258) 	567
Closing liabilities arising from
reinsurance contracts held 	2 649 	(168) 	(2 355) 	126 	3 027 	(202) 	(2 258) 	567
Net balance at the end of the year 	2 649 	(168) 	(2 355) 	126 	3 027 	(202) 	(2 258) 	567

-- 50 of 116 --

63	62	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.8 Movement in reinsurance contract balances: GMM continued
C.2.3.8.2 UK LIFE (RISK)
ANALYSIS BY REMAINING COVERAGE AND INCURRED CLAIMS
Group
R million
(Assets)/Liabilities 	Navigation
2024 	20231
Assets for Remaining
Coverage (ARC)
Assets for
Incurred
Claims (AIC) 	Total
Assets for Remaining
Coverage (ARC)
Assets for
Incurred
Claims (AIC) 	Total
Excluding loss
recovery
component
Loss
recovery
component
Excluding loss
recovery
component
Loss
recovery
component
Opening liabilities arising from
reinsurance contracts held 	7 862 	(2 348) 	(1 262) 	4 252 	6 513 	(1 673) 	(712) 	4 128
Net balance at beginning of the year 	A 	7 862 	(2 348) 	(1 262) 	4 252 	6 513 	(1 673) 	(712) 	4 128
Changes in the income statement
and OCI
Allocation of reinsurance
premiums paid 	5 738 	– 	– 	5 738 	3 482 	– 	– 	3 482
Amounts recoverable from reinsurers 	– 	– 	– 	– 	0 	0 	0 	0
Recoveries of incurred claims and
other insurance service expenses 	– 	– 	(5 349) 	(5 349) 	– 	– 	(3 272) 	(3 272)
Recoveries and reversals of recoveries
of losses on onerous underlying
contracts 	– 	18 	– 	18 	– 	(364) 	– 	(364)
Adjustments to assets for incurred
claims 	– 	– 	– 	– 	– 	– 	– 	–
B 	5 738 	18 	(5 349) 	407 	3 482 	(364) 	(3 272) 	(154)
Net expenses from reinsurance
contracts 	C = B 	5 738 	18 	(5 349) 	407 	3 482 	(364) 	(3 272) 	(154)
Net finance expenses from reinsurance
contracts 	D 	564 	52 	– 	616 	(169) 	59 	– 	(110)
Net changes to income statement
and OCI 	E = B + D 	6 302 	70 	(5 349) 	1 023 	3 313 	(305) 	(3 272) 	(264)
Cash Flows
Premiums paid 	(4 547) 	– 	– 	(4 547) 	(3 268) 	– 	– 	(3 268)
Claims recovered 	– 	– 	4 730 	4 730 	– 	– 	2 907 	2 907
Total cash flows 	F 	(4 547) 	– 	4 730 	183 	(3 268) 	– 	2 907 	(361)
Effect of movements in exchange rates 	G 	(337) 	89 	60 	(188) 	1 304 	(370) 	(185) 	749
Net balance at the end of the year 	H= A +E +F + G 	9 280 	(2 189) 	(1 821) 	5 270 	7 862 	(2 348) 	(1 262) 	4 252
Closing liabilities arising from
reinsurance contracts held 	9 280 	(2 189) 	(1 821) 	5 270 	7 862 	(2 348) 	(1 262) 	4 252
Net balance at the end of the year 	9 280 	(2 189) 	(1 821) 	5 270 	7 862 	(2 348) 	(1 262) 	4 252
1 The UK Life (Risk) comparative period been restated from the reconciliation published in the unaudited Discovery Group interim disclosures for the
six-month period ended 31 December 2023. The effect of these changes are noted in item 5 of D.1.4.

-- 51 of 116 --

65	64	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.9 Movement in reinsurance contract balances: GMM
C.2.3.9.1 SA LIFE AND INVEST (RISK)
ANALYSIS BY MEASUREMENT COMPONENT
Group
R million
(Assets)/Liabilities 	Navigation
2024 	2023
Estimates
of PVFCF
RA for
non-
financial
Risk
CSM
Total
Estimates
of PVFCF
RA for
non-financial
Risk
CSM
Total
Transition:
Modified
retro-
spective
Other
contracts
Transition:
Modified
retrospective
Other
contracts
Opening liabilities arising from
reinsurance contracts held 	6 094 	(698) 	(80) 	(4 749) 	567 	6 315 	(704) 	(75) 	(4 412) 	1 124
Net balance at beginning of the
year 	A 	6 094 	(698) 	(80) 	(4 749) 	567 	6 315 	(704) 	(75) 	(4 412) 	1 124
Changes in the income statement
and OCI
Changes that relate to current services
CSM recognised for services provided 	– 	– 	6 	338 	344 	– 	– 	4 	307 	311
Change in Risk Adjustment for
non-financial risk that relates to
expired risk 	– 	71 	– 	– 	71 	– 	63 	– 	– 	63
Experience adjustments 	(12) 	– 	– 	– 	(12) 	(221) 	– 	– 	– 	(221)
Changes that relate to future services 	0
Contracts initially recognised in the
period 	202 	(22) 	– 	(186) 	(6) 	221 	(25) 	– 	(209) 	(13)
Changes in estimates that adjust CSM 	16 	– 	(16) 	40 	40 	41 	(7) 	– 	(31) 	3
Changes in estimates that relate to
losses and reversal of losses on
underlying contracts 	(17) 	4 	– 	– 	(13) 	(62) 	2 	– 	– 	(60)
Changes that relate to past services 	0
Adjustment to assets for incurred
claims 	– 	(10) 	– 	– 	(10) 	– 	(1) 	– 	– 	(1)
Net Expenses from reinsurance
contracts held 	B 	189 	43 	(10) 	192 	414 	(21) 	32 	4 	67 	82
Net finance income from reinsurance
contracts 	C 	537 	(48) 	(10) 	(413) 	66 	269 	(26) 	(9) 	(404) 	(170)
Net changes to income statement
and OCI 	D = B + C 	726 	(5) 	(20) 	(221) 	480 	248 	6 	(5) 	(337) 	(88)
Cash flows 	E 	(921) 	– 	– 	– 	(921) 	(469) 	– 	– 	– 	(469)
Effect of movements in exchange rates 	F 	– 	– 	– 	– 	– 	– 	– 	– 	– 	–
Net balance at the end of the year G = A + D + E + F 	5 899 	(703) 	(100) 	(4 970) 	126 	6 094 	(698) 	(80) 	(4 749) 	567
Closing liabilities arising from
reinsurance contracts held 	5 899 	(703) 	(100) 	(4 970) 	126 	6 094 	(698) 	(80) 	(4 749) 	567
Net balance at the end of the year 	5 899 	(703) 	(100) 	(4 970) 	126 	6 094 	(698) 	(80) 	(4 749) 	567

-- 52 of 116 --

67	66	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.9 Movement in reinsurance contract balances: GMM continued
C.2.3.9.2 UK LIFE (RISK)
ANALYSIS BY MEASUREMENT COMPONENT
Group
R million
(Assets)/Liabilities 	Navigation
2024 	2023
Estimates
of PVFCF
RA for
non-
financial
Risk
CSM
Total
Estimates
of PVFCF
RA for
non-financial
Risk
CSM
Total
Other
contracts
Other
contracts
Opening liabilities arising from reinsurance
contracts held 	9 701 	(429) 	(5 020) 	4 252 	8 514 	(348) 	(4 038) 	4 128
Net balance at beginning of the year 	A 	9 701 	(429) 	(5 020) 	4 252 	8 514 	(348) 	(4 038) 	4 128
Changes in the income statement and OCI
Changes that relate to current services
CSM recognised for services provided 	– 	– 	495 	495 	– 	– 	391 	391
Change in Risk Adjustment for non-financial risk
that relates to expired risk 	– 	24 	– 	24 	– 	34 	– 	34
Experience adjustments 	22 	– 	– 	22 	(86) 	– 	– 	(86)
Changes that relate to future services
Contracts initially recognised in the period 	1 193 	(65) 	(1 318) 	(190) 	649 	(56) 	(777) 	(184)
Changes in estimates that adjust CSM 	(30) 	(2) 	33 	1 	(231) 	(28) 	282 	23
Changes in estimates that relate to losses and
reversal of losses on underlying contracts 	63 	(8) 	– 	55 	(311) 	(20) 	– 	(331)
Net Expenses from reinsurance contracts held 	B 	1 248 	(51) 	(790) 	407 	21 	(70) 	(104) 	(153)
Net finance income from reinsurance contracts 	C 	743 	(8) 	(119) 	616 	(114) 	59 	(55) 	(110)
Net changes to income statement and OCI 	D = B + C 	1 991 	(59) 	(909) 	1 023 	(93) 	(11) 	(159) 	(263)
Cash flows 	E 	183 	– 	– 	183 	(362) 	– 	– 	(362)
Effect of movements in exchange rates 	F 	(415) 	17 	210 	(188) 	1 642 	(70) 	(823) 	749
Net balance at the end of the year 	G = A + D + E + F 	11 460 	(471) 	(5 719) 	5 270 	9 701 	(429) 	(5 020) 	4 252
Closing liabilities arising from reinsurance
contracts held 	11 460 	(471) 	(5 719) 	5 270 	9 701 	(429) 	(5 020) 	4 252
Net balance at the end of the year 	11 460 	(471) 	(5 719) 	5 270 	9 701 	(429) 	(5 020) 	4 252

-- 53 of 116 --

69	68	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.10 Movement in reinsurance contract balances: PAA
C.2.3.10.1 SA LIFE AND INVEST: GROUP LIFE AND OTHER
ANALYSIS BY REMAINING COVERAGE AND INCURRED CLAIMS
Group
R million
(Assets)/Liabilities 	Navigation
2024 	2023
Asset for
Remaining
Coverage
Asset for Incurred Claims
Total
Asset for
Remaining
Coverage
Asset for Incurred Claims
Total
Estimates
of PVFCF
RA for
non-financial
risk
Estimates
of PVFCF
RA for
non-financial
risk
Opening assets arising from
reinsurance contracts held 	398 	(910) 	(17) 	(529) 	378 	(1 054) 	(15) 	(691)
Net balance at beginning of the
year 	A 	398 	(910) 	(17) 	(529) 	378 	(1 054) 	(15) 	(691)
Changes in the statement of
profit or loss and OCI
Reinsurance premiums expense 	305 	– 	– 	305 	282 	– 	– 	282
Claims recovered from reinsurer 	– 	(265) 	4 	(261) 	– 	(138) 	(2) 	(140)
Net finance income from
reinsurance contracts held 	– 	(48) 	(1) 	(49) 	– 	(31) 	– 	(31)
Net changes to statement of
profit or loss and OCI 	B 	305 	(313) 	3 	(5) 	282 	(169) 	(2) 	111
Cash Flows
Premiums paid net of commissions
and other attributable expenses 	(544) 	– 	– 	(544) 	(262) 	– 	– 	(262)
Reinsurance recoveries 	– 	393 	– 	393 	313 	– 	313
Total cash flows 	C 	(544) 	393 	– 	(151) 	(262) 	313 	– 	51
Net balance at end of the year 	D = A + B + C 	159 	(830) 	(14) 	(685) 	398 	(910) 	(17) 	(529)
Closing assets arising from
reinsurance contracts held 	159 	(830) 	(14) 	(685) 	398 	(910) 	(17) 	(529)
Net balance at end of the year 	159 	(830) 	(14) 	(685) 	398 	(910) 	(17) 	(529)

-- 54 of 116 --

71	70	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.10 Movement in reinsurance contract balances: PAA continued
C.2.3.10.2 SA INSURE AND OTHER
ANALYSIS BY REMAINING COVERAGE AND INCURRED CLAIMS
Group
R million
(Assets)/Liabilities 	Navigation
2024 	2023
Asset for
Remaining
Coverage
Asset for Incurred Claims
Total
Asset for
Remaining
Coverage
Asset for Incurred Claims
Total
Estimates
of PVFCF
RA for
non-financial
risk
Estimates
of PVFCF
RA for
non-financial
risk
Opening assets arising from
reinsurance contracts held 	776 	(845) 	(2) 	(71) 	260 	(440) 	(2) 	(182)
Net balance at beginning of
the year 	A 	776 	(845) 	(2) 	(71) 	260 	(440) 	(2) 	(182)
Changes in the statement of
profit or loss and OCI
Net expenses from reinsurance
contracts held 	– 	– 	– 	–
Reinsurance premiums expense 	732 	– 	– 	732 	635 	– 	– 	635
Recoveries and reversals of
recoveries of losses on onerous
underlying contracts 	– 	– 	– 	– 	– 	– 	– 	–
Claims recovered from reinsurer 	– 	(706) 	– 	(706) 	– 	(590) 	– 	(590)
Net changes to statement of
profit or loss and OCI 	B 	732 	(706) 	– 	26 	635 	(590) 	– 	45
Cash Flows
Premiums paid net of commissions
and other attributable expenses 	(592) 	– 	– 	(592) 	(119) 	– 	– 	(119)
Reinsurance recoveries 	– 	498 	– 	498 	– 	185 	185
Total cash flows 	C 	(592) 	498 	– 	(94) 	(119) 	185 	– 	66
Net balance at end of the year 	D = A +B + C 	916 	(1 053) 	(2) 	(139) 	776 	(845) 	(2) 	(71)
Closing assets arising from
reinsurance contracts held 	916 	(1 053) 	(2) 	(139) 	776 	(845) 	(2) 	(71)
Net balance at end of the year 	916 	(1 053) 	(2) 	(139) 	776 	(845) 	(2) 	(71)

-- 55 of 116 --

73	72	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.10 Movement in reinsurance contract balances: PAA continued
C.2.3.10.3 UK HEALTH (RISK)
ANALYSIS BY REMAINING COVERAGE AND INCURRED CLAIMS
Group
R million
(Assets)/Liabilities 	Navigation
2024 	2023
Asset for
Remaining
Coverage
Asset for Incurred Claims
Total
Asset for
Remaining
Coverage
Asset for Incurred Claims
Total
Estimates
of PVFCF
RA for
non-financial
risk
Estimates
of PVFCF
RA for
non-financial
risk
Opening assets arising from
reinsurance contracts held 	8 	(9) 	(3) 	(4) 	6 	(5) 	(2) 	(1)
Net balance at beginning of
the year 	A 	8 	(9) 	(3) 	(4) 	6 	(5) 	(2) 	(1)
Changes in the statement of
profit or loss and OCI
Reinsurance premiums expense 	(2) 	– 	– 	(2) 	1 847 	– 	– 	1 847
Claims recovered from reinsurer 	– 	2 	1 	3 	– 	(1 837) 	(1) 	(1 838)
Net changes to statement of
profit or loss and OCI 	B 	(2) 	2 	1 	1 	1 847 	(1 837) 	(1) 	9
Cash Flows
Premiums paid net of commissions
and other attributable expenses 	(10) 	– 	– 	(10) 	(1 845) 	– 	– 	(1 845)
Reinsurance recoveries 	– 	– 	– 	– 	– 	1 833 	– 	1 833
Total cash flows 	C 	(10) 	– 	– 	(10) 	(1 845) 	1 833 	– 	(12)
Effect of movements in exchange
rates 	D 	– 	– 	– 	– 	– 	– 	– 	–
Net balance at end of the year 	E = A +B + C + D 	(4) 	(7) 	(2) 	(13) 	8 	(9) 	(3) 	(4)
Closing assets arising from
reinsurance contracts held 	(4) 	(7) 	(2) 	(13) 	8 	(9) 	(3) 	(4)
Net balance at end of the year 	(4) 	(7) 	(2) 	(13) 	8 	(9) 	(3) 	(4)

-- 56 of 116 --

75	74	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.11 Insurance revenue
The following tables present an analysis of the insurance revenue recognised in the period.
Group
R million
Income/(expense)
SA Life and
Invest Risk
(GMM)
SA Life and
Invest
Participating
(VFA)
SA Life and
Invest: Group
Life and other
(PAA)
SA Insure
and other
immaterial
(PAA)
UK Life Risk
(GMM)1
UK Health
(PAA) 	Total
Year ended 30 June 2024
Contracts not measured under the PAA
Amounts relating to changes in liabilities for remaining coverage 	12 630 	2 572 	– 	– 	4 294 	– 	19 496
– CSM recognised for services provided 	1 858 	1 222 	– 	– 	1 241 	– 	4 321
– Change in risk adjustment for non-financial risk for risk expired 	611 	201 	– 	– 	201 	– 	1 013
– Expected incurred claims and other insurance service expenses 	10 214 	1 074 	– 	– 	3 146 	– 	14 434
– Experience adjustments 	(53) 	75 	– 	– 	(294) 	– 	(272)
Recovery of insurance acquisition cash flows 	2 142 	757 	– 	– 	2 610 	– 	5 509
Contracts not measured under the PAA 	14 772 	3 329 	– 	– 	6 904 	– 	25 005
Contracts measured under the PAA 	– 	– 	3 517 	6 861 	– 	16 474 	26 852
Total insurance revenue 	14 772 	3 329 	3 517 	6 861 	6 904 	16 474 	51 857
Year ended 30 June 2023
Contracts not measured under the PAA
Amounts relating to changes in liabilities for remaining coverage 	12 124 	2 168 	– 	– 	3 531 	– 	17 823
– CSM recognised for services provided 	1 836 	1 101 	– 	– 	1 102 	– 	4 039
– Change in risk adjustment for non-financial risk for risk expired 	595 	148 	– 	– 	213 	– 	956
– Expected incurred claims and other insurance service expenses 	9 653 	927 	– 	– 	2 397 	– 	12 977
– Experience adjustments 	40 	(8) 	– 	– 	(181) 	– 	(149)
Recovery of insurance acquisition cash flows 	1 713 	694 	– 	– 	2 047 	4 454
Contracts not measured under the PAA 	13 837 	2 862 	– 	– 	5 578 	– 	22 277
Contracts measured under the PAA 	– 	– 	3 307 	6 000 	– 	13 670 	22 977
Total insurance revenue 	13 837 	2 862 	3 307 	6 000 	5 578 	13 670 	45 254
1 The UK Life (Risk) column been restated from the reconciliation of the revenue published in the unaudited Discovery Group interim disclosures for the
six-month period ended 31 December 2023. The effect of these changes are noted in item 5 of D.1.4.

-- 57 of 116 --

77	76	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.12 Net investment result
The following table analyses the Group’s net investment result in profit or loss and OCI.
Group
R million
Income/(expense)
SA Life and
Invest Risk
(GMM)
SA Life and
Invest
Participating
(VFA)
SA Life and
Invest: Group
Life and other
(PAA)
SA Insure
and other
(PAA)
UK Life Risk
(GMM)
UK Health
(PAA)
Other
businesses 	Total
Year ended 30 June 2024
Investment return
Interest revenue from financial assets not measured at FVTPL 	22 	– 	– 	234 	58 	160 	386 	860
Net gains on FVTPL investments 	2 243 	7 843 	506 	1 	– 	60 	5 592 	16 245
Total investment return 	2 265 	7 843 	506 	235 	58 	220 	5 978 	17 105
Finance income/(expenses) from insurance contracts
Changes in fair value of underlying items of direct participation contracts 	– 	(7 789) 	– 	– 	– 	– 	– 	(7 789)
Interest accreted to the CSM 	(2 512) 	(1 112) 	– 	– 	(239) 	– 	– 	(3 863)
Interest on FCF and other finance (income)/expenses 1 	2 320 	1 091 	(381) 	– 	1 643 	– 	– 	4 673
Effect of changes in interest rates and other financial assumptions 	(4) 	– 	40 	– 	1 403 	– 	– 	1 439
Effect of changing FCF at current rates when adjusting the CSM at rates on initial recognition 	2 323 	– 	– 	– 	(44) 	– 	– 	2 279
Effect of movements in exchange rates 	(51) 	– 	5 	– 	– 	– 	– 	(46)
Net finance expenses from insurance contracts 	2 076 	(7 810) 	(336) 	– 	2 763 	– 	– 	(3 307)
Finance income/(expenses) from reinsurance contracts
Interest accreted 	(129) 	– 	53 	– 	119 	– 	– 	43
Other 	63 	– 	(4) 	– 	(735) 	– 	– 	(676)
Net finance Income from reinsurance contracts 	(66) 	– 	49 	– 	(616) 	– 	– 	(633)
Movement in investment contract liabilities 	– 	– 	– 	– 	– 	– 	(2 142) 	(2 142)
Movement in third party interests in consolidated funds 	– 	– 	– 	– 	– 	– 	(2 873) 	(2 873)
– 	– 	– 	– 	– 	– 	(5 015) 	(5 015)
Represented by:
Amounts recognised in statement of profit or loss 	727 	(7 810) 	(394) 	– 	232 	– 	– 	(7 245)
Amounts recognised in OCI 	1 283 	– 	107 	– 	1 915 	– 	– 	3 305
2 010 	(7 810) 	(287) 	– 	2 147 	– 	– 	(3 940)
Insurance finance income and expenses
Amounts recognised in statement of profit or loss 	986 	(7 810) 	(458) 	– 	380 	– 	– 	(6 902)
Amounts recognised in OCI 	1 090 	– 	122 	– 	2 383 	– 	– 	3 595
2 076 	(7 810) 	(336) 	– 	2 763 	– 	– 	(3 307)
Net finance income from reinsurance contracts
Amounts recognised in statement of profit or loss 	(259) 	– 	64 	– 	(148) 	– 	– 	(343)
Amounts recognised in OCI 	193 	– 	(15) 	– 	(469) 	– 	– 	(290)
(66) 	– 	49 	– 	(616) 	– 	– 	(633)
1 For SA Life and Invest GMM Risk, the interest accreted on FCF and other finance (income)/expense includes for Individual life finance income
of R4 195 million, and guaranteed endowments finance expense of R1 875 million.

-- 58 of 116 --

79	78	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.12 Net investment result continued
The following table analyses the Group’s net investment result in profit or loss and OCI.
The table has been restated from the previously published information in the unaudited interest results for the six months
ended 31 December 2023. The restated information includes the following changes:
 Changes which affect total net investment results
– Correction of prior period errors as per note D.1.4 item 5.
 Changes which do not affect total net investment results
– Allocation of the net gains on FVTPL investments have been corrected between the portfolios SA Life and Invest Risk (GMM),
SA Life and Group Risk (PAA) and Other - which includes umbrella funds.
– 	The net finance expenses from insurance contracts have been reassessed, in line with June 2024 analysis, reallocated the
items to correctly reflect the driver for the change
Group
R million
Income/(expense)
SA Life and
Invest Risk
(GMM)
SA Life and
Invest
Participating
(VFA)
SA Life
Group Risk
(PAA)
SA Insure
and other
immaterial
(PAA)
UK Life Risk
(GMM)
UK Health
(PAA)
Other
businesses 	Total
Year ended 30 June 2023
Investment return
Interest revenue from financial assets not measured at FVTPL 	6 	– 	– 	181 	54 	90 	285 	616
Net gains on FVTPL investments 	1 465 	8 326 	228 	311 	1 	6 901 	17 232
Total investment return 	1 471 	8 326 	228 	181 	365 	91 	7 186 	17 848
Finance income/(expenses) from insurance contracts
Changes in fair value of underlying items of direct participation contracts 	– 	(8 252) 	– 	– 	– 	– 	– 	(8 252)
Interest accreted to the CSM 	(2 281) 	(568) 	– 	– 	(145) 	– 	– 	(2 994)
Interest on FCF and other finance (income)/expenses 1 	1 478 	537 	(266) 	– 	672 	– 	– 	2 421
Effect of changes in interest rates and other financial assumptions 	(3 005) 	– 	84 	– 	(64) 	– 	– 	(2 985)
Effect of changing FCF at current rates when adjusting the CSM at rates on initial recognition 	446 	– 	– 	– 	– 	– 	446
Effect of movements in exchange rates 	96 	– 	(19) 	– 	817 	– 	– 	894
Net finance expenses from insurance contracts 	(3 266) 	(8 283) 	(201) 	– 	1 280 	– 	– 	(10 470)
Finance income/(expenses) from reinsurance contracts
Interest accreted 	(25) 	– 	43 	55 	– 	– 	73
Other 	195 	– 	(12) 	55 	– 	– 	238
Net finance Income from reinsurance contracts 	170 	– 	31 	– 	110 	– 	311
Movement in investment contract liabilities 	– 	– 	– 	– 	– 	– 	(3 099) 	(3 099)
Movement in third party interests in consolidated funds 	– 	– 	– 	– 	– 	– 	(2 978) 	(2 978)
– 	– 	– 	– 	– 	– 	(6 077) 	(6 077)
Represented by:
Amounts recognised in statement of profit or loss 	1 267 	(8 283) 	(355) 	– 	(24) 	– 	– 	(7 395)
Amounts recognised in OCI 	(4 363) 	– 	185 	– 	1 414 	– 	– 	(2 764)
(3 096) 	(8 283) 	(170) 	– 	1 390 	– 	– 	(10 159)
Insurance finance income and expenses
Net finance expenses from insurance contracts
Amounts recognised in statement of profit or loss 	1 553 	(8 283) 	(415) 	– 	56 	– 	– 	(7 089)
Amounts recognised in OCI 	(4 819) 	– 	214 	– 	1 224 	– 	– 	(3 381)
(3 266) 	(8 283) 	(201) 	– 	1 280 	– 	– 	(10 470)
Net finance income from reinsurance contracts
Amounts recognised in statement of profit or loss 	(286) 	– 	60 	– 	(80) 	– 	– 	(306)
Amounts recognised in OCI 	456 	– 	(29) 	– 	190 	– 	– 	617
170 	– 	31 	– 	110 	– 	– 	311
1 For SA Life and Invest GMM Risk, the interest accreted on FCF and other finance (income)/expense includes for Individual life finance income
of R2 284 million, and guaranteed endowments finance expense of R1 293 million.

-- 59 of 116 --

81	80	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.13 Effect of contracts initially recognised in the year
C.2.3.13.1 INSURANCE CONTRACTS
Group
R million
Assets/(Liabilities)
Profitable contracts issued 	Onerous contracts issued
Total
SA Life and
Invest Risk
(GMM)
SA Life and
Invest
Participating
(VFA)
UK Life Risk
(GMM)
SA Life and
Invest Risk
(GMM)
SA Life and
Invest
Participating
(VFA)
UK Life Risk
(GMM)
Year ended 30 June 2024
Insurance acquisition cash flows 	(1 482) 	(421) 	(3 766) 	(127) 	(113) 	(1 022) 	(6 931)
Claims and other insurance service expenses payable 	(7 216) 	(5 973) 	(4 994) 	(645) 	(1 834) 	(2 090) 	(22 752)
Estimates of present value of cash outflows 	(8 698) 	(6 394) 	(8 760) 	(772) 	(1 947) 	(3 112) 	(29 683)
Estimates of present value of cash inflows 	10 984 	6 940 	10 549 	743 	1 911 	2 897 	34 024
Risk adjustment for non-financial risk 	(398) 	(56) 	(307) 	(32) 	(14) 	(62) 	(868)
CSM 	(1 888) 	(490) 	(1 482) 	– 	– 	– 	(3 860)
Losses recognised on initial recognition 	– 	– 	– 	(61) 	(50) 	(277) 	(387)
Year ended 30 June 2023
Insurance acquisition cash flows 	(1 380) 	(437) 	(3 077) 	(156) 	(66) 	(827) 	(5 943)
Claims and other insurance service expenses payable 	(5 845) 	(6 733) 	(4 330) 	(630) 	(1 232) 	(1 915) 	(20 685)
Estimates of present value of cash outflows 	(7 225) 	(7 170) 	(7 407) 	(786) 	(1 298) 	(2 742) 	(26 628)
Estimates of present value of cash inflows 	9 474 	8 019 	8 846 	740 	1 280 	2 529 	30 890
Risk adjustment for non-financial risk 	(413) 	(67) 	(271) 	(37) 	(3) 	(59) 	(851)
CSM 	(1 836) 	(782) 	(1 167) 	– 	– 	– 	(3 785)
Losses recognised on initial recognition 	– 	– 	– 	(83) 	(21) 	(271) 	(375)
C.2.3.13.2 REINSURANCE CONTRACTS
Group
R million
Assets/(Liabilities)
Group of contracts with a net
cost on initial recognition 1
Total
SA Life and
Invest Risk
(GMM)
UK Life Risk
(GMM) 2
Year ended 30 June 2024
Estimates of present value of cash outflows 	(1 134) 	(9 103) 	(10 237)
Estimates of present value of cash inflows 	932 	7 910 	8 842
Risk adjustment for non-financial Risk 	22 	65 	87
Income recognised on initial recognition (for offset) 	(6) 	(190) 	(196)
CSM 	(186) 	(1 318) 	(1 504)
Year ended 30 June 2023
Estimates of present value of cash outflows 	(1 241) 	(6 331) 	(7 572)
Estimates of present value of cash inflows 	1 020 	5 682 	6 702
Risk adjustment for non-financial Risk 	25 	56 	81
Income recognised on initial recognition (for offset) 	(13) 	(184) 	(197)
CSM 	(209) 	(777) 	(986)
1 Group of contracts with a net cost on initial recognition refers to those reinsurance contracts with a CSM on initial recognition, that will reflect
as a future cost relative to the insurance contract CSM that will release as future revenue.
2 The UK Life (Risk) column been restated from the reconciliation published in the unaudited Discovery Group interim disclosures for the six-month period
ended 31 December 2023. The effect of these changes are noted in item 5 of D.1.4.

-- 60 of 116 --

82	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.14 Contractual service margin – expected recognition profile
The following table sets out when the Group expects to recognise the remaining CSM in profit or loss after the reporting date
for contracts not measured under the PAA.
Group
R million
(Assets)/Liabilities
Year of expected release of the CSM
Total	< 1 year
1 to 2
years
3 to 5
years
6 to 10
years
10 to 20
years 	>20 years
Assets arising from
insurance contract issued
Year ended 30 June 2024
SA Life and Invest Risk (GMM)
Balance at beginning
of the period 	25 307 	25 597 	26 186 	29 469 	39 435 	71 632 	25 307
Accretion of interest 	2 378 	2 527 	8 718 	19 559 	63 082 	344 304 	440 568
Recognised in income
statement 	(2 088) 	(1 938) 	(5 435) 	(9 593) 	(30 885) 	(415 936) 	(465 875)
Balance at end of the period 	25 597 	26 186 	29 469 	39 435 	71 632 	– 	–
SA Life and Invest Risk (VFA)
Balance at beginning of
the period 	6 306 	6 377 	6 031 	5 756 	6 263 	5 074 	6 306
Accretion of interest 	1 058 	1 088 	3 920 	8 350 	16 006 	1 660 	32 082
Recognised in income
statement 	(987) 	(1 434) 	(4 195) 	(7 843) 	(17 195) 	(6 734) 	(38 388)
Balance at end of the period 	6 377 	6 031 	5 756 	6 263 	5 074 	– 	–
UK Life Risk (GMM)
Balance at beginning of
the period 	13 312 	12 347 	11 471 	9 232 	6 276 	2 367 	13 312
Accretion of interest 	249 	227 	586 	749 	827 	411 	3 049
Recognised in income
statement 	(1 214) 	(1 103) 	(2 825) 	(3 705) 	(4 736) 	(2 778) 	(16 361)
Balance at end of the period 	12 347 	11 471 	9 232 	6 276 	2 367 	– 	–
Total balance at beginning
of year 	44 925
Year ended 30 June 2023
SA Life and Invest Risk (GMM)
Balance at beginning of
the period 	28 252 	28 532 	29 081 	31 775 	41 229 	73 004 	28 252
Accretion of interest 	2 440 	2 622 	9 067 	19 946 	63 837 	327 204 	425 116
Recognised in income
statement 	(2 160) 	(2 073) 	(6 373) 	(10 492) 	(32 062) 	(400 208) 	(453 368)
Balance at end of the period 	28 532 	29 081 	31 775 	41 229 	73 004 	– 	–
SA Life and Invest Risk (VFA)
Balance at beginning of
the period 	6 068 	5 881 	5 686 	5 596 	6 460 	5 644 	6 068
Accretion of interest 	1 077 	1 120 	3 926 	8 699 	18 170 	5 344 	38 336
Recognised in income
statement 	(1 264) 	(1 315) 	(4 016) 	(7 835) 	(18 986) 	(10 988) 	(44 404)
Balance at end of the period 	5 881 	5 686 	5 596 	6 460 	5 644 	– 	–
UK Life Risk (GMM)
Balance at beginning of
the period 	13 806 	12 734 	11 781 	9 395 	6 312 	2 295 	13 806
Accretion of interest 	206 	191 	498 	641 	671 	281 	2 488
Recognised in income
statement 	(1 276) 	(1 146) 	(2 884) 	(3 724) 	(4 688) 	(2 576) 	(16 294)
Balance at end of the period 	12 736 	11 779 	9 395 	6 312 	2 295 	– 	–
Total balance at beginning
of year 	48 126

-- 61 of 116 --

83
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.14 Contractual service margin – expected recognition profile continued
The following table sets out when the Group expects to recognise the remaining CSM in profit or loss after the reporting date
for contracts not measured under the PAA.
Group
R million
Assets/(Liabilities)
Year of expected release of the CSM
Total	< 1 year
1 to 2
years
3 to 5
years
6 to 10
years
10 to 20
years 	>20 years
Liabilities arising from
reinsurance contracts held
Year ended 30 June 2024
SA Life and Invest Risk (GMM)
Balance at beginning of
the period 	5 070 	5 169 	5 298 	5 861 	7 051 	10 273 	5 070
Accretion of interest 	457 	480 	1 601 	3 269 	8 974 	40 606 	55 387
Recognised in income
statement 	(358) 	(351) 	(1 038) 	(2 079) 	(5 752) 	(50 879) 	(60 457)
Balance at end of the year 	5 169 	5 298 	5 861 	7 051 	10 273 	– 	–
UK Life Risk (GMM)
Balance at beginning of
the period 	5 719 	5 337 	4 986 	4 084 	2 882 	1 193 	5 719
Accretion of interest 	141 	126 	317 	408 	489 	268 	1 749
Recognised in income
statement 	(523) 	(477) 	(1 219) 	(1 610) 	(2 178) 	(1 461) 	(7 46)
Balance at end of the year 	5 337 	4 986 	4 084 	2 882 	1 193 	– 	–
Total balance at beginning
of year 	10 789
Year ended 30 June 2023
SA Life and Invest Risk (GMM)
Balance at beginning of
the period 	4 829 	4 907 	5 002 	5 467 	6 506 	9 478 	4 829
Accretion of interest 	423 	445 	1 478 	3 009 	8 206 	37 711 	51 272
Recognised in income
statement 	(345) 	(350) 	(1 013) 	(1 970) 	(5 234) 	(47 189) 	(56 102)
Balance at end of the year 	4 907 	5 002 	5 467 	6 506 	9 478 	– 	–
UK Life Risk (GMM)
Balance at beginning of
the period 	5 020 	4 643 	4 304 	3 454 	2 355 	881 	5 020
Accretion of interest 	88 	80 	200 	252 	277 	113 	1 010
Recognised in income
statement 	(465) 	(419) 	(1 050) 	(1 351) 	(1 751) 	(994) 	(6 030)
Balance at end of the year 	4 643 	4 304 	3 454 	2 355 	881 	– 	–
Total balance at beginning
of year 	9 849

-- 62 of 116 --

84	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.15 Insurance finance income and expenses reserve – expected run-off profile
The following table sets out when the Group expects to recognise the remaining insurance finance income and expense
reserve the reporting date for contracts not measured under the PAA and the long-term claims in the Group Life business.
Group
R million
Income/(Expense)
Year of expected run-off of the IFIE reserve
Total	< 1 year
1 to 2
years
3 to 5
years
6 to 10
years
10 to 20
years 	>20 years
Assets arising from
insurance contract issued
Year ended 30 June 2024
SA Life and Invest Risk (GMM)
Balance at beginning of
the period 	5 532 	7 268 	9 167 	13 662 	14 612 	18 519 	5 532
Movement in IFIE reserve 	1 736 	1 899 	4 495 	950 	(33 131) 	(18 519) 	(5 532)
Balance at end of the period 	7 268 	9 167 	13 662 	14 612 	18 519 	– 	–
SA Life and Invest: Group Life
and other (PAA)
Balance at beginning of
the period 	(337) 	(466) 	(601) 	(935) 	(1 229) 	(46) 	(337)
Movement in IFIE reserve 	(129) 	(135) 	(334) 	(294) 	1 183 	46 	337
Balance at end of the period 	(466) 	(601) 	(935) 	(1 229) 	(46) 	– 	–
UK Life Risk (GMM)
Balance at beginning of
the period 	(2 385) 	(3 010) 	(3 378) 	(3 877) 	(4 145) 	(3 276) 	(2 385)
Movement in IFIE reserve 	(625) 	(368) 	(499) 	(268) 	869 	3 276 	2 385
Balance at end of the period 	(3 010) 	(3 378) 	(3 877) 	(4 145) 	(3 276) 	– 	–
Total balance at beginning
of year 	2 810
Year ended 30 June 2023
SA Life and Invest Risk (GMM)
Balance at beginning of
the period 	6 622 	8 282 	10 194 	16 025 	22 128 	14 283 	6 622
Movement in IFIE reserve 	1 660 	1 912 	5 831 	6 103 	(7 845) 	(14 283) 	(6 622)
Balance at end of the period 	8 282 	10 194 	16 025 	22 128 	14 283 	–
SA Life and Invest: Group Life
and other (PAA)
Balance at beginning of
the period 	(214) 	(318) 	(429) 	(743) 	(1 054) 	(610) 	(214)
Movement in IFIE reserve 	(104) 	(111) 	(314) 	(311) 	444 	610 	214
Balance at end of the period 	(318) 	(429) 	(743) 	(1 054) 	(610) 	– 	–
UK Life Risk (GMM)
Balance at beginning of
the period 	(53) 	(1 035) 	(1 878) 	(3 183) 	(3 737) 	(3 043) 	(53)
Movement in IFIE reserve 	(982) 	(843) 	(1 305) 	(554) 	694 	3 043 	53
Balance at end of the period 	(1 035) 	(1 878) 	(3 183) 	(3 737) 	(3 043) 	– 	–
Total balance at beginning
of year 	6 355

-- 63 of 116 --

85
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.15 Insurance finance income and expenses reserve – expected run-off profile continued
The following table sets out when the Group expects to recognise the remaining insurance finance income and expense
reserve the reporting date for contracts not measured under the PAA and the long-term claims in the Group Life business.
Group
R million
(Income)/Expense
Year of expected run-off of the IFIE reserve
Total	< 1 year
1 to 2
years
3 to 5
years
6 to 10
years
10 to 20
years 	>20 years
Liabilities arising from
reinsurance contracts from
reinsurance contracts held
Year ended 30 June 2024
SA Life and Invest Risk (GMM)
Balance at beginning of
the period 	1 552 	1 739 	1 935 	2 350 	2 452 	66 	1 552
Movement in IFIE reserve 	187 	196 	415 	102 	(2 386) 	(66) 	(1 552)
Recognised in income
statement 	– 	– 	– 	– 	– 	– 	–
Balance at end of the year 	1 739 	1 935 	2 350 	2 452 	66 	–
SA Life Group Risk (PAA)
Balance at beginning of
the period 	(44) 	(61) 	(79) 	(123) 	(162) 	(7) 	(44)
Movement in IFIE reserve 	(17) 	(18) 	(44) 	(39) 	155 	7 	44
Balance at end of the period 	(61) 	(79) 	(123) 	(162) 	(7) 	–
UK Life Risk (GMM)
Balance at beginning of
the period 	187 	6 	(64) 	(103) 	(143) 	(153) 	187
Movement in IFIE reserve 	(181) 	(70) 	(39) 	(39) 	(10) 	153 	(187)
Recognised in income
statement 	– 	– 	– 	– 	– 	– 	–
Balance at end of the year 	6 	(64) 	(103) 	(143) 	(153) 	– 	(0)
Total balance at beginning
of year 	1 695
Year ended 30 June 2023
SA Life and Invest Risk (GMM)
Balance at beginning of
the period 	1 358 	1 519 	1 693 	2 138 	2 432 	1 588 	1 358
Movement in IFIE reserve 	161 	174 	445 	294 	(844) 	(1 588) 	(1 358)
Recognised in income
statement 	– 	– 	– 	– 	– 	– 	–
Balance at end of the year 	1 519 	1 693 	2 138 	2 432 	1 588 	– 	–
SA Life Group Risk (PAA)
Balance at beginning of
the period 	(30) 	(44) 	(59) 	(103) 	(146) 	(84) 	(30)
Movement in IFIE reserve 	(14) 	(15) 	(43) 	(43) 	61 	84 	30
Balance at end of the year 	(44) 	(59) 	(102) 	(146) 	(85) 	– 	–
UK Life Risk (GMM)
Balance at beginning of
the period 	672 	352 	125 	(100) 	(156) 	(136) 	672
Movement in IFIE reserve 	(320) 	(227) 	(225) 	(56) 	20 	136 	(672)
Recognised in income
statement 	– 	– 	– 	– 	– 	– 	–
Balance at end of the year 	352 	125 	(100) 	(156) 	(136) 	– 	–
Total balance at beginning
of year 	2 000

-- 64 of 116 --

86	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.16 Claims development
The following table outlines the expected runoff of the in-claims liabilities reconciled with the aggregate carrying amount of the
groups of insurance contracts. The comparison between actual in-period claims and previous estimates of the claims amount
are shown below the table.
Estimate of cumulative claims gross of reinsurance
Group
R million
Expected gross
of reinsurance
claim payments
Expected net
of reinsurance
claim payments
Year ended 30 June 2024
< 1 year 	1 702 	1 368
1 – 2 years 	1 461 	1 175
2 – 3 years 	1 317 	1 062
3 – 4 years 	1 209 	979
4 – 5 years 	1 129 	914
6 – 10 years 	4 726 	3 838
10 – 20 years 	5 648 	4 565
> 20 years 	1 648 	1 368
Total income disability liability for incurred claims 	18 840 	15 269
Effect of discounting 	(9 920) 	(8 062)
Risk adjustment 	121 	94
Other claims settled within 1 year 	4 608 	3 149
Total liabilities for incurred claims in the Statement of
financial position 	13 649 	10 450
Included in the LIC balance for the following portfolios:
SA Life and Invest (Risk) | GMM 	7 619 	5 264
SA Life and Invest: Group Life and Other | PAA 	6 030 	5 186
Total actual recurring benefit liability claims payments made in the
period 01 July to 30 June 	1 707 	1 341

-- 65 of 116 --

87
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.16 Claims development continued
Estimate of cumulative claims net of reinsurance
Group
R million
Expected gross
of reinsurance
claim payments
Expected gross
of reinsurance
claim payments
Year ended 30 June 2023
< 1 year 	1 445 	1 167
1 – 2 years 	1 275 	1 001
2 – 3 years 	1 171 	924
3 – 4 years 	1 090 	868
4 – 5 years 	1 007 	800
6 – 10 years 	4 240 	3 380
10 – 20 years 	5 232 	4 164
> 20 years 	2 069 	1 785
Total income disability liability for incurred claims 	17 529 	14 089
Effect of discounting 	(9 677) 	(7 700)
Risk adjustment 	140 	111
Creditors and debtors included in LIC 	3 901 	2 209
Total liabilities for incurred claims in the Statement of
financial position 	11 893 	8 709
Included in the LIC balance for the following portfolios:
SA Life and Invest (Risk) |GMM 	6 621 	4 364
SA Life and Invest: Group Life and Other | PAA 	5 272 	4 345
Total actual recurring benefit liability claims payments made in the
period 01 July to 30 June 	1 529 	1 173

-- 66 of 116 --

88	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.17 Significant accounting estimates and judgements in applying accounting policies
In preparing these results, estimates, assumptions, and judgements are made that could materially affect the reported
amounts of assets and liabilities within the next financial year. Accounting estimates and judgements are regularly reviewed
and are based on historical experience, current best estimates, and expectations of future outcomes as well as anticipated
changes in the environment. The following represents the most material key assumptions applied by management in
preparing these results.
I. INSURANCE CONTRACTS SCOPE AND GROUPING
DEFINITION AND CLASSIFICATION
a. Definition
IFRS 17 does not specify what significant insurance risk is. Discovery’s policy defines significant insurance risk as follows:
The possibility that the present value of losses arising on the insurance contract exceeds 10% of the present value of
income and receipts collected when applying a worst-case scenario upon the inception of the insurance contract.
b. Classification
Eligibility for VFA
Within Discovery, the unit-linked products offered by Discovery Life are examples of insurance contracts with direct
participation features. The VFA is used to measure insurance contracts with direct participating features.
Discovery exercises judgement in determining whether the VFA eligibility criteria are met at initial recognition. Judgement is
applied for the following eligibility criteria to use VFA:
 Discovery expects to pay to the policyholder an amount equal to a substantial share of the fair value returns on the
underlying items and
 Discovery expects a substantial proportion of any change in the amounts to be paid to the policyholder to vary with the
change in fair value of the underlying items.
Within Discovery, a “substantial share” and “substantial proportion” is deemed to represent a proportion that exceeds 50%
as a rebuttable presumption.
UNIT OF ACCOUNT, AGGREGATION AND RECOGNITION OF INSURANCE AND REINSURANCE CONTRACTS
Discovery uses judgement to determine at what level of granularity Discovery has reasonable and supportable information
that is sufficient to conclude that all contracts within a set are sufficiently homogeneous and will be allocated to the same
group without performing an individual contract assessment.
Discovery performs stress testing on portfolios measured using GMM/VFA. The stresses are modelled at the policy inception
date and may differ between portfolios but will correspond to the most significant non-financial stresses currently run as
part of the risk appetite work. If any policy that was originally determined to be profitable becomes onerous under any of
the three additional stresses calculated, that policy is classified as profitable-at-risk.
II. CONTRACTS MEASURED UNDER THE GMM AND VFA
Discovery provides detailed qualitative information about the inputs, assumptions, and estimation techniques that are
considered significant and material for measuring insurance and reinsurance contracts. Where applicable, Discovery also
provides quantitative information. However, detailed disclosure of quantitative information is not provided when it is
impracticable to do so. This impracticality may arise due to one or a combination of the following reasons:
 The assumptions are set at a highly granular level to support the unique dynamic underwriting approach used in the
product design. The quantitative inputs are therefore extensive.
 The dynamic underwriting approach leads to assumptions which are interdependent therefore the quantitative inputs
in one category may be misleading or misinterpreted if not considered together with other assumptions and inputs.
 The assumptions are partly derived from internal data which is commercially sensitive and impacts Discovery’s
competitive position.
III. EXPECTED FULFILMENT CASH FLOWS (EFCF)
In line with the requirements of IFRS 17, Discovery applies judgement to determine which cash flows within the boundary of
insurance contracts relate directly to the fulfilment of the contracts, including the extent to which fixed and variable
overheads are directly attributable to fulfilling insurance contracts.

-- 67 of 116 --

89
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.17 Significant accounting estimates and judgements in applying accounting policies
continued
Discovery primarily uses deterministic projections to estimate the present value of future cash flows. The following
assumptions were used when estimating future cash flows:
The assumptions used are best estimate assumptions, with the addition of a margin for risk in the assumption being allowed
for in the risk adjustment.
A. MORTALITY AND MORBIDITY
Assumptions of future mortality and morbidity experience are derived from reinsurers and industry data and compared to
actual past experience. Where appropriate, the assumptions are adjusted to reflect actual past experience or for expected
changes in future experience.
The assumptions are modified for each policy based on actual data from underwriting performed on the policy and
compared against standard industry tables for reasonability. The key mortality and morbidity assumptions are reviewed and
benchmarked against the industry to ensure the reasonability of assumptions for Discovery Life. An adjustment to the
standard mortality and morbidity assumptions is made to reflect the expected impact of engagement in the Vitality
programme. It has been observed that higher rates of engagement result in lower mortality and morbidity claims.
For VitalityLife the mortality assumptions are set using mortality tables published by the Continuous Mortality Investigation
(CMI), a subsidiary of the Institute and Faculty of Actuaries, and using the CMI projection model to allow for future mortality
improvements. Where appropriate, the assumptions are adjusted to reflect actual past experience or for expected changes
in future experience. Morbidity assumptions are derived from reinsurer and industry data where available and adjusted for
actual past experience where appropriate. An adjustment to the standard mortality and morbidity assumptions is made to
reflect the expected impact of engagement in the Vitality programme.
A possible increase in mortality rates increases estimates of future cash outflows and thus decreases the CSM. For a
sensitivity analysis, refer to Section C.2.4.1.
The sensitivity of the policyholder liabilities due to changes in mortality and morbidity assumptions are set out in section
C.2.4.3.1 and C.2.4.3.2.
B. SURRENDER AND LAPSE RATES
Lapse rates are based on actual past experience where available. The lapse analysis is done by considering the in–force
duration of policies. For durations longer than actual data, lapse rates are set based on expectations of future experience
based on internal and external expert advice as well as available industry benchmarking. The lapse experience investigation
covers at least the last two years of lapse experience to identify trends.
Lapse assumptions are varied between different types of policies where the lapse experience is expected to differ
significantly. Allowance is made for the estimated impact of the economic environment. For Discovery Life and VitalityLife,
an adjustment is made to the lapse assumptions to reflect the expected impact of engagement in the Vitality programme
because it has been observed that higher rates of engagement result in lower lapses.
For Discovery Life, the surrender rates are also based on actual past experience where available.
Possible increases in lapse and surrender rates could increase or decrease estimates of future cash outflows and thus
decrease or increase the CSM, depending on the product specifics.
The sensitivity of the policyholder assets and liabilities due to changes in lapse rate assumptions are set out in section
C.2.4.3.1 and C.2.4.3.2.

-- 68 of 116 --

90	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.17 Significant accounting estimates and judgements in applying accounting policies
continued
C. DISCOUNT RATES AND INVESTMENT RETURNS
Discount rate
The bottom-up approach was used to derive the discount rate for the cash flows of portfolios with no tangible asset
backing. Under this approach, the discount rate is determined as the risk-free yield, adjusted for differences in liquidity
characteristics of the insurance contracts sold, where applicable.
The adjustment for the liquidity should reflect the contract’s liquidity from the policyholder’s perspective, i.e., it should
consider both the explicit and implicit impediments for the policyholder to terminate the contract.
From Discovery’s perspective, there is an immaterial liquidity risk on the whole of life insurance portfolio given that the
products:
 do not charge a surrender penalty on lapse. There is no direct impediment for the policyholder to lapse their contract.
 most policyholders select age-based premium escalation patterns - this provides a broad match between the increase
in premium and the escalating risk over time, leading to a significantly lower implicit impediment to lapse their contract
as value does not accumulate to the extent it would in a level-premium contract for example.
For Discovery, the risk-free yield curve will be ‘current’ and reflect the risk-free yield curve derived on the last day of the
reporting period. The nominal risk-free yield curve is used to discount nominal cash flows, while real cash flows are discounted
using the real risk-free yield curve.
Risk-free rates are determined by reference to the market interest rates in the currency of the underlying cash flows for the
groups of contracts.
The yield curves that were used to discount the estimates of future cash flows that do not vary based on the returns of the
underlying items are as follows:
R million 	< 1 year
1 to 2
years
3 to 5
years
6 to 10
years
10 to 20
years 	>20 years
30 June 2024
Insurance contract cash flows
SA Life and Invest (Risk) | GMM 	8.5%	8.5% 	8.6%	8.6% 	9.5%	9.5% 	11.3%	11.3% 	13.4%	13.4% 	12.6%	12.6%
SA Life and Invest (Participating) |VFA 	8.5%	8.5% 	8.6%	8.6% 	9.5%	9.5% 	11.3%	11.3% 	13.4%	13.4% 	12.6%	12.6%
UK Life (Risk) | GMM 	4.9%	4.9% 	4.7%	4.7% 	4.2%	4.2% 	3.9%	3.9% 	4.0%	4.0% 	3.6%	3.6%
SA Life and Invest: Group Life | PAA 	8.5%	8.5% 	8.6%	8.6% 	9.5%	9.5% 	11.3%	11.3% 	13.4%	13.4% 	12.6%	12.6%
Reinsurance contract cash flows
SA Life and Invest (Risk) | GMM 	8.5%	8.5% 	8.6%	8.6% 	9.5%	9.5% 	11.3%	11.3% 	13.4%	13.4% 	12.6%	12.6%
SA Life and Invest (Participating) |VFA 	8.5%	8.5% 	8.6%	8.6% 	9.5%	9.5% 	11.3%	11.3% 	13.4%	13.4% 	12.6%	12.6%
UK Life (Risk) | GMM 	4.9%	4.9% 	4.7%	4.7% 	4.2%	4.2% 	3.9%	3.9% 	4.0%	4.0% 	3.6%	3.6%
SA Life and Invest: Group Life | PAA 	8.5%	8.5% 	8.6%	8.6% 	9.5%	9.5% 	11.3%	11.3% 	13.4%	13.4% 	12.6%	12.6%
30 June 2023
Insurance contract cash flows
SA Life and Invest (Risk) | GMM 	9.1%	9.1% 	9.2%	9.2% 	9.7%	9.7% 	11.7%	11.7% 	13.9%	13.9% 	13.4%	13.4%
SA Life and Invest (Participating) |VFA 	9.1%	9.1% 	9.2%	9.2% 	9.7%	9.7% 	11.7%	11.7% 	13.9%	13.9% 	13.4%	13.4%
UK Life (Risk) | GMM 	6.1%	6.1% 	6.0%	6.0% 	5.5%	5.5% 	4.6%	4.6% 	4.0%	4.0% 	3.3%	3.3%
SA Life and Invest: Group Life | PAA 	9.1%	9.1% 	9.2%	9.2% 	9.7%	9.7% 	11.7%	11.7% 	13.9%	13.9% 	13.4%	13.4%
Reinsurance contract cash flows
SA Life and Invest (Risk) | GMM 	9.1%	9.1% 	9.2%	9.2% 	9.7%	9.7% 	11.7%	11.7% 	13.9%	13.9% 	13.4%	13.4%
SA Life and Invest (Participating) |VFA 	9.1%	9.1% 	9.2%	9.2% 	9.7%	9.7% 	11.7%	11.7% 	13.9%	13.9% 	13.4%	13.4%
UK Life (Risk) | GMM 	6.1%	6.1% 	6.0%	6.0% 	5.5%	5.5% 	4.6%	4.6% 	4.0%	4.0% 	3.3%	3.3%
SA Life and Invest: Group Life | PAA 	9.1%	9.1% 	9.2%	9.2% 	9.7%	9.7% 	11.7%	11.7% 	13.9%	13.9% 	13.4%	13.4%

-- 69 of 116 --

91
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.17 Significant accounting estimates and judgements in applying accounting policies
continued
Discovery Life
To determine the risk-free rate in South Africa, the daily nominal and real yield curves produced and published daily by the
Discovery Bank Treasury function. These curves are consistent with the current market value of South African Government
Bond issuances, and consistent with observable current market prices.
Discovery Life considers for inclusion all bonds included in the GOVI index while applying exclusion criteria designed to only
include homogeneous bonds within the curve construction. Negotiable Certificates of Deposit are also used making appropriate
adjustments to allow for credit risk.
The South African Government does not issue bonds across all maturities which implicitly creates the need to interpolate
between various securities and extrapolate beyond the last liquid bond used in the construction of the yield curve.
The sensitivity of the policyholder liabilities due to changes in real curve assumptions are set outset out in section C.2.4.3.1
and C.2.4.3.2.
Vitality Life
To determine the risk-free rate in South Africa, the daily nominal and real yield curves produced and published daily by the
Discovery Bank Treasury function. These curves are consistent with the current market value of South African Government
Bond issuances, and consistent with observable current market prices.
D. EXPENSE ASSUMPTIONS
IFRS 17 does not specify a methodology for attributing directly attributable fixed overhead expenses to the respective
groups of insurance contracts and to individual policies. It requires that the methods used be systematic and rational.
Discovery has applied judgement in developing its methodology and has consistently applied this methodology period-to-
period, except as noted below.
Estimates of future expenses relating to fulfilment of contracts in the scope of IFRS 17 are based on the results of the latest
expense and budget information. Expenses comprise expenses directly attributable to the groups of contracts including an
allocation of fixed and variable overheads.
Expenses are considered non-recurring when they relate to the start-up of a new business area or when they are material
and are specific to an event that is not expected to occur in the future.
The allocation of expenses between initial and renewal is based on the latest expense analysis, where expenses are directly
allocated based on the function performed. Where an expense could relate to both initial and renewal functions, the
expenses are allocated proportionately based on estimates of the functions performed.
Per Discovery’s policy, expenses are projected to increase in line with consumer price inflation. Non-recurring expenses are
excluded from the expense analysis used to derive the assumption.
From 1 July 2023, Discovery Life has further refined its methodology for allocating directly attributable renewal expenses by
allowing for the effort required to maintain the policy as well as the size of the policy’s premium relative to the rest of the
in-force book . As the change in methodology is a change in estimate, this change has been applied prospectively and
therefore differs from the estimate used prior to 1 July 2023 given practicality and availability of historical information. The
new methodology better reflects the drivers of renewal expense costs.
Given the diversified product range in UK Life, from 1 July 2022, UK Life has further refined its methodology used for
allocating the directly attributable fixed overhead expenses related to new business activities (i.e. directly attributable but
fixed initial expenses). As the change in methodology is a change in estimate, this change has been applied prospectively
and therefore differs from the estimate used in performing the fully retrospective approach used with the initial transition
to IFRS 17 given practicality and availability of historical information. The new methodology better reflects the drivers of
fixed initial expenses given the core strategy and mix of business written by UK Life as well as the related effort to
underwrite and administer the various products. This change in estimate has been implemented from 1 July 2022.
The sensitivity of the policyholder liabilities due to changes in expense assumptions are set out in section C.2.4.3.1 and
C.2.4.3.2.

-- 70 of 116 --

92	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
C: 	Insurance and reinsurance contracts related disclosure continued
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.17 Significant accounting estimates and judgements in applying accounting policies
continued
CONTRACTUAL SERVICE MARGIN
The CSM is a component of the asset or liability for the group of insurance contracts that represents the future unearned
profit. The CSM of a group of contracts is recognised in profit or loss to reflect services provided in each year based on the
number of coverage units provided in the year.
The determination of coverage units require significant judgements due to consideration of the quantity of the benefits
provided, the expected coverage period and time value of money for each contract. The coverage units are reviewed and
updated at each reporting date.
The quantity of services provided by insurance contracts may include insurance coverage, investment-return services and
investment-related services, as applicable. Discovery determines the quantity of the benefits provided under each contract as
follows:
Portfolio 	Benefit type
Measurement
model 	Risk Management
Insurance contracts
SA Life and Invest (Risk)
and UK life (Risk)
Lump sum benefits paid on
death, disability or disablement
and survival
GMM
For contracts where coverage for an
insured event is provided, the
quantity of benefits is considered to
be the maximum amount payable
under each insurance contract at
each point in time. For contracts
where the company provides
investment-return services on
insurance contracts in Invest
without direct participation features,
it is assumed that the company
provides an equal service to all
policyholders in the generation of
an investment return for each
policyholder.
Annuity-type payment on
death of disability
The expected maximum amount at
risk at each point in time.
SA Life and Invest
(Participating)
Investment linked insurance
contracts.
VFA
The coverage unit should allow for
the coverage provided for the
insured event as well as the
management of the underlying
items on behalf of the policyholder.
On VFA contracts, the determination
of the coverage unit is primarily
dependent on the investment
services provided under the
contract given this constitutes the
majority of the service provided to
policyholders over the lifetime of
the contract.
Reinsurance contracts
SA Life and Invest (Risk)
and UK life (Risk)
Quota share reinsurance
GMM
Same basis as underlying insurance
contract
Excess of loss and stop loss
reinsurance
Expected amount of underlying
claims to be covered in each period

-- 71 of 116 --

93
C.2.3 	INSURANCE AND REINSURANCE CONTRACT DISCLOSURES AND
RECONCILIATIONS continued
C.2.3.17 Significant accounting estimates and judgements in applying accounting policies
continued
For GMM contracts, Discovery has elected to allow for the real time value of money in the equal allocation of CSM to coverage
units:
 For Discovery Life and VitalityLife’s life insurance policies this is allowed for implicitly by assuming that the same coverage is
provided in real terms over time. Practically this is achieved by projecting benefits with a 0% CPI rate solely for the
determination of the coverage units.
 For Discovery Life’s guaranteed endowment and annuity business modelled using the GMM approach, this is allowed for by
explicitly discounting the coverage units at the real rate of return.
For VFA contracts, Discovery’s chosen approach is to allow for the nominal time value of money in the equal allocation of CSM
to coverage units.
RISK ADJUSTMENT
When applying a confidence level technique, the first step in the process is to calculate the best estimate reserve, where there
is an equal chance that the actual amount needed to pay future claims will be higher or lower than the calculated best
estimate. The risk adjustment is then calculated such that there is a specified percentage probability that the reserves will be
sufficient to cover future claims. For Discovery, the determination of specified percentage is set out in C.12.2. and C.12.3.3.
III. CONTRACTS MEASURED UNDER THE PAA
INSURANCE ACQUISITION CASH FLOWS
Discovery uses judgement in determining the initial and renewal periods for which the insurance acquisition cash flows are
attributed to groups. For VitalityHealth, the initial and subsequent renewal period is set at ten years.
In the current and prior year, Discovery did not identify any facts and circumstances indicating that the assets for insurance
acquisition cash flows may be impaired.
RISK ADJUSTMENT
For contracts measured under the PAA, the explicit risk adjustment for non-financial risk is estimated to measure the LIC.
The risk adjustment will be determined by applying a confidence level technique. For Discovery, the determination of
specified percentage is set out in C.12.2. and C.12.4.1.
REINSURANCE
All prospective liabilities are valued gross of reinsurance and then adjusted for the expected effect of reinsurance. For
outstanding reported claims and IBNR, a specific allowance is made for reinsurance recoveries.
The Global Linkage Benefit is fully reinsured. The cost of the future reinsurance is dependent on the cost at which the
reinsurer can buy assets to match the liability under this benefit. Assumptions are made around the cost at which the
reinsurer can purchase these benefits based on the current and historical costs of these assets.

-- 72 of 116 --

DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4	94
S E C T I O N D
ADOPTION OF NEW STANDARDS AND
INTERPRETATIONS AND RESTATEMENTS
D.1.1 Adoption of new standards and interpretations and restatements
D.1.2 	Impact of restatements on the Group statement of financial
position
D.1.4 Restatements as result of prior period errors
D.1.5 Changes in presentation of specified items in the primary
statements and associated restatements for prior period corrections
D.1.3 	Adoption of IFRS 17 Insurance Contracts
DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4

-- 73 of 116 --

95
D.1. 	Adoption of new standards and interpretations and restatements
D.1.1 	ADOPTION OF NEW STANDARDS AND INTERPRETATIONS AND
RESTATEMENTS
Introduction and overview
The section provides information on the material new standards, amendments and interpretations that became effective for
Discovery for its financial year commencing 1 July 2023. In addition, the section sets out the correction of prior period errors
and the changes in presentation of specified line items.
Overview
The financial year ended 30 June 2024 has been marked as a year of significant changes to the measurement and presentation
of items in the primary financial statements, namely the Group statement of financial position, the Group income statement,
the Group statement of other comprehensive income, Group statement of changes in equity and Group statement of cash
flows. The notes to the financial statements, including the accounting policies which accompany the Group financial statements
have also consequently been amended.
The changes to the financial statements have arisen from the following key events:
 Change 1: Adoption of IFRS 17 Insurance Contracts
 Change 2: Restatements as result of prior period errors identified
 Change 3: Changes in presentation of specified items in the primary statements and associated restatements for prior period
corrections
CHANGE 1: ADOPTION OF IFRS 17 INSURANCE CONTRACTS
IFRS 17 became effective for the Discovery Group 1 July 2023, with a required restatement of the comparative preceding year,
namely the financial year ended 30 June 2023, including a restatement of the opening Group statement of financial position as
at 1 July 2022.
IFRS 17 is a new accounting standard for insurance contracts that provides guidelines on recognising, measuring, presenting,
and disclosing insurance contracts. IFRS 17 replaces the previous standard, IFRS 4 Insurance Contracts.
The framework established by IFRS 17 outlines the specific requirements that companies must adhere to when reporting
information related to both the insurance contracts they issue and the reinsurance contracts they hold.
The summary of the impact of the adoption of IFRS 17 on the Group statement of financial position as at 1 July 2022 and
30 June 2023 is set out in section D.1.2.
For further details on the adoption of IFRS 17 Insurance Contracts also refer section D.1.3.

-- 74 of 116 --

96	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
D.1.1 	ADOPTION OF NEW STANDARDS AND INTERPRETATIONS AND
RESTATEMENTS continued
Overview continued
CHANGE 2: RESTATEMENT AS RESULT OF PRIOR PERIOD ERRORS IDENTIFIED
During the preparation of financial statements management may identify prior period errors that could have arisen due to
miscalculations, oversights or misapplication of information that was available at the time. Errors can affect the recognition,
measurement, presentation and disclosure of accounting transactions. Under IFRS Accounting Standards, management is
required to restate information for material prior period errors. Immaterial prior period errors are corrected in the current
financial period.
During the financial year ended 30 June 2024, management has identified prior period errors that required correction and
accordingly restated the prior period information.
The summary of the impact of the restatement on the Group statement of financial position as at 1 July 2022 and 30 June 2023
is set out in section D.1.2.
For further details on the prior period errors, also refer section D.1.4.
CHANGE 3: CHANGES IN PRESENTATION OF SPECIFIED ITEMS IN THE PRIMARY STATEMENTS AND ASSOCIATED
RESTATEMENTS FOR PRIOR PERIOD CORRECTIONS
Discovery continually evaluates its presentation and disclosures to developing market practices, changes in IFRS Accounting
Standards and changes in its business composition that may indicate a need for change in presentation or disclosures in order
to enhance the relevant and understanding gained by users of the financial statements.
With the adoption of IFRS 17 and the developments within IFRS Accounting Standards on presentation of financial statements,
Discovery has enhanced its presentation of the primary financial statements. Changes in addition to those as a result of
adoption of IFRS 17 are further discussed in section D.1.5.
The summary of the impact of the presentation on the Group statement of financial position as at 1 July 2022 and 30 June 2023
is set out in section D.1.2.
D. 	Adoption of new standards and interpretations and restatements
continued

-- 75 of 116 --

97
D.1.2 	IMPACT OF RESTATEMENTS ON THE GROUP STATEMENT OF FINANCIAL
POSITION
Introduction
The section provides summary information on the impact of the restatements as a result of the adoption of IFRS 17,
the correction of prior period errors and presentation changes on the Group statement of financial position for 1 July 2022
and 30 June 2023.
The information is set out to reconcile for the user the information as previously published for the year end 30 June 2023 under
IFRS 4 basis to the new restated results, setting out the respective adjustments to the final restated balances in the Group
statement of financial position as at 1 July 2022 and 30 June 2023.
RECONCILIATION OF THE RESTATED GROUP STATEMENT OF FINANCIAL POSITION 1 JULY 2022
Group
R million
30 June
2022
As previously
reported
under
IFRS 45
D.1.3.
Restated
IFRS 17
remeasurement
and
reclassification6
D.1.4.
Other
restatements
D.1.5.
Other
presentation
changes
1 July
2022
Restated
under
IFRS 17
Assets
Goodwill 	4 912 	– 	– 	– 	4 912
Intangible assets 	6 539 	– 	45 	– 	6 584
Property and equipment 	3 811 	– 	– 	– 	3 811
Assets arising from insurance contracts issued 	56 645 	(26 884) 	– 	– 	29 761
Assets arising from reinsurance contracts held 	511 	362 	– 	– 	873
Deferred tax asset 	4 455 	1 357 	(95) 	– 	5 717
Deferred acquisition costs1 	640 	(623) 	– 	(17) 	–
Assets arising from contracts with customers 	1 692 	– 	– 	17 	1 709
Investment in equity-accounted investees 	6 008 	330 	– 	– 	6 338
Financial assets
– Loans and advances to customers at amortised
cost 	3 944 	– 	– 	– 	3 944
– Investments at amortised cost 	7 161 	– 	– 	– 	7 161
– Investments at fair value through profit or loss 	141 494 	– 	(3 399) 	– 	138 095
– Derivative financial instruments at fair value
through profit or loss 	276 	– 	– 	– 	276
Contract receivables and other receivables2 	13 113 	(7 848) 	(41) 	– 	5 224
Non-current assets held for sale 	171 	– 	– 	– 	171
Current tax asset 	220 	– 	(37) 	– 	183
Cash and cash equivalents3 	19 775 	(5 988) 	3 399 	– 	17 186
TOTAL ASSETS 	271 367 	(39 294) 	(128) 	– 	231 945
Equity
Capital and reserves
Ordinary share capital and share premium 	10 178 	– 	– 	– 	10 178
Perpetual preference share capital 	779 	– 	– 	– 	779
Other reserves 4 	3 621 	(1 208) 	42 	– 	2 455
Retained earnings 	38 972 	(11 373) 	(197) 	– 	27 402
Equity attributable to equity holders of the Company 	53 550 	(12 581) 	(155) 	– 	40 814
Non-controlling interest 	5 	– 	– 	– 	5
TOTAL EQUITY 	53 555 	(12 581) 	(155) 	– 	40 819
1 The deferred acquisition costs for insurance contracts will no longer be presented separately in the Group statement of financial position under IFRS 17 as all
insurance cash flows, payables and receivables are presented on a net basis, as part of the liability or an asset arising from insurance contract issued.
2 Previously named Insurance receivables, contract receivables and other receivables. The line item description has been updated to exclude the insurance
receivables as under IFRS 17 all insurance cash flows, payables and receivables are presented on a net basis, as part of the liability or an asset arising from
insurance contract issued.
3 The treatment of the Prudential Assurance Company Limited (PAC) arrangement under IFRS 17 has resulted in a fundamental change in the way Discovery is
required to reflect the underlying assets and liabilities within the PAC arrangement. Under IFRS 17, the entire PAC arrangement is reflected as an overarching
insurance contract. Discovery is treated as the reinsurer for those VitalityLife policies underwritten on the PAC life insurance license (up to 31 December 2015).
One key difference is the manner in which the cash and cash equivalents, which are held as the required capital backing for the policies, are reflected. Under
IFRS 17, the cash backing the capital requirement and reserves are presented and measured as a non-distinct loan to policyholder. This differs from IFRS 4,
where the cash and cash equivalents of the capital backing the arrangement were treated as separable components and accordingly disclosed separately. In
addition to the resultant change in cash and cash equivalents on 1 July 2022 of R5 988 million.
4 Included in the Other reserves line item is the new IFRS 17 reserve for the cumulative IFIE recognised in OCI.
5 The previously reported values relate to the IFRS 4 Group statement of financial position for the year-ended 30 June 2023 as was published in September 2023.
6 The IFRS 17 remeasurement and reclassification column has been restated from the reconciliation of restated Group statement of financial position published
in the Discovery Group interim disclosures for the six-month period ended 31 December 2023. The effect of these changes are noted in item 5 of D.1.4.

-- 76 of 116 --

98	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
D. 	Adoption of new standards and interpretations and restatements
continued
D.1.2 	IMPACT OF RESTATEMENTS ON THE GROUP STATEMENT OF FINANCIAL
POSITION continued
Group
R million
30 June
2022
As previously
reported
under
IFRS 45
D.1.3
Restated
IFRS 17
remeasurement
and
reclassification6
D.1.4
Other
restatements
D.1.5
Other
presentation
changes
1 July
2022
Restated
under
IFRS 17
Liabilities
Liabilities arising from insurance contracts issued 	108 067 	(24 143) 	– 	– 	83 924
Liabilities arising from reinsurance contracts held 	13 192 	(7 940) 	– 	– 	5 252
Deferred tax liability 	9 335 	(3 008) 	– 	– 	6 327
Contract liabilities to customers 	944 	– 	– 	– 	944
Third-party interest in consolidated funds 	– 	– 	– 	24 320 	24 320
Financial liabilities
– Borrowings at amortised cost 	20 584 	– 	– 	– 	20 584
– Other financial payables at amortised cost 	15 123 	(6 280) 	65 	(833) 	8 075
– Deposits from customers 	10 881 	– 	– 	– 	10 881
– Investment contracts at fair value through
profit or loss 	38 637 	14 638 	– 	(24 320) 	28 955
– Derivative financial instruments at fair value
through profit or loss 	202 	– 	– 	202
Provisions 	– 	20 	– 	150 	170
Other payables 	– 	– 	– 	1 003 	1 003
Employee benefits 	320 	– 	– 	(320) 	–
Current tax liability 	527 	– 	(38) 	– 	489
TOTAL LIABILITIES 	217 812 	(26 713) 	27 	– 	191 126
TOTAL EQUITY AND LIABILITIES 	271 367 	(39 294) 	(128) 	– 	231 945
1 The deferred acquisition costs for insurance contracts will no longer be presented separately in the Group statement of financial position under IFRS 17 as
all insurance cash flows, payables and receivables are presented on a net basis, as part of the liability or an asset arising from insurance contract issued.
2 Previously named Insurance receivables, contract receivables and other receivables. The line item description has been updated to exclude the insurance
receivables as under IFRS 17 all insurance cash flows, payables and receivables are presented on a net basis, as part of the liability or an asset arising from
insurance contract issued.
3 The treatment of the Prudential Assurance Company Limited (PAC) arrangement under IFRS 17 has resulted in a fundamental change in the way Discovery
is required to reflect the underlying assets and liabilities within the PAC arrangement. Under IFRS 17, the entire PAC arrangement is reflected as an
overarching insurance contract. Discovery is treated as the reinsurer for those VitalityLife policies underwritten on the PAC life insurance license (up to
31 December 2015). One key difference is the manner in which the cash and cash equivalents, which are held as the required capital backing for the
policies, are reflected. Under IFRS 17, the cash backing the capital requirement and reserves are presented and measured as a non-distinct loan to
policyholder. This differs from IFRS 4, where the cash and cash equivalents of the capital backing the arrangement were treated as separable components
and accordingly disclosed separately. In addition to the resultant change in cash and cash equivalents on 1 July 2022 of R5 988 million.
4 Included in the Other reserves line item is the new IFRS 17 reserve for the cumulative IFIE recognised in OCI.
5 The previously reported values relate to the IFRS 4 Group statement of financial position for the year-ended 30 June 2023 as was published in
September 2023.
6 The IFRS 17 remeasurement and reclassification column has been restated from the reconciliation of restated Group statement of financial position
published in the Discovery Group interim disclosures for the six-month period ended 31 December 2023. The effect of these changes are noted in item 5
of D.1.4.

-- 77 of 116 --

99
D.1.2 	IMPACT OF RESTATEMENTS ON THE GROUP STATEMENT OF FINANCIAL
POSITION continued
Reconciliation of the restated Group statement of financial position 30 June 2023
Group
R million
30 June
2023
As previously
reported
under
IFRS 45
D.1.2
Restated
IFRS 17
remeasurement
and
reclassification6
D.1.3
Other
restatements
D.1.4
Other
presentation
changes
30 June 2023
Restated
under
IFRS 17
Assets
Goodwill 	5 406 	– 	– 	– 	5 406
Intangible assets 	6 982 	– 	82 	– 	7 064
Property and equipment 	3 910 	– 	– 	– 	3 910
Assets arising from insurance contracts issued 	63 865 	(30 241) 	– 	– 	33 624
Assets arising from reinsurance contracts held 	709 	(105) 	– 	– 	604
Deferred tax asset 	4 404 	2 085 	(119) 	– 	6 370
Deferred acquisition costs1 	799 	(779) 	– 	(20) 	–
Assets arising from contracts with customers 	2 201 	– 	– 	20 	2 221
Investment in equity-accounted investees 	7 024 	374 	– 	– 	7 398
Financial assets
– Loans and advances to customers at amortised
cost 	4 702 	– 	– 	– 	4 702
– Investments at amortised cost 	9 910 	– 	– 	– 	9 910
– Investments at fair value through profit or loss 	155 426 	– 	(2 911) 	– 	152 515
– Derivative financial instruments at fair value
through profit or loss 	119 	– 	– 	– 	119
Contract receivables and other receivables2 	16 059 	(10 333) 	(42) 	– 	5 684
Current tax asset 	41 	– 	– 	– 	41
Cash and cash equivalents3 	20 370 	(4 110) 	2 911 	– 	19 171
TOTAL ASSETS 	301 927 	(43 109) 	(79) 	– 	258 739
Equity
Capital and reserves
Ordinary share capital and share premium 	10 351 	– 	– 	– 	10 351
Perpetual preference share capital 	779 	– 	– 	– 	779
Other reserves4 	8 622 	(3 982) 	50 	– 	4 690
Retained earnings 	44 218 	(10 124) 	(194) 	– 	33 900
Equity attributable to equity holders of the Company 	63 970 	(14 106) 	(144) 	– 	49 720
Non-controlling interest 	4 	– 	– 	– 	4
TOTAL EQUITY 	63 974 	(14 106) 	(144) 	– 	49 724
1 The deferred acquisition costs for insurance contracts will no longer be presented separately in the Group statement of financial position under IFRS 17 as all
insurance cash flows, payables and receivables are presented on a net basis, as part of the liability or an asset arising from insurance contract issued.
2 Previously named Insurance receivables, contract receivables and other receivables. The line item description has been updated to exclude the insurance
receivables as under IFRS 17 all insurance cash flows, payables and receivables are presented on a net basis, as part of the liability or an asset arising from
insurance contract issued.
3 The treatment of the Prudential Assurance Company Limited (PAC) arrangement under IFRS 17 has resulted in a fundamental change in the way Discovery is
required to reflect the underlying assets and liabilities within the PAC arrangement. Under IFRS 17, the entire PAC arrangement is reflected as an overarching
insurance contract. Discovery is treated as the reinsurer for those VitalityLife policies underwritten on the PAC life insurance license (up to 31 December 2015).
One key difference is the manner in which the cash and cash equivalents, which are held as the required capital backing the policies, are reflected. Under IFRS
17, the cash backing the capital requirement and reserves are presented and measured as a non-distinct loan to policyholder. This differs from IFRS 4, where
the cash and cash equivalents of the capital backing the arrangement were treated as separable components and accordingly disclosed separately. In addition
to the resultant change in cash and cash equivalents 30 on June 2023 R4 110 million, it also resulted in a change in cash utilized and generated by operations
of R2 744 million for the year ended 30 June 2023.
4 Included in the Other reserves line item is the new IFRS 17 reserve for the cumulative IFIE recognised in OCI.
5 The previously reported values relate to the IFRS 4 Group statement of financial position for the year-ended 30 June 2023 as was published in September 2023.
6 The IFRS 17 remeasurement and reclassification column has been restated from the reconciliation of restated Group statement of financial position published
in the Discovery Group interim disclosures for the six-month period ended 31 December 2023. The effect of these changes are noted in in item 5 of D.1.4.

-- 78 of 116 --

100	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
D.1.2 	IMPACT OF RESTATEMENTS ON THE GROUP STATEMENT OF FINANCIAL
POSITION continued
Reconciliation of the restated Group statement of financial position 30 June 2023
continued
Group
R million
30 June 2023
As previously
reported5
Restated
IFRS 17
remeasurement
and
reclassification 6
Other
restatements
Other
presentation
changes
30 June 2023
Restated
Liabilities
Liabilities arising from insurance contracts issued 	114 807 	(20 147) 	– 	– 	94 660
Liabilities arising from reinsurance contracts held 	14 669 	(9 850) 	– 	– 	4 819
Deferred tax liability 	9 559 	(2 851) 	(2) 	– 	6 706
Contract liabilities to customers 	656 	– 	– 	– 	656
Third-party interest in consolidated funds 	– 	– 	– 	28 346 	28 346
Financial liabilities
– Borrowings at amortised cost 	20 586 	– 	– 	– 	20 586
– Other financial payables at amortised cost 	14 780 	(5 375) 	67 	(904) 	8 568
– Deposits from customers 	14 333 	– 	– 	– 	14 333
– Investment contracts at fair value through
profit or loss 	48 044 	9 205 	– 	(28 346) 	28 903
– Derivative financial instruments at fair value
through profit or loss 	20 	– 	– 	– 	20
Provisions 	– 	15 	– 	172 	187
Other payables 	– 	– 	– 	1 066 	1 066
Employee benefits 	334 	– 	– 	(334) 	–
Current tax liability 	165 	– 	– 	– 	165
TOTAL LIABILITIES 	237 953 	(29 003) 	65 	– 	209 015
TOTAL EQUITY AND LIABILITIES 	301 927 	(43 109) 	(79) 	– 	258 739
1 The deferred acquisition costs for insurance contracts will no longer be presented separately in the Group statement of financial position under IFRS 17 as
all insurance cash flows, payables and receivables are presented on a net basis, as part of the liability or an asset arising from insurance contract issued.
2 Previously named Insurance receivables, contract receivables and other receivables. The line item description has been updated to exclude the insurance
receivables as under IFRS 17 all insurance cash flows, payables and receivables are presented on a net basis, as part of the liability or an asset arising from
insurance contract issued.
3 The treatment of the Prudential Assurance Company Limited (PAC) arrangement, under IFRS 17, has resulted in a fundamental change in the way Discovery
is required to reflect the underlying assets and liabilities within the PAC arrangement. Under IFRS 17, the entire PAC arrangement is reflected as an
overarching insurance contract. Discovery is treated as the reinsurer for those VitalityLife policies underwritten on the PAC life insurance license (up to
31 December 2015). One key difference is the manner in which the cash and cash equivalents, which are held as the required capital backing for the
policies, are reflected. Under IFRS 17, the cash backing the capital requirement and reserves are presented and measured as a non-distinct loan to
policyholder. This differs from IFRS 4, where the cash and cash equivalents of the capital backing the arrangement were treated as separable components
and accordingly disclosed separately. In addition to the resultant change in cash and cash equivalents 30 June 2023 R4 110 million, it also resulted in a
change in cash utilized and generated by operations of R2 744 million for the year ended 30 June 2023.
4 Included in the Other reserves line item is the new IFRS 17 reserve for the cumulative IFIE recognised in OCI.
5 The previously reported values relate to the IFRS 4 Group statement of financial position for the year-ended 30 June 2023 as was published in
September 2023.
6 The IFRS 17 remeasurement and reclassification column has been restated from the reconciliation of restated Group statement of financial position
published in the Discovery Group interim disclosures for the six-month period ended 31 December 2023. The effect of these changes are noted in item 5
of D.1.4.
D. 	Adoption of new standards and interpretations and restatements
continued

-- 79 of 116 --

101
D.1.3 	ADOPTION OF IFRS 17 INSURANCE CONTRACTS
Introduction
As noted above, IFRS 17
Insurance Contracts became effective for the Discovery Group from 1 July 2023, with comparative
restatement of the preceding year, namely the financial year ended 30 June 2023, including a restatement of the opening
Group statement of financial position as at 1 July 2022. IFRS 17 replaces the previous standard, IFRS 4 Insurance Contracts.
IFRS 17 is not limited to insurance companies but also those companies that issue any contract that results in the transfer
of significant insurance risk. For Discovery, the contracts within the scope of IFRS 17 are almost entirely aligned with those
recognised in IFRS 4.
Whilst the underlying contractual terms and economic risks and rewards of each insurance contract remain unaltered, IFRS
17 impacts the accounting treatment of insurance contracts and, most notably, the timing of recognition of insurance-related
profits and losses for accounting purposes. Importantly, it also separates the insurance-related profit or losses between
those arising from insurance service results and those arising from financial results. IFRS 17 does not result in a change in the
underlying business value of contracts, including:
 No direct change to cash flows or underlying risk and reward of contracts. Future tax cash flow impacts are expected to be
immaterial.
 Immaterial impact on regulatory or economic solvency, capital position and capital management.
 The ability to pay dividends unaffected as cash flows and solvency remain unchanged.
 Immaterial impact on Embedded Value.
Adoption of IFRS 17
Upon first-time adoption, IFRS 17 requires the IFRS Accounting Standard to be applied fully retrospectively as if the IFRS
Accounting Standard always applied unless impracticable. If impracticable to do so, the entity can elect to either apply a
modified retrospective approach or use the fair value approach. Discovery applied a fully retrospective restatement from
inception for all material groups of insurance contracts. Discovery did not measure any of its portfolios using the fair value
approach.
The fully retrospective approach requires that Discovery identify, recognise, and measure groups of insurance contracts as
if IFRS 17 had always applied. Based on the work completed, the restatement is much more pronounced for the long-term
insurance business of Discovery Life in SA and VitalityLife in the UK. In contrast, the impact of the retrospective restatement
is limited for the short-term businesses except for VitalityHealth where the impact is more significant due to change in the
treatment of insurance acquisition costs.
The changes resulting from the transition to IFRS 17 can be summarised as follows:
 Those changes that result in differences between the IFRS 17 margins relative to the IFRS 4 margins. These changes
result in concomitant temporary changes in equity. For example, to the extent that changes resulted in the strengthening
of contractual service margins that will release to profit in future periods, such changes are mirrored by a reduction in
shareholders’ equity upon transition.
 Other changes, such as remeasurement basis of the expected future cash flows or recognised assets and liabilities from
short-term insurance, e.g., deferred acquisition costs. These remeasurements would result in a change in equity on transition
without a visible offset of insurance margins but similarly will indirectly result in higher or lower net profits in future periods
(for a reduction or increase in equity respectively).
In the case of Discovery, increases in insurance margins, most notably contractual service margin (CSM), have a far more
material impact. Such resulting increases of additional IFRS 17 margins on transition will be available as future profit. The main
cause for this significant increase in CSM is that Discovery has a more recent and rapidly growing history compared to very
long-standing insurers.

-- 80 of 116 --

102	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
D. 	Adoption of new standards and interpretations and restatements
continued
D.1.3 	ADOPTION OF IFRS 17 INSURANCE CONTRACTS continued
The most significant changes that result in an increase in IFRS 17 margins relative to margins under IFRS 4 can be summarised
as follows:
 The measurement under IFRS 17 includes only those cash inflows and outflows relating directly to the fulfilment of the
group of insurance contracts, termed directly attributable expenses. In addition to claims and benefits, these may include
certain directly attributable overhead expenses. However, non-directly attributable expenses such as general marketing and
sponsorships, allocated group executive and group function costs and research and development activities of new products,
are not included in the initial recognition value of the contract. Under IFRS 17, these non-directly attributable expenses are
immediately expensed and are therefore not considered when determining the expected fulfilment cash flows (EFCF) of the
insurance contracts being measured. The immediate expensing of such non-directly attributable expenses increases the
available margin on the portfolio compared to the IFRS 4 treatment where such expenses were brought into account when
determining the available margins. It should be noted that such expenses are brought into consideration when determining
the pricing of products and these increased IFRS 17 margins are therefore similarly available for recognition as profits in
future or to absorb adverse changes.
 Contracts are measured at a more granular level where portfolios are established and as a minimum with annual business
cohorts of no more than twelve months apart. Each of these cohorts is further categorised into separate groups based
on expected profitability being profitable, profitable at risk, and onerous groups. Losses are immediately expensed when
they arise on onerous contracts, effectively eliminating any cross-subsidisation or set-off applied within a portfolio. This
immediate write-off of shortfalls on contracts effectively increases the available margin on the remainder of the portfolio,
which will be recognised to profit in future.
 Other items, including, amongst others, the different treatment of certain basis changes and variances through the margin,
the different rates at which interest is accreted on the margins, and small differences in the run-off of the margins over time
are less material in the case of Discovery. Unlike IFRS 4, IFRS 17 separately recognises the finance-related consequences of
insurance contracts from the underlying insurance activities. Finance income and expense related to insurance contracts
and the changes in the measurement of finance-related items are recognised as insurance finance income and expense
(IFIE) either immediately in profit or loss or disaggregated and allocated using a systematic allocation to profit or loss with
variances being recognised through OCI.
 Discovery has elected to apply the OCI option to certain long-term insurance contracts. The exclusion of certain elements of
IFIE from the profit or loss is largely aligned to Discovery’s treatment under IFRS 4 where it excluded the impact of economic
assumptions, net of associated derivatives, from its normalised profit and normalised headline earnings. The use of OCI
removes the need for this normalisation after the adoption of IFRS 17.
Tax changes
To transition to and implement IFRS 17, amendments in tax legislation in both South Africa (Section 28 and 29A of the South
African Income Tax Act) and the United Kingdom (The Insurance Contracts (Tax) Change in Accounting Standards Regulations
2022, 2022. No. 1165). The amendments legislated phasing-in periods of the impact, which were 3 years for Discovery Insure,
6 years for Discovery Life Limited, and 10 years for Vitality Life Limited. The main impact on the consolidated group at transition
was the recognition and remeasurement of the related deferred tax assets and liabilities on the respective reduction in equity
on transition, reflecting the change in the timing of income tax.
Other changes
Other changes, resulting in a change in equity on transition without a visible offset of insurance margins:
 The remeasurement of best estimates of the future fulfilment cash flows and measurement and accounting treatment of
insurance acquisition cash flows, i.e., deferred acquisition costs, on the short-term business lines and
 Associated deferred tax and future tax impacts of the changes noted above.

-- 81 of 116 --

103
D.1.3 	ADOPTION OF IFRS 17 INSURANCE CONTRACTS continued
Impact on adoption
With finalisation of the adoption of IFRS 17, the transition change is primarily a result of the increased IFRS 17 margins, as
represented by the CSM plus the risk adjustment. Other factors contributing to the change in equity include alterations in
the methodology used to determine fulfilment cash flows, difference in short-term business lines such as risk adjustment for
non-financial risks, and the tax effects of changes in the measurement of insurance contracts. The concomitant net impact of
transition adjustments (after tax) to the balance of the Group’s shareholders’ equity were as follows:
R million
Group total equity 30 June 2022 	53 555
IFRS 17 adjustments, net of tax
Retained earnings R11 373 million and IFIE OCI of R1 208 million 	(12 581)
Group total equity 1 July 2022
Post IFRS 17 but pre restatement for prior period errors 	40 974
The impact of the above reduction in equity is effectively offset by a significant increase in insurance margins, most notably
CSM, that is available for release to profit in future years or to absorb any adverse changes. On this basis, the total value
created through the insurance activities of the Group remains largely unchanged, however, the timing of recognition of
insurance related profits has been deferred. The strengthened IFRS 17 margins result in higher future release of profits and in
less volatility due to its ability to absorb negative variances, while the election of OCI results in less volatility as a result of its
ability to manage variances in financial risks.
For detail summary of the IFRS 17 accounting policies, refer to the Group Annual Financial Statements for the year ended
30 June 2024, Annexure B – note 12, which will be issued at a future date.
D.1.4 	RESTATEMENTS AS RESULT OF PRIOR PERIOD ERRORS
Introduction
As mentioned earlier, management identified prior period errors which require that Discovery restate period information.
The section sets out a summary of the prior period corrections made.
Below is a summary of the impact of the restatements as a result of the correction of prior period errors on the Group
Statement of financial position for 1 July 2022 and 30 June 2023.
The information is set out to reconcile the information as previously published for the year end 30 June 2023 under IFRS 4
basis, setting out the respective adjustments to the final restated balances in the Group statement of financial position as at
1 July 2022 and 30 June 2023.
Details on the corrections are provided after the tables.
Group statement of financial position 1 July 2022
R million
Group
30 June 2022
(previously
reported) 2
Item 1
Correction
Increase
(decrease) 3
Item 2
Correction
Increase
(decrease)
Item 3
Correction
Increase
(decrease)
Item 4
Correction
Increase
(decrease)
Group
1 July 2022
Restated
Intangible assets 	6 539 	– 	– 	45 	– 	6 584
Deferred tax asset 	4 455 	– 	(95) 	– 	– 	4 360
Financial assets
– Investments at fair value through
profit or loss 	141 494 	– 	– 	– 	(3 399) 	138 095
Insurance receivables, contract
receivables and other receivables 	13 113 	(41) 	– 	– 	– 	13 072
Current tax asset 	220 	– 	(37) 	– 	– 	183
Cash and cash equivalents 	20 370 	– 	– 	– 	3 399 	23 769
Other reserves1 	3 621 	– 	– 	42 	– 	3 663
Retained earnings 	38 972 	(106) 	(94) 	3 	– 	38 775
Other financial payables at
amortised cost 	15 123 	65 	– 	– 	– 	15 188
Current tax liability 	527 	– 	(38) 	– 	– 	489
1 Other reserves reflect the impact on foreign currency translation reserve (FCTR).
2 The previously reported values relate to the IFRS 4 Group statement of financial position for the year-ended 30 June 2023 as was published in September 2023.
3 Differences in the restatement note from the note published in the interim results for the six months ended 31 December 2023 booklet are due to rounding.

-- 82 of 116 --

104	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
D.1.4 	RESTATEMENTS AS RESULT OF PRIOR PERIOD ERRORS continued
Group statement of financial position 30 June 2023
R million
Group
30 June 2023
(previously
reported) 2
Item 1
Correction
Increase
(decrease) 3
Item 2
Correction
Increase
(decrease)
Item 3
Correction
Increase
(decrease)
Item 4
Correction
Increase
(decrease)
Group
30 June 2023
Restated
Intangible assets 	6 982 	– 	– 	82 	– 	7 064
Deferred tax asset 	4 404 	– 	(119) 	– 	– 	4 285
Financial assets
– Investments at fair value through
profit or loss 	155 426 	– 	– 	– 	(2 911) 	152 515
Insurance receivables, contract
receivables and other receivables 	16 059 	(42) 	– 	– 	– 	16 017
Cash and cash equivalents 	20 370 	– 	– 	– 	2 911 	23 281
Other reserves1 	8 622 	(7) 	(22) 	79 	– 	8 672
Retained earnings 	44 218 	(102) 	(95) 	3 	– 	44 024
Deferred tax liability 	9 559 	– 	(2) 	– 	– 	9 557
Other financial payables at
amortised cost 	14 780 	67 	– 	– 	– 	14 847
1 Other reserves reflect the impact on foreign currency translation reserve (FCTR).
2 The previously reported values relate to the IFRS 4 Group statement of financial position for the year-ended 30 June 2023 as was published in
September 2023.
3 Differences in the restatement note from the note published in the interim results for the six months ended 31 December 2023 booklet are due to rounding.
ITEM 1: MEASUREMENT OF THE PRE-EXISTING RELATIONSHIP OF RECEIVABLES AND PAYABLES
During the year ended 30 June 2024, Discovery identified that it had incorrectly adjusted specified debtors and creditors that
were reflective of pre-existing relationships in its business acquisition of Standard Life Healthcare in July 2010 and the
DiscoveryCard acquisition in March 2019. The incorrect treatment did not affect the goodwill at acquisition. It did, however,
result in an overstatement of debtors and understatement of creditors as well as an overstatement of profit in the periods to
30 June 2022. Discovery corrected the errors in the earliest period presented, 1 July 2022.
The restatement has had no change to operating, investing, and financing cash flows. The correction does not impact the prior
or current reported period Group income statement, basic or diluted earnings per share.
D. 	Adoption of new standards and interpretations and restatements
continued

-- 83 of 116 --

105
D.1.4 	RESTATEMENTS AS RESULT OF PRIOR PERIOD ERRORS continued
ITEM 2: CALCULATION OF DEFERRED TAX ASSET
During the year ended 30 June 2024, Discovery reviewed the interest expense deductions in its UK business lines with the
assistance of external specialists and identified restrictions that impacted income tax in a prior period. This resulted in the
overstatement of the deferred tax asset as at 30 June 2022. Discovery corrected the error in the earliest period presented,
being 1 July 2022.
The finalised value of the correction is different to the value communicated during the interim disclosures for the six-month
period ended 31 December 2023. The finalised values are stated below, with the previously reported numbers for 1 July 2022
being a deferred tax asset decrease of R105 million (30 June 2023: R126 million) with an equal decrease in Retained earnings of
R105 million (30 June 2023: Retained earnings decrease R105 million and FCTR R21 million).
The restatement has had no change to operating, investing, and financing cash flows. The correction does not impact the prior
or current reported period Group income statement, basic or diluted earnings per share.
ITEM 3: CALCULATION OF FOREIGN CURRENCY TRANSLATION RESERVE
During the year ended 30 June 2024, Discovery identified that it had incorrectly calculated the foreign currency translation
reserve (FCTR), a component of equity, for specified assets and liabilities. In this transaction, balances arising from an
intergroup transaction for the year ended 30 June 2019 were incorrectly eliminated. This treatment resulted in certain foreign-
denominated intangible assets not being revalued. Discovery corrected the error in the earliest period presented, being
1 July 2022.
The restatement has had no change to operating, investing, and financing cash flows. The correction does not impact the prior
or current reported period Group income statement, basic or diluted earnings per share.

-- 84 of 116 --

107	106	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
D.1.4 	RESTATEMENTS AS RESULT OF PRIOR PERIOD ERRORS continued
ITEM 4: CASH AND CASH EQUIVALENTS
During the year ended 30 June 2024, Discovery identified that in its UK business it had incorrectly presented specified highly
liquid investments held for short-term cash commitments as investments at fair value through profit or loss, instead of cash
equivalents. The treatment resulted in the understatement of the cash and cash equivalents and an overstatement of the
investments at fair value through profit or loss in prior periods. Discovery corrected the error in the earliest period presented,
which was 1 July 2022.
The restatement resulted in a change to investing cash flows of R1 038 million for the year ended 30 June 2024, and increase
in cash and cash equivalent balances. The correction does not impact the prior or current reported period Group income
statement, basic or diluted earnings per share.
For the impact in the Group statement of cash flows, please refer to section D.1.5.
ITEM 5: CORRECTION OF IFRS 17 TRANSITION AND RESTATED RESULTS AS PUBLISHED IN THE UNAUDITED
INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
As noted earlier, IFRS 17 became effective for Discovery from 1 July 2023. In its unaudited interim results for the six months
ended 31 December 2023, Discovery included in its results the impact of adoption of IFRS 17 as well as provided the restated
information. During the finalisation of its annual results for the year ended 30 June 2024, Discovery identified corrections to the
previously published information. The below summarises the corrections to the previously published IFRS 17 information.
Details on the corrections are provided after the tables.
Group statement of financial position
1 July 2022 	30 June 2023
R million
IFRS 17
remeasurement
and
reclassification
previously
reported1
Item 5A
Adjustment:
Increase
(decrease)
in equity
Item 5B
Adjustment:
Increase
(decrease)
in equity
IFRS 17
remeasurement
and
reclassification
as reported in
these results
IFRS 17
remeasurement
and
reclassification
previously
reported1
Item 5A
Adjustment:
Increase
(decrease)
in equity
Item 5B
Adjustment:
Increase
(decrease)
in equity
IFRS 17
remeasurement
and
reclassification
as reported in
these results
Assets arising from insurance contracts issued 	(25 782) 	29 	(1 131) 	(26 884) 	(30 951) 	1 745 	(1 035) 	(30 241)
Deferred tax asset 	1 338 	19 	– 	1 357 	2 042 	43 	– 	2 085
TOTAL ASSETS 	(38 211) 	48 	(1 131) 	(39 294) 	(43 862) 	1 788 	(1 035) 	(43 109)
Other reserves 	(1 420) 	212 	– 	(1 208) 	(5 628) 	1 646 	– 	(3 982)
Retained earnings 	(11 150) 	(223) 	– 	(11 373) 	(9 804) 	(320) 	– 	(10 124)
TOTAL EQUITY 	(12 570) 	(11) 	– 	(12 581) 	(15 432) 	1 326 	– 	(14 106)
Liabilities arising from insurance contracts held 	(23 012) 	– 	(1 131) 	(24 143) 	(19 112) 	– 	(1 035) 	(20 147)
Liabilities arising from reinsurance contracts held 	(7 985) 	45 	– 	(7 940) 	(9 826) 	(24) 	– 	(9 850)
Deferred tax liability 	(3 022) 	14 	– 	(3 008) 	(3 337) 	486 	– 	(2 851)
TOTAL LIABILITIES 	(25 641) 	59 	(1 131) 	(26 713) 	(28 430) 	462 	(1 035) 	(29 003)
TOTAL EQUITY AND LIABILITIES 	(38 211) 	48 	(1 131) 	(39 294) 	(43 862) 	1 788 	(1 035) 	(43 109)
1 The previously reported values relate to the Restated IFRS 17 Group statement of financial position for the year ended 30 June 2023 published in
the unaudited interim results for the six months ended 31 December 2023.
D. 	Adoption of new standards and interpretations and restatements
continued

-- 85 of 116 --

108	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
D.1.4 	RESTATEMENTS AS RESULT OF PRIOR PERIOD ERRORS continued
Group income statement for the year ended 30 June 2023
30 June 2023
R million
Group
(previously
reported) 1
Item 5A:
Adjustment
Item 5C:
Adjustment
Group
Restated
Insurance revenue 	47 208 	(1 954) 	– 	45 254
Insurance service expenses 	(41 634) 	1 707 	101 	(39 826)
Net expenses from reinsurance contracts 	(188) 	62 	– 	(126)
Insurance service result 	5 386 	(185) 	101 	5 302
Net financial result from insurance finance income and
expense 	(7 458) 	63 	– 	(7 395)
– Net finance income/(expenses) from insurance
contracts 	(7 172) 	83 	– 	(7 089)
– Net finance income/(expenses) from reinsurance
contracts 	(286) 	(20) 	– 	(306)
Net fair value (losses)/gains on financial assets at fair value
through profit or loss 	16 726 	– 	506 	17 232
Fair value adjustments to liabilities under investment
contracts 	(2 593) 	– 	(506) 	(3 099)
Net insurance and investment results 	9 699 	(122) 	101 	9 678
Net income 	29 897 	(122) 	101 	29 876
Marketing and administration expense 	(18 439) 	– 	(101) 	(18 540)
Operating profit 	10 430 	(122) 	– 	10 308
Profit before financing and income tax 	10 950 	(122) 	– 	10 828
Foreign exchange gains/(losses) 	151 	(2) 	– 	149
Profit before income tax 	9 182 	(124) 	– 	9 058
Income tax expense 	(2 516) 	30 	– 	(2 486)
Profit for the year 	6 666 	(94) 	– 	6 572
1 The previously reported values relate to the Restated IFRS 17 Group income statement for the full year ended 30 June 2023 published in the unaudited interim
results for the six months ended 31 December 2023.
D. 	Adoption of new standards and interpretations and restatements
continued

-- 86 of 116 --

109
D.1.4 	RESTATEMENTS AS RESULT OF PRIOR PERIOD ERRORS continued
Group statement of other comprehensive income
30 June 2023
R million
Group
(previously
reported) 1
Item 5A
Adjustment
Group
Restated
Items that are or may be reclassified subsequently to profit or loss:
Currency translation differences 	3 287 	144 	3 431
– unrealised gains 	3 287 	144 	3 431
Net finance income/(expense) from insurance contracts issued 	(3 712) 	1 268 	(2 444)
– unrealised income/(expense) 	(5 072) 	1 691 	(3 381)
– tax on unrealised (income)/expense 	1 360 	(423) 	937
Net finance (expense)/income from reinsurance contracts held 	433 	21 	454
– unrealised income/(expense) 	589 	28 	617
– tax on unrealised expense/(income) 	(156) 	(7) 	(163)
Other comprehensive income/(losses) for the period, net of tax 	410 	1 433 	1 843
Total comprehensive income for the period 	7 076 	1 339 	8 415
1 The previously reported values relate to the Restated IFRS 17 Group statement of other comprehensive income for the full year ended 30 June 2023
published in the unaudited interim results for the six months ended 31 December 2023.

-- 87 of 116 --

110	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
D.1.4 	RESTATEMENTS AS RESULT OF PRIOR PERIOD ERRORS continued
ITEM 5A: CORRECTION OF UK LIFE INSURANCE BUSINESS LINE
Consistent with the unaudited interim results for the six months ended 31 December 2023, including the restated comparative
information, the arrangement with the Prudential Assurance Company Limited (PAC arrangement) is accounted for as an
insurance contract. Included within the PAC arrangement are specified cash flows that are akin to collateral and loan
movements. Under IFRS 17, these cash flows are accounted for as a ‘non-distinct loan to policyholders’, resulting in the cash
flows not being presented within insurance revenue and insurance service expenses, and variances recognised in the
contractual service margin.
After the completion of the reviewed IFRS 17 unaudited interim results for the six months ended 31 December 2023,
management identified that certain of these cash flows were incorrectly modelled and presented in the results previously
published. Further, a model change was made to reflect the hedged position of the PAC arrangement as a result of the
transfer of interest rate hedges to the PAC balance sheet towards the end of June 2022. This has resulted in an uplift in the
carrying value of the insurance contract assets (specifically the present value of fulfilment cash flows) with an equal and
opposite change recognised as insurance finance income and expenses in the Group statement of other comprehensive
income, and ultimately equity.
The restatement has had no change to operating, investing, and financing cash flows.
ITEM 5B: CORRECTION OF UK HEALTH PRESENTATION OF PRE-ACQUISITION INSURANCE ACQUISITION
CASH FLOWS
IFRS 17 requires that pre-acquisition insurance acquisition cash flows for UK Health Private Medical Insurance (PMI) portfolio be
presented together with the recognised groups of insurance contracts that form the UK Health (PAA) portfolio. As previously
communicated, the UK Health (PAA) portfolio consists solely of the PMI portfolio. The pre-acquisition insurance acquisition cash
flows therefore relate solely to those recognised PMI contracts. At the interim reporting period, the pre-acquisition insurance
acquisition cash flows which are assets, were presented separately from those recognised PMI contracts which was presented
as insurance contract liability. These balances should instead be presented together as a single asset or liability arising from
insurance contracts.
The correction does not impact the prior or current reported period Group income statement, basic or diluted earnings per
share. The restatement has had no change to operating, investing, and financing cash flows.
ITEM 5C: CORRECTION OF DISCOVERY INSURE AND VITALITY INVEST
Discovery identified incorrect presentation of items within the Group income statements as a result of incorrect presentation
when it released its unaudited interim results. The correction and restatement do not impact the basic or diluted earnings per
share and has had no change to operating, investing, and financing cash flows. The corrections are as follows:
 Discovery Insure had incorrectly presented marketing and administration expenses as insurance service expenses. This
resulted in an overstatement of the insurance service expenses for the affected period, offset with understatement of the
marketing and administration expenses.
 Vitality Invest incorrectly presented the fair value remeasurement of liabilities under investments contracts within the net fair
value gains on financial assets at fair value through profit or loss. This resulted in an understatement of the gains on
financial assets at fair value through profit or loss and understatement of fair value adjustments to liabilities under
investment contracts.
D. 	Adoption of new standards and interpretations and restatements
continued

-- 88 of 116 --

111
D.1.5 	CHANGES IN PRESENTATION OF SPECIFIED ITEMS IN PRIMARY STATEMENTS
AND ASSOCIATED RESTATEMENTS FOR PRIOR PERIOD CORRECTIONS
Introduction
Discovery continually evaluates its presentation and disclosures to developing market practices, changes in IFRS Accounting
standards and changes in its business composition that may indicating a need for change in presentation or disclosures. During
the year under review, in addition to those changes necessitated from the adoption of IFRS 17 Insurance Contracts, Discovery
has made the following enhancements in its financial statements.
Group statement of financial position
Discovery has enhanced the presentation of certain transactions within the Group statement of financial position by
introducing new line items. While these changes do not impact the total value of liabilities, they provide users with a clearer
understanding of the financial information. The key adjustments are as follows:
 A new line item, Third-party interest in consolidated funds, has been introduced to separately reflect the interests of third
parties in consolidated unit funds. Previously, these interests were included under Investment contracts at fair value through
profit or loss.
 Two new line items have been introduced.
– Provisions, which was previously included within the Other payables line item in the Group statement of financial position,
is now separately presented.
– Other payables, which includes, Employee benefits that was previously disclosed separately in the Group statement of
financial position, as well as non-financial payables that was previously included within Other payables.
– The line item formerly known as Other payables has been renamed Other financial payables at amortised cost.
Additionally, the order of line items within the Group statement of financial position has been amended to better represent
their liquidity, arranging them, where possible, from least to most liquid. For instance, Assets from reinsurance contracts held
has been moved from above Cash and cash equivalents to above Deferred tax asset. Apart from the changes noted above, no
reclassifications or restatements of values between line items have been made.

-- 89 of 116 --

113	112	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
D.1.5 	CHANGES IN PRESENTATION OF SPECIFIED ITEMS IN PRIMARY STATEMENTS
AND ASSOCIATED RESTATEMENTS FOR PRIOR PERIOD CORRECTIONS
continued
Group statement of cash flows
Discovery has implemented changes to its Group statement of cash flows to enhance the understandability, correct for prior
period errors and to accommodate the growth of Discovery Bank within the Group and to align with best practices in the
market. In implementing changes, Discovery also identified some items that were previously incorrectly presented. The changes
have been incorporated into the Group statement of cash flows for the year ended 30 June 2024, and the prior period has been
restated accordingly.
The information is set out to reconcile the information as previously published for the year ended 30 June 2023 under IFRS 4
basis, setting out the respective adjustments to the final restated balances in the Group statement of cash flows.
Details on the changes are provided after the reconciliation.
Group
R million
30 June 2023
As previously
reported
under IFRS 41 	Item 1 	Item 2 	Item 3 	Item 4 	Item 5
Group
30 June 2023
Restated
Cash flows from operating activities 	2 549 	2 744 	– 	– 	(1 072) 	– 	4 221
Cash generated by operations 	8 308 	2 899 	– 	(574) 	– 	(9 550) 	1 083
Purchase of investments held to back policyholder liabilities 	(62 773) 	– 	– 	– 	– 	62 773 	–
Proceeds from disposal of investments held to back policyholder liabilities 	55 908 	– 	– 	– 	– 	(55 908) 	–
Dividends received 	728 	– 	– 	– 	– 	(728) 	–
Interest received 	3 718 	(155) 	– 	1 318 	– 	(3 056) 	1 825
Interest paid 	(1 501) 	– 	– 	(744) 	– 	– 	(2 245)
Taxation paid 	(1 839) 	– 	– 	– 	– 	– 	(1 839)
Net movement in operating assets and liabilities 	– 	– 	– 	– 	(1 072) 	6 469 	5 397
– Increase in operating assets 	– 	– 	– 	– 	(1 072) 	(4 225) 	(5 297)
– Increase in operating liabilities 	– 	– 	– 	– 	– 	10 694 	10 694
Cash flows from investing activities 	(2 236) 	– 	(1 038) 	– 	1 072 	– 	(2 202)
– Purchase of financial assets 	(30 996) 	– 	8 549 	– 	22 417 	– 	–
– Proceeds from disposal of financial assets 	30 932 	– 	(9 587) 	– 	(21 345) 	– 	–
Cash flows from financing activities 	(1 234) 	– 	– 	– 	– 	– 	(1 234)
Net increase in cash and cash equivalents 	(921) 	2 744 	(1 038) 	– 	– 	– 	785
Cash and cash equivalents at beginning of the year 	19 619 	(5 988) 	3 399 	– 	– 	– 	17 030
Effects of exchange rate changes on cash and cash equivalents 	1 639 	(866) 	550 	– 	– 	– 	1 323
Cash and cash equivalents at end of the year 	20 337 	(4 110) 	2 911 	– 	– 	– 	19 138
Reconciliation to statement of financial position
Cash and cash equivalents 	20 370 	19 171
Bank overdraft included in borrowings at amortised cost 	(33) 	(33)
Cash and cash equivalents at end of the year 	20 337 	19 138
1 The previously reported values relate to the IFRS4 Group statement of cash flows for the year ended 30 June 2023, as published in September 2023.
D. 	Adoption of new standards and interpretations and restatements
continued

-- 90 of 116 --

114	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
D.1.5 	CHANGES IN PRESENTATION OF SPECIFIED ITEMS IN PRIMARY STATEMENTS
AND ASSOCIATED RESTATEMENTS FOR PRIOR PERIOD CORRECTIONS
continued
ITEM 1: ADOPTION OF IFRS 17
Although IFRS 17 did not affect the cash flows arising from insurance contracts, as mentioned in the Group statement of
financial position in section D.1.2 (footnote 5), the adoption of IFRS 17 has resulted in a change in the presentation of cash
and cash equivalents within the PAC arrangement. Consequently, this has also led to a change in the Group’s statement of
cash flows.
ITEM 2: UK INVESTMENTS INCORRECTLY CLASSIFIED
As outlined in section D.1.4, Item 4, Cash and Cash Equivalents, Discovery identified that it had incorrectly presented certain
highly liquid investments held specifically for short-term cash commitments in its UK business as investments at fair value
through profit or loss, rather than as cash equivalents. As a result, these investments have been reclassified as cash
equivalents, leading to a change in the Group’s statement of cash flows.
Please note: Consistent with the significant judgements disclosed in our financial statements, to meet the requirements
for cash equivalents, Discovery conducts assessments of its money market investments. These investments will only be
classified as cash equivalents if they meet the following criteria (1) The purpose of the investment is to fulfil short-term
cash commitments (2) The instrument demonstrates high credit quality within the relevant jurisdiction, as indicated by
its credit rating (3) The primary objective of the investment is to protect capital and provide liquidity (4) The investment
can be readily converted into known amount of cash, similar to bank balances (5) The fund is invested solely in
interest-bearing instruments, similar to deposits, with institutions of high credit quality. Additionally, the investment
must not introduce speculative grade or equity-type risks and exposures. This can be demonstrated by the yield returns
relative to other deposit-type investments within the same jurisdiction.
ITEM 3: CORRECTION OF PRESENTATION OF BANKING INTEREST RECEIVED AND PAID
Interest received, and interest paid are now separately disclosed in the Group’s statement of cash flows. Previously, Discovery
Group had presented bank interest income and bank interest expense under cash generated from operations. In line with
other presentational changes, Discovery will now present bank interest income under interest received, and bank interest
expense under interest paid.
ITEM 4: CHANGE IN PRESENTATION AND CORRECTION OF SPECIFIED ITEMS OF FINANCIAL ASSETS
Previously, Discovery had included the cash flows arising from the purchases and disposals of financial assets within its
investing activities. These consisted of purchases and disposals of financial assets not directly linked to policyholder assets and
liabilities as well those financial assets purchased and disposed within the Discovery Bank operations.
These activities are now being reclassified under operating activities, as these financial assets are utilised for purposes of
managing capital and liquidity as well as increased investment returns, in line with the associated changes to the presentation
of operating assets and operating liabilities, as noted in Item 5.
ITEM 5: OPERATING ASSETS AND OPERATING LIABILITIES
Discovery provides insurance and banking services and is classified as a financial institution. Under IAS 7, a financial institution
is permitted to present certain movements in operating assets and liabilities on a net basis. Discovery has enhanced its
disclosures and introduced changes to align more closely with other diversified financial institutions.
Changes in operating assets and operating liabilities are now presented separately in the Group’s statement of cash flows.
These changes now include:
 Working capital changes with quick turnover and short maturities, which were previously disclosed in the note for cash
generated from operations as part of working capital changes arising from operations.
 Specific activities undertaken by Discovery as a financial institution, including cash receipts and payments made on
behalf of customers, which reflect the activities of the customers rather than those of Discovery. This also includes receipts
and payments related to investments, loans, and advances. These were previously disclosed in the note for cash generated
from operations as part of working capital changes, with other activities forming part of investments acquired or disposed of
as investments held to back policyholder liabilities in the Group’s statement of cash flows.
 Cash flows arising from the purchases and disposals of financial assets, as noted in Item 4, which were previously
disclosed as investing activities.
 For investments at fair value through profit or loss, Discovery had previously included interest and dividends received,
presented as Net fair value gains and losses on financial assets at fair value through profit or loss in the Group income
statement, as part of interest received and dividends received in the Group’s statement of cash flows. These will now be
included as part of the gains or losses on financial assets at fair value through profit or loss within cash generated from
operations.
 Other operating assets and liabilities: Discovery has reclassified certain items which are working capital in nature,
previously recognised under cash generated from operations as non-cash adjustments to profit before tax, to now be
presented as changes in working capital. This includes movements in assets arising from contracts with customers, liabilities
related to customers, as well as trading and derivative assets and liabilities.
Discovery has restated the comparative information accordingly. This correction does not affect basic or diluted earnings
per share.
D. 	Adoption of new standards and interpretations and restatements
continued

-- 91 of 116 --

S E C T I O N E
ACCOUNTING
POLICIES
E.1 	New Accounting Standards and amendments
to published Accounting Standards not yet
effective
E.2 	Normalised headline earnings
E.3 	Basis of preparation
115

-- 92 of 116 --

116	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
E. 	Accounting policies
E.1 	NEW ACCOUNTING STANDARDS AND AMENDMENTS TO PUBLISHED
ACCOUNTING STANDARDS NOT YET EFFECTIVE
 For new Accounting standards and interpretation that became effective for the financial year commencing 1 July 2023, refer to
section D New Standards and interpretations and restatements. The section includes the first time adoption of IFRS 17
Insurance Contracts.
 Discovery has not early adopted any other IFRS Accounting Standards, amendments or interpretations that have been issued
but not yet effective. Discovery does not expect any new IFRS Accounting Standards, amendments or interpretations that have
been issued but not yet effective to have a material impact on the recognised amounts.
E.2 	NORMALISED HEADLINE EARNINGS
Discovery assesses its performance using normalised headline earnings, an alternative profit measure not under the IFRS
Accounting Standards, alongside its IFRS Accounting Standards profit measures. Management considers that Normalised
Headline Earnings Per Share (NHEPS) is an appropriate alternative performance measure to enhance the comparability and
understanding of the financial performance of the Group.
Measures not in terms of IFRS Accounting Standards are not uniformly defined or used by all entities and may not be
comparable with similarly labelled measures and disclosures provided by other entities.
Discovery calculates headline earnings in accordance with the latest SAICA circular ’Headline Earnings’. NHEPS is calculated
by starting with headline earnings and adjusted to exclude material items that are not considered to be part of Discovery’s
normal operations as follows:
 Once-off transactions – eg, restructuring costs, transaction costs related to interest rate derivatives and initial deferred tax
assets raised on previously unrecognised assessed losses
 Unusual items – the Group considers items to be unusual when they have limited predictive value, or it is reasonable that
items of a similar nature would not necessarily arise for several future reporting periods
 Income or expenses not considered to be part of the Group’s normal operations – for example, amortisation of intangibles
from business combinations and fair value gains or losses on foreign exchange contracts not designated as hedges
Management is responsible for the calculation of NHEPS and determining the inclusions and exclusions in accordance with the
policy. The Discovery Limited Audit Committee reviews the normalised headline earnings for transparency and consistency.
E.3 	BASIS OF PREPARATION
Statement of compliance
Discovery Limited is a company incorporated in South Africa.
The condensed consolidated financial statements for the year ended 30 June 2024 consolidate the results of Discovery and its
subsidiaries (together the Group) and equity account the Group’s interest in associates and joint ventures. The annual results
comprise the group statement of financial position at 30 June 2024, group income statement, group statement of other
comprehensive income, group statement of changes in equity and group statement of cash flows for the year ended
30 June 2024 and selected explanatory notes. The condensed consolidated financial results are prepared in accordance with the
JSE Limited Listings and Debt Listings Requirements, framework concepts and the measurement and recognition requirements
of IFRS® Accounting Standards as issued by the International Accounting Standards Board (IFRS Accounting Standards), including
IAS 34 Interim Financial Reporting, the SAICA Financial Reporting Guides as issued by the Accounting Practices Committee and
Financial Pronouncements as issued by the Financial Reporting Standards Council (FRSC) as well as the requirements of the
Companies Act of South Africa. The accounting policies adopted are consistent with the accounting policies applied in the prior
annual financial statements, except as noted in D.1. New accounting standards effective which includes the adoption of IFRS 17
Insurance Contracts.
These annual results do not include all the notes typically included in the annual financial statements.

-- 93 of 116 --

INDEPENDENT AUDITORS’
REPORT ON REVIEW OF
CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS
117

-- 94 of 116 --

118	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
To the shareholders of Discovery Limited
We have reviewed the accompanying condensed consolidated financial statements of Discovery Limited and its subsidiaries (“the Group”),
included on pages 8 to 116, which comprise the Group statement of financial position as at 30 June 2024, the Group income statement
and the Group statements of other comprehensive income, changes in equity and cash flows for the year then ended, and selected
explanatory notes as included in Sections A, B, C, D and E to the condensed consolidated financial statements.
DIRECTORS’ RESPONSIBILITY FOR THE CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS
The directors are responsible for the preparation and presentation of these condensed consolidated financial statements in accordance
with the JSE Limited Listings and JSE Debt Listings requirements, IFRS Accounting Standards, including IAS 34 Interim Financial Reporting,
the SAICA Financial Reporting Guides as issued by the Accounting Practices Committee and Financial Pronouncements as issued by
Financial Reporting Standards Council as set out in note E.3 to the financial statements, and the requirements of the South African
Companies Act, and for such internal control as the directors determine is necessary to enable the preparation of financial statements
that are free from material misstatement, whether due to fraud or error.
AUDITORS’ RESPONSIBILITY
Our responsibility is to express a conclusion on these condensed consolidated financial statements. We conducted our review in
accordance with International Standard on Review Engagements (ISRE) 2410, Review of Interim Financial Information Performed by
the Independent Auditors of the Entity, which applies to a review of historical information performed by the independent auditors of
the Group. ISRE 2410 requires us to conclude whether anything has come to our attention that causes us to believe that the financial
statements are not prepared in all material respects in accordance with the applicable financial reporting framework. This standard
also requires us to comply with relevant ethical requirements.
A review of financial statements in accordance with ISRE 2410 is a limited assurance engagement. We perform procedures, primarily
consisting of making inquiries of management and others within the entity, as appropriate, and applying analytical procedures, and
evaluate the evidence obtained.
The procedures performed in a review are substantially less than those performed in an audit conducted in accordance with International
Standards on Auditing. Accordingly, we do not express an audit opinion on these financial statements.
CONCLUSION
Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed consolidated
financial statements of the Group for the year ended 30 June 2024 are not prepared, in all material respects, in accordance with the JSE
Limited Listings and JSE Debt Listings requirements, IFRS Accounting Standards, including IAS 34 Interim Financial Reporting, the SAICA
Financial Reporting Guides as issued by the Accounting Practices Committee and Financial Pronouncements as issued by Financial
Reporting Standards Council as set out in note E.3 to the financial statements, and the requirements of the South African Companies Act.
KPMG Inc. 	Deloitte & Touche
Registered Auditor 	Registered Auditors
Per: Mark Danckwerts 	Per: Stephen Munro
Chartered Accountant (SA) 	Chartered Accountant (SA)
Registered Auditor 	Registered Auditor
Director 	Partner
85 Empire Road 	5 Magwa Crescent
Parktown 	Waterfall City
2193 	2090
South Africa 	South Africa
19 September 2024 	19 September 2024
INDEPENDENT AUDITORS’ REPORT ON REVIEW OF
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

-- 95 of 116 --

119
EMBEDDED VALUE
STATEMENT
Table 1: Group embedded value
Table 2: Value of in-force covered business
Table 3: Group embedded value earnings
Table 5: Experience variances
Table 6: Methodology and assumption changes
Table 7: Embedded value of new business
Table 9: Embedded value sensitivity
Table 10: Value of new business sensitivity
Table 8: Embedded value economic assumptions
Table 4: Components of Group
embedded value earnings

-- 96 of 116 --

120	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
EMBEDDED VALUE STATEMENT
Independent auditors’ report on the review of the
Embedded Value Statement of Discovery Limited
and its subsidiaries
TO THE DIRECTORS OF DISCOVERY LIMITED
INTRODUCTION
We have reviewed the Embedded Value Statement of Discovery Limited and its subsidiaries (together “the Discovery Group”) for the year
ended 30 June 2024 (the Report). The Report is prepared for the purpose of determining the embedded value and performance of the
Discovery Group. The directors of Discovery Limited are responsible for the preparation and presentation of the Report in accordance
with the embedded value basis set out in the Basis of Preparation section of the Report as set out in Table 8, and for determining that the
basis of preparation is acceptable in the circumstances. Our responsibility is to express a conclusion on this Report based on our review.
SCOPE OF REVIEW
We conducted our review in accordance with the International Standard on Review Engagements ISRE 2410, Review of Interim Financial
Information Performed by the Independent Auditor of the Entity. A review of financial information consists of making inquiries, primarily
of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially
less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to
obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not
express an audit opinion.
CONCLUSION
Based on our review, nothing has come to our attention that causes us to believe that the Report is not prepared, in all material respects,
in accordance with the embedded value basis set out in the Basis of Preparation section of the Report as set out in Table 8.
BASIS OF ACCOUNTING AND RESTRICTION ON USE
Without modifying our conclusion, we draw attention to the Basis of Preparation section of the Report as set out in Table 8, which
describes the basis of accounting. The Report is prepared for the purpose of determining the embedded value and performance of the
Discovery Group. As a result, the Report may not be suitable for another purpose. Our report is intended solely for the directors of
Discovery Limited and should not be used by any other parties. We agree to the publication of our report in the Discovery Reviewed
Annual Financial Results and cash dividend declaration and the Discovery Annual Financial Statements for the year ended 30 June 2024,
provided it is clearly understood by the recipients of the Discovery Reviewed Annual Financial Results and cash dividend declaration and
the Discovery Annual Financial Statements for the year ended 30 June 2024 that they enjoy such receipt for information only and that we
accept no duty of care to them in respect of our report.
KPMG Inc. 	Deloitte & Touche
Registered Auditor 	Registered Auditors
Per: Mark Danckwerts 	Per: Stephen Munro
Chartered Accountant (SA) 	Chartered Accountant (SA)
Registered Auditor 	Registered Auditor
Director 	Partner
19 September 2024 	19 September 2024

-- 97 of 116 --

121
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2024
The embedded value of the Discovery Group consists of the following components:
 the adjusted net worth attributed to the business at the valuation date;
 plus: the present value of expected future shareholder cash flows from the in-force covered business;
 less: the cost of required capital.
The present value of future shareholder cash flows from the in-force covered business is calculated as the value of projected future
after-tax shareholder cash flows of the business in-force at the valuation date, discounted at the risk discount rate.
The required capital are the assets attributed to the covered business above the amount required to back covered business liabilities,
whose distribution to shareholders is restricted as they are allocated to cover regulatory and internal capital requirements.
The value of new business is the present value, at the point of sale, of the projected future after-tax shareholder cash flows of the new
business written by the Discovery Group, discounted at the risk discount rate, less an allowance for the reserving strain, initial expenses
and cost of required capital. The value of new business is calculated using the current reporting date assumptions.
The embedded value includes the insurance and administration profits of the covered business in the Discovery Group. Covered business
includes business written in South Africa through Discovery Life (“Life”), Discovery Invest (“Invest”), Discovery Health (“Health”) and
Discovery Vitality (“Vitality”), and in the United Kingdom through VitalityLife and VitalityHealth. For Vitality Group, Ping An Health Insurance,
Discovery Insure, Discovery Bank and Umbrella Funds, no published value has been placed on the current in-force business.
In August 2011, the Discovery Group raised R800 million through the issue of non-cumulative, non-participating, non-convertible
preference shares. For embedded value purposes this capital, net of share issue expenses, has been excluded from the adjusted
net worth.
IFRS 17 Insurance Contracts became effective for the Discovery Group from 1 July 2023, with comparative restatement of the preceding
year, namely the financial year ended 30 June 2023, including a restatement of the opening Group statement of financial position as at
1 July 2022. The change in the accounting standard does not have a material impact on the embedded value for covered businesses, other
than second order impacts relating to the modelling of taxable income and minor modelling updates identified as part of the transition.
In respect of non-covered businesses which were impacted by the transition to IFRS 17, such as Discovery Insure and Ping An Health
Insurance, transitional impacts to the Group’s shareholder funds were experienced which would serve to change previously disclosed
embedded values. These changes are immaterial in aggregate, and so the disclosure of the prior period in the embedded value statement
has not been restated. The cumulative effect of the changes was recognised in the period for the twelve months ended 30 June 2024.
The 30 June 2024 embedded value results and disclosures were subjected to an external review.

-- 98 of 116 --

122	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2024
Table 1: Group embedded value
R million
30 June
2024
30 June
2023
%
change
Shareholders’ funds1 	57 719 	63 974 	(10)
Adjustment to shareholders’ funds from published basis2 	(38 431) 	(45 688) 	(16)
Adjusted net worth3 	19 288 	18 286 	5
Value of in-force covered business before cost of required capital 	94 258 	83 906 	12
Cost of required capital 	(3 192) 	(4 016) 	(21)
Discovery Group embedded value 	110 354 	98 176 	12
Number of shares (millions) 	661.0 	658.4
Embedded value per share 	R166.95 	R149.11 	12
Diluted number of shares (millions) 	665.0 	661.3
Diluted embedded value per share4 	R165.94 	R148.45 	12
1 Shareholders’ funds and the adjustment to shareholders’ funds from the published basis for the year ended 30 June 2024 are on an IFRS 17 basis, whereas for the
comparative period they are on an IFRS 4 basis. The key differences in the adjustment to shareholders’ funds from the published basis between an IFRS 17 and IFRS 4
basis include the change to the net assets under insurance contracts for Life and VitalityLife and the recapture of the FinRe liability and allowance for a deferred
acquisition cost asset for VitalityHealth.
2 A breakdown of the adjustment to shareholders’ funds is shown in the table below. Note that where relevant, adjustments have been converted using the closing
exchange rate of R23.07/GBP (June 2023: R23.99/GBP).
R million
30 June
2024
30 June
2023
Life net assets under insurance contracts 	(19 865) 	(25 491)
Vitality Life Limited net assets under insurance contracts 	(11 314) 	(12 051)
VitalityHealth and Vitality Health Insurance Limited deferred acquisition costs (net of deferred tax) 	(4 351) 	(5 001)
VitalityLife receivable relating to the Unemployment Cover benefit (net of deferred tax) 	(8) 	(13)
Goodwill relating to the acquisition of Standard Life Healthcare and the PAC joint venture 	(2 855) 	(2 969)
Intangible assets (net of deferred tax) in covered businesses 	(803) 	(893)
Net preference share capital 	(779) 	(779)
Reversal of 1 Discovery Place IFRS 16 financial lease accounting 	1 462 	1 333
Equity settled share based payment mark-to-market adjustment 	82 	176
(38 431) 	(45 688)
In respect to the table directly above:
• Prior to 30 June 2024, the adjustment for “VitalityHealth and Vitality Health Insurance Limited deferred acquisition costs (net of deferred tax)” also included the
adjustment for the FinRe liability which has since been recaptured.
• The “equity settled share based payment mark-to-market adjustment” reflects the difference between the provision in the IFRS equity and the mark-to-market value
of the equity settled share based payments.

-- 99 of 116 --

123
3 The following table sets out the capital position of the covered businesses with the required capital on a consistent basis to that used in the embedded value:
R million
30 June
2024
30 June
2023
Shareholders’ funds 	57 719 	63 974
Adjustment to shareholders’ funds 	(38 431) 	(45 688)
Adjusted net worth 	19 288 	18 286
Excess of available capital over adjusted net worth 	48 318 	40 336
Available capital 	67 606 	58 622
Required capital 	44 610 	41 987
Excess available capital 	22 996 	16 635
The excess of available capital over adjusted net worth reflects the difference between the adjusted net worth for embedded value purposes and the available capital on
a statutory solvency basis for covered business. This includes:
– The net preference share capital of R779 million which is included as available capital.
– The difference between Vitality Life Limited’s Solvency UK Pillar 1 Own Funds and its adjusted net worth.
– The difference between Life’s Pillar 1 Own Funds and its adjusted net worth.
The following table sets out the required capital for each of the covered businesses:
R million
30 June
2024
30 June
2023
Health and Vitality 	1 238 	1 108
Life and Invest 	27 935 	26 011
VitalityHealth 	4 138 	4 238
VitalityLife 	11 299 	10 630
Total required capital 	44 610 	41 987
– For Health and Vitality, the required capital was set equal to two times the monthly renewal expense and Vitality benefit cost.
– For Life and Invest, the required capital was set equal to 1.25 times the SAM Pillar 1 Solvency Capital Requirement.
– For VitalityHealth, prior to 30 June 2024, the required capital was set equal to 1.35 times the Solvency UK Pillar 1 Solvency Capital Requirement.
Regulatory approval for the adoption of internally derived risk factors for calculating premium and reserve risk capital was received, and as a
consequence the level of risk appetite capital held in excess of the regulatory minimum was recalibrated. From 30 June 2024 the required capital is set
equal to 1.55 times the Solvency UK Pillar 1 Solvency Capital Requirement.
– For the VitalityLife business on the PAC licence, prior to 30 June 2024, the required capital was set equal to 1.5 times the UK Solvency I long-term
insurance capital requirement, with an allowance for the diversification of risk, as per the agreement with PAC following the long-term delay of the Part
VII transfer. From 30 June 2024 the VitalityLife business on the PAC licence is classified as an insurance contract under IFRS 17. In line with the terms of
the contract, the 1.5 times the UK Solvency I long-term insurance capital requirement is now reserved for. As a result, this amount no longer contributes
to required capital in the embedded value, reducing the cost of required capital, and the release of the reserve is included in the value of in-force. For
the business sold on the Vitality Life Limited licence, the required capital was set equal to 1.4 times the Solvency UK Pillar 1 Solvency Capital
Requirement. For the period under review, the increase in the required capital for the business sold on the Vitality Life Limited licence exceeded the
removal of the required capital previously held for the VitalityLife business on the PAC licence, and therefore the overall required capital for
VitalityLife increased.
4 The diluted embedded value per share adjusts for the effect of vested treasury shares, share options exercised, and vesting of share awards where the impact is dilutive.
This adjustment has been aligned to the diluted number of shares shown elsewhere in the financial statements. Disclosure of prior periods in the embedded value
statement have been restated accordingly.
Table 2: Value of in-force covered business
R million
Value before
cost of
required
capital
Cost of
required
capital
Value after
cost of
required
capital
at 30 June 2024
Health and Vitality 	27 441 	(527) 	26 914
Life and Invest1 	37 570 	(1 757) 	35 813
VitalityHealth 2 	14 353 	(449) 	13 904
VitalityLife 2,3 	14 894 	(459) 	14 435
Total 	94 258 	(3 192) 	91 066
at 30 June 2023
Health and Vitality 	25 985 	(512) 	25 473
Life and Invest1 	33 301 	(1 665) 	31 636
VitalityHealth2 	12 797 	(698) 	12 099
VitalityLife 2 	11 823 	(1 141) 	10 682
Total 	83 906 	(4 016) 	79 890
1 Included in the Life and Invest value of in-force covered business is R2 318 million (June 2023: R2 005 million) in respect of investment management services provided on
off balance sheet investment business. The net assets of the investment service provider are included in the adjusted net worth.
2 The value of in-force has been converted using the closing exchange rate of R23.07/GBP (June 2023: R23.99/GBP).
3 The reduction in the cost of required capital for VitalityLife is largely driven by the removal of the required capital from the VitalityLife business on the PAC licence, which
no longer contributes to the embedded value cost of required capital calculation.

-- 100 of 116 --

124	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
Table 3: Group embedded value earnings
Year ended
R million
30 June
2024
30 June
2023
Embedded value at end of period 	110 354 	98 176
Less: embedded value at beginning of period 	(98 176) 	(86 258)
Increase in embedded value 	12 178 	11 918
Dividends paid 	1 269 	69
Employee share option schemes 	(683) 	(553)
Net change in capital 	131 	–
Transfer to hedging reserve 	61 	(76)
Acquisition of subsidiaries with non-controlling interest 	(6) 	(6)
IFRS 17 impact on non-covered businesses1 	(2) 	–
Embedded value earnings 	12 948 	11 352
Annualised return on opening embedded value 	13.2% 	13.2%
1 The embedded value for prior periods has not been restated for the transition to IFRS 17. This item represents the difference between IFRS 4 and IFRS 17 equity on
non-covered business, such as Discovery Insure (decrease in equity at 30 June 2023) and Ping An Health Insurance (increase in equity at 30 June 2023), and an opening
IFRS balance sheet restatement as a result of prior period errors (decrease in equity at 30 June 2023). These impacts largely offset as at 30 June 2023. These impacts
have not been included in the embedded value earnings and so a minor adjustment is required to reconcile the change from the embedded value at the beginning of
the period.
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2024
Table 4: Components of Group embedded value earnings
Year ended
30 June 2024
Year ended
30 June
2023
R million
Net
worth
Cost of
required
capital
Value of
in-force
covered
business
Embedded
value
Embedded
value
Total profit from new business (at point of sale) 	(4 513) 	(264) 	6 609 	1 832 	1 440
Profit from existing business
– 	Expected return 	7 696 	(72) 	2 716 	10 340 	8 589
– 	Change in methodology and assumptions1 	218 	1 117 	1 050 	2 385 	(4 854)
– 	Experience variances 	(485) 	– 	1 049 	564 	3 204
Impairment, amortisation and fair value adjustment2 	(60) 	– 	– 	(60) 	(67)
Increase in goodwill and intangibles 	(308) 	– 	– 	(308) 	(263)
Non-covered businesses3 	1 064 	– 	24 	1 088 	24
Non-recurring expenses 	(96) 	– 	– 	(96) 	(193)
Acquisition costs4 	(32) 	– 	(1) 	(33) 	(48)
Finance costs 5 	(2 796) 	– 	– 	(2 796) 	(2 848)
Foreign exchange rate movements6 	(503) 	43 	(1 095) 	(1 555) 	5 070
Other 7 	2 	– 	– 	2 	90
Return on shareholders' funds5,8 	1 585 	– 	– 	1 585 	1 208
Embedded value earnings 	1 772 	824 	10 352 	12 948 	11 352
1 The changes in methodology and assumptions will vary over time to reflect adjustments to the model and assumptions as a result of changes to the operating and
economic environment. The current period’s changes are described in detail in Table 6 below (for previous periods refer to previous embedded value statements).
2 This item reflects the amortisation of the intangible assets reflecting the banking costs, Cambridge Mobile Telematics system spend and capital expenditure in Discovery
Group Europe Limited.
3 This item includes the profits of non-covered businesses (including Discovery Insure, Vitality Group and Ping An Health Insurance) and costs of start-up businesses
(including Discovery Bank and an Umbrella Fund offering in Invest). Head office costs which relate to non-covered business are included in this item, as well as
cR160 million of expenses which are currently incurred by the covered businesses but will be met by non-covered businesses in due course, and hence have not been
included in the relevant covered businesses’ embedded value expense analysis.
4 Acquisition costs relate to commission paid on the Life and Invest business and expenses incurred in writing Health and Vitality business that has been written over the
period but will only be activated and on risk after the valuation date. These policies are not included in the embedded value or the value of new business and therefore
the costs are not deducted from the value of new business.
5 Finance costs and return on shareholders’ funds are shown gross of intercompany charges (R1 046 million at 30 June 2024 and R1 198 million at 30 June 2023).
6 This item includes foreign exchange gains / (losses) emerging through the income statement, in addition to translation impacts on the cost of required capital and value
of in-force.
7 This item includes, among other items, the tangible tax impact from movements in covered business intangible assets, which are excluded from the net worth.
8 The return on shareholders’ funds is shown net of tax and management charges.

-- 101 of 116 --

125
Table 5: Experience variances
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
Year
ended
30 June
2024
Year
ended
30 June
2023
R million
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force 	Total 	Total
Renewal expenses 	103 	– 	(24) 	(1) 	(160) 	– 	27 	– 	(55) 	(8)
Lapses and surrenders 1,2 	(24) 	(296) 	50 	93 	– 	673 	– 	12 	508 	537
Mortality and morbidity3 	– 	– 	25 	66 	(884) 	– 	112 	– 	(681) 	(8)
Policy alterations2 	– 	27 	(676) 	104 	– 	– 	(41) 	(83) 	(669) 	(387)
Backdated cancellations 	– 	– 	– 	– 	– 	– 	– 	– 	– 	–
Premium and fee
income 3,4 	183 	– 	(27) 	351 	389 	– 	(58) 	(84) 	754 	682
Inflation-linked
indexation 	– 	– 	(22) 	(214) 	– 	– 	– 	84 	(152) 	745
Economic 5 	– 	– 	117 	(35) 	186 	– 	1 	– 	269 	606
Commission 	– 	– 	– 	– 	– 	– 	– 	– 	– 	(36)
Tax 6 	115 	– 	222 	(193) 	14 	– 	(11) 	– 	147 	121
Reinsurance7 	– 	– 	– 	– 	(3) 	– 	(155) 	(26) 	(184) 	24
Maintain modelling
term 8 	– 	325 	– 	117 	– 	104 	– 	– 	546 	589
Vitality benefits 	(181) 	– 	– 	– 	– 	– 	(5) 	– 	(186) 	(37)
Other9 	177 	– 	(41) 	48 	(14) 	– 	120 	(23) 	267 	376
Total 	373 	56 	(376) 	336 	(472) 	777 	(10) 	(120) 	564 	3 204
1 For VitalityHealth, the lapse and surrender experience reflects improved retention rates. For Health and Vitality, the lapse and surrender experience was driven by an
increase in the number of employer groups who have widened the eligible schemes that employees can join beyond the Discovery Health Medical Scheme. Better than
expected lapse experience has been observed for the other covered businesses.
2 For Life and Invest, the policy alterations experience relates mainly to persistent pressures within the economic environment. This is partially offset by positive experience on
lapses as well as premium and fee income.
3 For VitalityHealth, high claims experience persists in the UK private medical insurance market as the challenges facing the NHS, since late 2022, continue to drive usage of
private medical insurance for services previously accessed in the NHS. Higher than expected premium increases were realised in line with this usage and is reflected as a
positive variance under premium and fee income.
4 Other than higher than expected premium and fee income, this experience variance item includes the impact of positive integration experience for individual life business in Life.
5 For VitalityHealth, investment return continued to contribute to profitability as interest rates in the UK remain high.
6 The tax variance arises due to the timing difference between the expected tax payments and actual payments.
7 For VitalityLife, the reinsurance experience includes an increase in reinsurance premium provisions related to prior periods, and the greater than expected cost of financing
reinsurance.
8 For Health and Vitality, Life and Invest, and VitalityHealth, the projection term is rebased at each year-end. Therefore, an experience variance arises because the total term
of the in-force covered business is effectively increased by twelve months.
9 The key Other experience relates to cash flow timing variances in Life and Invest and profits/losses from companies within the Health and VitalityLife segments which are
not part of covered business.

-- 102 of 116 --

126	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2024
Table 6: Methodology and assumption changes
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
Year
ended
30 June
2024
Year
ended
30 June
2023
R million
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force 	Total 	Total
Modelling changes 1 	– 	– 	46 	1 172 	– 	313 	(1 052) 	1 810 	2 289 	(20)
Expenses 	– 	340 	(21) 	(353) 	– 	– 	– 	– 	(34) 	(623)
Lapses2 	– 	– 	17 	(297) 	– 	– 	(423) 	51 	(652) 	(1 285)
Mortality and morbidity3 	– 	– 	(154) 	(347) 	– 	– 	– 	– 	(501) 	(138)
Benefit changes 	– 	(57) 	– 	– 	– 	– 	– 	– 	(57) 	(18)
Vitality 	– 	– 	– 	– 	– 	– 	– 	– 	– 	–
Tax 	– 	– 	– 	– 	– 	– 	– 	– 	– 	(13)
Economic assumptions 4 	– 	(1 114) 	9 	(720) 	– 	275 	47 	1 092 	(411) 	(4 680)
Premium and fee
income 	– 	44 	33 	121 	– 	– 	– 	– 	198 	1 646
Reinsurance and
financing5 	– 	– 	1 476 	(1 088) 	– 	– 	(9) 	25 	404 	195
Other 6 	– 	– 	228 	357 	– 	– 	21 	543 	1 149 	82
Total 	– 	(787) 	1 634 	(1 155) 	– 	588 	(1 416) 	3 521 	2 385 	(4 854)
1 For Life and Invest, this item includes a refinement to the value of in-force calculation to align the assumed cash flow timing with that assumed in the IFRS reserving
calculation. For VitalityHealth, the item represents the combined impact of a reduction in required capital following the adoption of regulatory approved internally derived
risk factors for calculating premium and reserve risk capital, an increase in the risk appetite capital held in excess of the regulatory minimum and a methodology update
that more accurately reflects those assets that are restricted from distribution in the cost of required capital calculations. For VitalityLife, the item reflects the reduction in
cost of required capital due to the implementation of the Solvency UK Risk Margin Reforms, a correction to the modelled investment income on swap collateral assets and a
reallocation of the capitalised impact of deferred tax relief on future earnings between adjusted net worth and value of in-force.
2 For Life and Invest, the individual life lapse and policy alterations basis was strengthened (including an allowance for lapse and policy alterations experience to remain
elevated in the short term) and various management actions were introduced which partially offset the impact. For VitalityLife, the lapse and cancelled-from-inception basis
was updated to reflect recent experience.
3 For Life, various updates to the mortality and morbidity basis were introduced to bring assumptions in line with updated estimates of future claims.
4 For Health and Vitality, and Life and Invest, the item includes the impact of transitioning to internally derived yield curves, which are consistent with the IFRS 17 reporting
basis, as at 30 June 2024. However, this impact is minor and the driver for this experience item relates to the cost of updating the underlying real yield curve rate
assumptions. For VitalityLife, this item includes the impact of updating the assumptions relative to the Solvency UK yield curves and the IFRS interest rates. Note that for
VitalityLife, following the implementation of IFRS 17, the risk-free rate assumption is based on the Solvency UK yield curves instead of a single interest rate derived from the
curves, and the inflation assumption is based on a market inflation curve instead of a long-term view of market inflation. For VitalityHealth, the impact of updating the
assumptions relative to the Solvency UK yield curves results in an increase to the annuity factor.
5 For Life and Invest, the reinsurance and financing item primarily relates to the impact of internal financing arrangements, where the future expected cash flows arising from
part of the negative reserves are monetised to match other positive policy liabilities.
6 For Life and Invest, this item includes a once-off tax timing gain that will be phased in over several years as a result of the impact of the IFRS 17 transition. For VitalityLife,
this once-off item reflects the value of the deferral of tax resulting from the OCI unwind into taxable future earnings.

-- 103 of 116 --

127
Table 7: Embedded value of new business
Year ended
R million
30 June
2024
30 June
2023
%
Change
Health and Vitality
Gross profit from new business (at point of sale) 	1 103 	954
Cost of required capital 	(52) 	(39)
Present value of future profits from new business (at point of sale) after cost
of required capital 	1 051 	915 	15
New business annualised premium income1 	7 716 	4 959 	56
Life and Invest
Present value of future profits from new business (at point of sale)2 	560 	516
Cost of required capital 	(79) 	(87)
Present value of future profits from new business (at point of sale) after cost
of required capital 	481 	429 	12
New business annualised premium income3 	3 214 	2 965 	8
Annualised profit margin4 	2.0% 	1.8%
Annualised profit margin excluding Invest business 	3.8% 	2.5%
VitalityHealth 5
Present value of future profits from new business (at point of sale) 	491 	269
Cost of required capital 	(63) 	(87)
Present value of future profits from new business (at point of sale) after cost
of required capital 	428 	182 	135
New business annualised premium income6 	2 443 	2 001 	22
Annualised profit margin4 	2.6% 	1.4%
VitalityLife
Present value of future profits from new business (at point of sale) 	(58) 	3
Cost of required capital 	(70) 	(89)
Present value of future profits from new business (at point of sale) after cost
of required capital 	(128) 	(86) 	49
New business annualised premium income 7 	1 462 	1 124 	30
Annualised profit margin4 	(1.3%) 	(1.0%)
1 Health new business annualised premium income is the gross contribution to the medical schemes. The new business annualised premium income shown above excludes
premiums in respect of members who join an existing employer where the member has no choice of medical scheme, as well as premiums in respect of new business
written during the period but only activated after 30 June 2024. The total Health and Vitality new business annualised premium income written over the period, inclusive of
Sasolmed, was R11 481 million (June 2023: R9 133 million).
2 Included in the Life and Invest embedded value of new business is R15 million (June 2023: R21 million) in respect of investment management services provided on off
balance sheet investment business. Risk business written prior to the valuation date allows certain Invest business to be written at financially advantageous terms, the
impact of which has been recognised in the value of new business.
3 Life new business is defined as Life policies to which Life became contractually bound during the reporting period, including policies whose first premium is due after the
valuation date. Invest new business is defined as business where at least one premium has been received and which has not been refunded after receipt. Invest new
business also includes Discovery Retirement Optimiser policies to which Life and Invest became contractually bound during the reporting period, including policies whose
first premium is due after the valuation date.
The new business annualised premium income of R3 214 million (June 2023: R2 965 million) (single premium APE:R1 545 million (June 2023: R1 430 million)) shown above
excludes automatic premium increases and servicing increases in respect of existing business. The total new business annualised premium income written over the period,
including automatic premium increases of R2 249 million (June 2023: R2 208 million) and servicing increases of R779 million (June 2023: R716 million), was R6 242 million
(June 2023: R5 889 million) (single premium APE: R1 626 million (June 2023: R1 499 million)). Single premium business is included at 10% of the value of the single premium.
Policy alterations and internal replacement policies, including Discovery Retirement Optimisers added to existing Life Plans, are shown in Table 5 as experience variances
and not included as new business. Term extensions on existing contracts are not included as new business.
4 The annualised profit margin is the value of new business expressed as a percentage of the present value of future premiums.
5 The VitalityHealth value of new business is calculated as the value at point of sale of the new business written premium in-force at the valuation date multiplied by the
Margin multiplied by the Annuity Factor less the new business cash flows from point of sale to the valuation date. The assumptions for the Margin and Annuity Factor are
shown in Table 8.
6 VitalityHealth new business is defined as individuals and employer groups which incepted during the reporting period. The new business annualised premium income
shown above has been adjusted to exclude premiums in respect of members who join an existing employer group after the first month, as well as premiums in respect of
new business written during the period but only activated after 30 June 2024.
7 VitalityLife new business is defined as policies to which VitalityLife became contractually bound during the reporting period, including policies whose first premium is due
after the valuation date.

-- 104 of 116 --

128	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2024
BASIS OF PREPARATION
Table 8: Embedded value economic assumptions
30 June
2024
30 June
2023
Beta coefficient 	0.75 	0.75
Equity risk premium (%) 	3.5 	3.5
Risk discount rate (%)
– 	Health and Vitality1 	14.875 	15.125
– 	Life and Invest1 	15.375 	15.875
– 	VitalityHealth 	6.573 	7.000
– 	VitalityLife 	6.495 	7.042
Rand/GB Pound exchange rate
– 	Closing 	23.07 	23.99
– 	Average 	23.55 	21.43
Margin over expense inflation to derive medical inflation (%)
South Africa 	3.00 	3.00
Expense inflation (%)2
South Africa 	– 	Health and Vitality 	6.87 	7.96
– 	Life and Invest 	7.05 	8.13
United Kingdom 	4.01 	3.75
Pre-tax investment return (%)
South Africa 	– 	Cash1 	11.25 	11.75
– 	Life and Invest bonds3 	12.75 	13.25
– 	Health and Vitality bonds3 	12.25 	12.50
– 	Equity 	16.25 	16.75
United Kingdom 	– 	VitalityHealth risk-free rate 	3.95 	4.38
– 	VitalityLife risk-free rate 	3.87 	4.42
– 	VitalityLife IFRS interest rate return 	3.87 	3.98
– 	VitalityLife investment return 	4.91 	4.31
Long-term corporation tax rate (%)
South Africa 	27 	27
United Kingdom 	25 	25
VitalityHealth margin assumptions
– 	Margin (net of tax and cost of required capital) (%) 	12.35 	12.10
– 	Annuity Factor 	6.42 	6.28
Projection term
– 	Health and Vitality 	20 years 	20 years
– 	Life – VIF 	40 years 	40 years
– 	Group Life 	20 years 	20 years
– 	VitalityLife 	No cap 	No cap
– 	VitalityHealth4 	20 years 	20 years
1 Derived as a margin over (or below for cash) the respective pre-tax investment return for bonds.
2 The inflation assumption is derived as the difference between the nominal and real yield curve at each duration. As an indication, the cash flow weighted average
inflation is shown in the table. For the United Kingdom, the expense inflation assumption is aligned with the long-term market view of inflation.
3 As indications, the cash flow weighted averages derived from the relevant yield curve(s) are shown.
4 The VitalityHealth projection term of 20 years is used in the derivation of the Annuity Factor.

-- 105 of 116 --

129
The Discovery Group embedded value is calculated based on a risk discount rate using the Capital Asset Pricing Model (CAPM) approach
with specific reference to the Discovery Group beta coefficient. The assumed beta is fixed at 0.75. This has been set such that the risk
discount rate proxies the result of a Weighted Average Cost of Capital approach with reference to the capital structure of the Group and
the observed beta calculated using daily returns over a long time period. The observed beta is calculated with reference to the ALSI. The
assumed beta will only change if the capital structure of the Group and/or the observed beta calculated using daily returns over a long
time period suggest the beta assumption should depart significantly from the assumption at the financial year-end. As beta values reflect
the historic performance of share prices relative to the market, they may not allow fully for non-market related and non-financial risk.
Investors may want to form their own view on an appropriate allowance for these risks which have not been modelled explicitly.
Life and Invest mortality, morbidity and lapse and surrender assumptions were derived from internal experience, where available,
augmented by reinsurance and industry information.
The Health and Vitality lapse assumptions were derived from the results of recent experience investigations.
The VitalityHealth assumptions were derived from internal experience and augmented by future expectations.
VitalityLife assumptions were derived from internal experience, where available, augmented by reinsurance, industry and Discovery Group
information.
Renewal expense assumptions were based on the results of the latest expense and budget information.
The initial expenses included in the calculation of the embedded value of new business are the actual costs incurred excluding expenses
of an exceptional or non-recurring nature.
The South African investment return assumptions for Life, Invest, Health and Vitality were set relative to an internally derived nominal
yield curve, which is consistent with the IFRS 17 reporting basis.
The current and projected tax position of the policyholder funds within the Life company has been taken into account in determining the
net investment return assumption.
The risk-free rate assumption for VitalityHealth was based on the single interest rate derived from the Prudential Regulatory Authority
yield curve. VitalityLife has transitioned to the use of full yield curves to represent its risk-free rate assumption following the
implementation of IFRS 17. For consistency, VitalityLife has also transitioned to the use of a market inflation curve from a long-term
market view of inflation.
VitalityHealth calculate the value of in-force at the valuation date as the in-force written premium multiplied by the Margin multiplied by
the Annuity Factor, as set out in the table above. The Annuity Factor assumption is derived from assumed future lapse rates and premium
increases. The Margin assumption reflects assumed profit margins after tax and the cost of required capital. The assumptions underlying
the Annuity Factor and Margin are set taking into account the current experience and future expectations of the business at different
durations.
The cost of required capital is calculated using the difference between the risk discount rate and the net of tax asset return on tangible
assets. The Vitality Life Limited required capital amount is assumed to earn the investment return assumption, which is set based on the
return on a portfolio of government and corporate bonds assumed to back the required capital. The Life and Invest cost of required
capital is calculated assuming shareholder cash flow is limited to the cash flow available after having met both the required capital
amount and an internally defined liquidity target capital requirement of tangible assets.
The embedded value has been calculated in accordance with the Actuarial Society of South Africa’s Advisory Practice Note (“APN”) 107:
Embedded Value Reporting, except the recommended disclosure of Free Surplus and Required Capital has been adjusted to take into
account the nature of the capital requirements in the covered businesses, as can be seen in Table 1 note 2.

-- 106 of 116 --

131	130	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2024
BASIS OF PREPARATION
The risk discount rate uses the CAPM approach with specific reference to the Discovery Group beta coefficient. As beta values reflect the
historic performance of share prices relative to the market, they may not allow fully for non-market related and non-financial risk. Investors
may want to form their own view on an appropriate allowance for these risks which have not been modelled explicitly. The sensitivity of the
embedded value and the embedded value of new business at 30 June 2024 to changes in the risk discount rate is included in the tables
below.
For each sensitivity illustrated below, all other assumptions have been left unchanged. No allowance has been made for management action
such as risk premium increases where future experience is worse than the base assumptions.
Table 9: Embedded value sensitivity
Discovery
Group 	Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
Embedded
value
%
change	R million
Adjusted
net worth
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Base 	19 288 	27 441 	(527) 	37 570 	(1 757) 	14 353 	(449) 	14 894 	(459) 	110 354
Impact of:
Risk discount rate + 1% 	19 288 	25 960 	(569) 	34 460 	(1 853) 	13 624 	(588) 	13 844 	(519) 	103 647 	(6)
Risk discount rate – 1% 	19 288 	29 076 	(479) 	41 224 	(1 642) 	15 159 	(293) 	16 111 	(363) 	118 081 	7
Lapses – 10% 	19 062 	28 314 	(552) 	40 746 	(1 851) 	16 710 	(522) 	15 721 	(553) 	117 075 	6
Interest rates – 1% 1 	19 487 	27 331 	(508) 	37 938 	(1 729) 	15 159 	(474) 	14 459 	(581) 	111 082 	1
Equity and property market value – 10% 	19 239 	27 441 	(527) 	36 769 	(1 746) 	14 353 	(449) 	14 894 	(459) 	109 515 	(1)
Equity and property return + 1% 	19 288 	27 441 	(527) 	37 967 	(1 753) 	14 353 	(449) 	14 894 	(459) 	110 755 	–
Renewal expenses – 10% 	19 404 	30 074 	(488) 	38 283 	(1 707) 	15 526 	(449) 	15 170 	(456) 	115 357 	5
Mortality and Morbidity – 5% 	19 583 	27 441 	(527) 	40 107 	(1 610) 	16 977 	(449) 	15 328 	(448) 	116 402 	5
Projection term + 1 year 	19 288 	27 749 	(531) 	37 645 	(1 760) 	14 462 	(452) 	14 894 	(459) 	110 836 	–
1 All economic assumptions were reduced by 1%.
The following table shows the effect of using different assumptions on the embedded value of new business.
Table 10: Value of new business sensitivity
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
Value of
new
business
%
change	R million
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Base 	1 103 	(52) 	560 	(79) 	491 	(63) 	(58) 	(70) 	1 832
Impact of:
Risk discount rate + 1% 	1 014 	(57) 	390 	(83) 	366 	(81) 	(156) 	(78) 	1 315 	(28)
Risk discount rate – 1% 	1 201 	(47) 	757 	(74) 	631 	(41) 	56 	(56) 	2 427 	32
Lapses – 10% 	1 177 	(57) 	741 	(83) 	786 	(72) 	112 	(115) 	2 489 	36
Interest rates – 1% 1 	1 111 	(50) 	558 	(77) 	631 	(67) 	13 	(76) 	2 043 	12
Equity and property return + 1% 	1 103 	(52) 	584 	(79) 	491 	(63) 	(58) 	(70) 	1 856 	1
Renewal expense – 10% 	1 282 	(50) 	604 	(77) 	642 	(63) 	(20) 	(64) 	2 254 	23
Mortality and morbidity – 5% 	1 103 	(52) 	647 	(72) 	828 	(63) 	(25) 	(64) 	2 302 	26
Projection term + 1 year 	1 121 	(53) 	563 	(79) 	511 	(63) 	(58) 	(70) 	1 872 	2
Acquisition costs – 10% 	1 142 	(52) 	734 	(79) 	525 	(63) 	158 	(70) 	2 295 	25
1 All economic assumptions were reduced by 1%.

-- 107 of 116 --

DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4	132
ANNEXURE A
New business annualised premium income
Income from non-insurance business lines
DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4

-- 108 of 116 --

133
ANNEXURE A
This Annexure does not form part of the IFRS results. Discovery assesses its performance using alternative non-IFRS profit and income
measures. These measures enhance the comparability and understanding of the financial performance of the Group.
New business annualised premium income
for the year ended 30 June 2024
The new business annualised premium income (API) set out below provides a view of the scale of new business across all operations of
the Group and does not necessarily reflect the new business attributable to the legal entities within the Group. For instance, DHMS new
business is attributable to the medical scheme but is under the administration and marketing of Discovery Health which earns a fee in
respect of such services.
Core new business API, increased by 18% for the year ended 30 June 2024 when compared to the corresponding prior period.
R million
Group
30 June
2024
Group
June
2023
%
Change
Discovery Health1 	11 069 	8 761 	26%
Discovery Life 	2 942 	2 838 	4%
Individual Life 	2 778 	2 663 	4%
Group Life 	164 	175 	(6%)
Discovery Invest 	3 300 	3 050 	8%
Discovery Insure 	1 388 	1 249 	11%
Discovery Vitality 	412 	372 	11%
Discovery Umbrella 	626 	382 	64%
Core new business API from SA Composite 	19 737 	16 652 	19%
VitalityHealth 	2 488 	2 064 	21%
VitalityLife 	1 956 	1 721 	14%
Core new business API from UK Composite 	4 444 	3 785 	17%
Core new business API from VG Composite: Ping An Health Insurance (PAHI)
own license 	2 486 	2 185 	14%
Core new business API of Group, excluding products in run down
or discontinued2 	26 667 	22 622 	18%
Total new business API of Group including products in run down
or discontinued 2 	27 157 	23 108 	18%
1 New business API for Discovery Health includes new business API for all businesses administered by Discovery Health, including DHMS, Closed Schemes and
offerings such as GAP cover and FlexiCare cover. The new business API for New Closed Schemes includes contracted new business API and business in the
first twelve months of on-boarding. Closed Schemes refer to those restricted to certain employers and industries. In the year under review, Discovery secured
the administration of the Sasolmed Medical Scheme. Excluding Sasolmed, core new business API declined 2%.
2 Products in run down or discontinued include Discovery Insure Commercial, VitalityInvest and PAHI reinsurance business.
CALCULATION OF NEW BUSINESS API
New business API is calculated at 12 times the monthly premium for new recurring premium policies and 10% of the value of new single
premium policies It also includes both automatic premium increases and servicing increases on existing long-term insurance policies.
The amounts exclude indirect taxes.
The new business API in the table above differs from the new business API disclosed in the embedded value largely as a results of:
 The timing of inclusion of the policyholders in the calculation of new business API – in the embedded value, new business is included
from the earlier of the date that the first premium has been received or when the policy is on risk, whereas in table above, new business
is included when the policy has been contractually committed.
 Inclusion of automatic premium increases and servicing increases on existing life policies – these are included in the table above but
excluded in the embedded value API values disclosed.
Refer to the footnotes to Table 7: Embedded Value of New Business for a more detailed description of the differences in new business
disclosures between the embedded value and the table above. 	.

-- 109 of 116 --

134	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
Income from non-insurance business lines
for the year ended 30 June 2024
The table below includes income from business lines and activities not covered by the new business API definition, as outlined in the
previous table. For Discovery Bank, banking fees and commissions are presented net of related expenses. This information differs from
that provided in note A.4, which reflects the gross revenue streams for goods or services within the scope of IFRS 15 Revenue from
Contracts with Customers.
R million
Group
June
2024
Group
June
2023 	Change %
Discovery Health – Income excluded from API measure 	1 260 	1 205 	5%
Discovery Bank 	2 102 	1 517 	39%
Discovery Bank – Net banking fee and commission income (NIR) 	1 324 	943 	40%
Discovery Bank – Net bank interest and similar income (NII) 	778 	574 	36%
Vitality Global income1 	2 829 	2 627 	8%
Vitality Network 	1 894 	1 632 	16%
Vitality Health International (excluding PAHI) 	935 	995 	(6%)
Total income from non-insurance business lines 	6 191 	5 349 	16%
1 Vitality Global income includes gross recurring and lump sum revenues earned by Vitality Group and solution revenue from external clients, while that from
internal clients and rewards is specifically excluded.
ANNEXURE A continued

-- 110 of 116 --

ANNEXURE B
Impact of corrections on normalised
profit from operations for six-months
ended 31 December 2023
135

-- 111 of 116 --

136	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
ANNEXURE B
Impact of corrections on normalised profit from operations for six-months
ended 31 December 2023
NORMALISED PROFIT FROM OPERATIONS
The following table reflects the estimation of the correction in the treatment of the negative reserves and equity as noted in
Section D of the results booklet for the six-months ended 31 December 2023:
Updated
As previously
published in
March 2024
R million
Group
December
2023
Unaudited
Group
December
2023
Unaudited 	Change
Normalised profit from SA composite 	4 355 	4 355
Normalised profit from UK Composite* 	725 	812 	(87)
Normalised profit from Vitality Global composite 	455 	455 	–
Normalised profit from operations 	5 535 	5 622 	(87)
* Change related to VitalityLife.
TOTAL EQUITY
Updated
As previously
published in
March 2024
R million
Group
December
2023
Unaudited
Group
December
2023
Unaudited 	Change
Equity attributable to equity holders of the Company 	51 827 	52 202 	(375)
Non-controlling interest 	4 	4 	–
Total equity 	51 831 	52 206 	(375)

-- 112 of 116 --

ANNEXURE C
Regulatory capital
137

-- 113 of 116 --

138	DISCOVERY R E V I E W E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 4
Regulatory capital
For Group subsidiaries that operate in the insurance and financial services sectors, the relevant regulator specifies the minimum amount
and type of capital that must be held by each of the subsidiaries in addition to their insurance liabilities. The minimum required capital
must be maintained at all times throughout the period.
Discovery Life and Discovery Insure are regulated under the Insurance Act 18 of 2017 (Insurance Act), and the related Prudential
Standards, while VitalityHealth and VitalityLife are regulated under the European Solvency II regulatory regime.
The table below summarises the capital requirements of insurance companies on the statutory basis, across the Group subsidiaries, and
the actual solvency capital held in relation to these requirements as at the end of the reporting period.
June 2024 	June 2023
Statutory capital requirements 	Cover 	Statutory capital requirements 	Cover
Discovery Life 	R22 365 million 	1.8 times 	R20 814 million 	1.9 times
Discovery Insure 	R1 222 million 	1.6 times 	R1 113 million 	1.6 times
VitalityHealth 	£116 million 	1.6 times 	£130.8 million 	1.4 times
R2 670 million 	R3 139 million
VitalityLife 	£350 million 	2.0 times 	£272.1 million 	2.1 times
R8 070 million 	R6 528 million
Discovery Bank’s common equity tier 1 (CET1) ratio is 17.63% (FY2023: 16.82%). In addition, the Bank holds an internal management buffer
to cater for future unexpected growth and volatility in risk-weighted exposures, as well as an estimation risk buffer.
ANNEXURE C

-- 114 of 116 --

139
Transfer secretaries Computershare Investor Services (Pty) Limited
(Registration number: 2004/003647/07)
Rosebank Towers, 15 Biermann Avenue, Rosebank, 2196
Private Bag X9000, Saxonwold, 2132
Sponsors and debt sponsors Rand Merchant Bank (a division of FirstRand Bank Limited)
Secretary and registered office AC Ceba (FCG)(F.Inst D),
Discovery Limited
(Incorporated in the Republic of South Africa)
(Registration number: 1999/007789/06)
Company tax reference number: 9652/003/71/7
JSE share code: 	DSY ISIN: ZAE000022331
JSE share code: 	DSBP ISIN: ZAE000158564
JSE company code: 	DSYI
1 Discovery Place, Sandton, 2196
PO Box 786722, Sandton, 2146
Tel: (011) 529 2888 Fax: (011) 539 8003
Directors ME Tucker (UK) (Chairperson), A Gore* (Group Chief Executive), LM Chiume1, R Farber, WM Hlahla, FN Khanyile,
D Macready, Dr TV Maphai2, TT Mboweni, KC Ramon1, M Schreuder, B Swartzberg*, BA van Kralingen,
DM Viljoen* (Group Chief Financial Officer), SV Zilwa2.
* Executive.
1 Appointed effective 18 September 2023.
2 Retired effective 16 November 2023.
Debt officer DM Viljoen
Annual financial results
– prepared by G Pieterse CA(SA), J Symons CA(SA)
– supervised by DM Viljoen CA(SA)
Embedded value statement
– prepared by P Bolink FASSA
– supervised by A Rayner FASSA, FIA
ADMINISTRATION

-- 115 of 116 --

Discovery Limited | +27 11 529 2888 | askthecfo@discovery.co.za | www.discovery.co.za
Copyright 2024. Discovery Ltd is the licensed controlling company of the designated Discovery Insurance Group.

-- 116 of 116 --